Methods of using non-natural melanocortin analogues to treat cancer and / or chemotherapy-related conditions

By using non-natural melanocortin analogs during anticancer drug treatment, the problem of patients' treatment tolerance being limited by side effects has been solved, resulting in increased weight and muscle mass, and improved quality of life and treatment outcomes.

CN123124984APending Publication Date: 2026-11-17CARLOHEXIS
View PDF 22 Cites 0 Cited by

Patent Information

Application Number
CN202480087750.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-08
Filing Date
2024-02-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In current anticancer drug treatments, patients often have limited tolerance to treatment due to side effects such as anorexia, weight loss, and muscle wasting, which affects treatment efficacy and quality of life.

Method used

Before, during, and/or after the administration of anticancer drugs, patients are given non-natural melanocorticoid analogues to prevent or reduce these side effects and to maintain or increase weight, muscle mass, fat mass, etc.

Benefits of technology

By using melanocortin analogues, significant increases in body weight, muscle mass, fat mass, and bone density are achieved, appetite is improved, side effects are reduced, treatment tolerance is increased, cancer treatment time is prolonged, and quality of life is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124984A_ABST
    Figure CN123124984A_ABST
Patent Text Reader

Abstract

This article provides methods for treating, preventing, or reducing symptoms and / or side effects associated with anticancer agents (e.g., chemotherapy agents) by administering a non-naturally occurring melanocortin analogue before, during, and / or after administration of an anticancer agent. The methods reduce side effects associated with the anticancer agent, such as anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, and loss of appetite, thereby enhancing tolerance to the anticancer agent and survival in subjects with cancer or non-cancer diseases or conditions treated, reduced, or prevented by administration of the anticancer agent.
Need to check novelty before this filing date? Find Prior Art

Description

Cross-references to related applications

[0001] This patent application claims the benefit of U.S. Provisional Patent Application 63 / 618587, filed January 8, 2024, which is incorporated herein by reference in its entirety.

[0002] By referencing the merged sequence list This application contains a sequence list conforming to the ST.26 standard, which was filed concurrently with the Patent Centre in .xml format and is hereby incorporated by reference in its entirety. A copy of the .xml file created on February 16, 2024, is named 146316_8019_WO00_SL.xml and has a size of 1,552,278 bytes. Background Technology

[0003] Treatment with anticancer agents (including chemotherapy) is often limited because patients may have certain conditions such as anorexia, vomiting, weight loss, fat and muscle wasting, and fatigue. These conditions may be caused by the subject's cancer or are side effects of the anticancer agents. Because subjects may have one or more of these conditions, limitations on the use of anticancer agents may include restrictions on the duration and dosage of cancer treatment. Therefore, these conditions limit the subject's tolerance to anticancer agents, thereby reducing overall treatment efficacy, decreasing the quality of life for cancer patients, and increasing the risk that treatment may not achieve its intended effect.

[0004] Despite recent advances in cancer treatment, new approaches are still needed to make anticancer agents and related cancer treatments more tolerable for patients, including reducing adverse side effects compared to conventional methods while maintaining or enhancing robust therapeutic activity.

[0005] Record the rats’ body weight before, between, and after administration of any dose of TCMCB07 and / or cisplatin. Summary of the Invention

[0006] In some embodiments, the present invention includes a method for treating, preventing, or reducing one or more side effects associated with an anticancer agent in a subject, the method comprising administering to the subject a non-naturally occurring melanocortin analogue before, during, and / or after administration of the anticancer agent, wherein the one or more side effects are selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

[0007] In some embodiments, the present invention includes a method for maintaining or increasing the weight of a subject before, during, and / or after administration of an anticancer agent, the method comprising administering to the subject a non-naturally occurring melanocorticoid analogue, wherein the subject's weight is maintained or increased by preventing or reducing the subject's anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and / or loss of appetite.

[0008] In some embodiments, the present invention includes a method for maintaining or increasing the weight of a subject before, during, and / or after administration of an anticancer agent, the method comprising administering to the subject a non-naturally occurring melanocorticoid analogue, wherein the subject's weight is maintained or increased by preventing or reducing one or more side effects associated with the anticancer agent, the one or more side effects being selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

[0009] In some embodiments, the present invention includes the use of a non-naturally occurring melanocortin analogue to treat, prevent, or reduce one or more side effects associated with an anticancer agent in a subject, the one or more side effects being selected from the group consisting of: anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, and loss of appetite, wherein the non-naturally occurring melanocortin analogue is administered to the subject before, during, and / or after administration of the anticancer agent.

[0010] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues to maintain or increase the weight of a subject before, during, and / or after administration of an anticancer agent, wherein the subject's weight is maintained or increased by preventing or reducing anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and / or loss of appetite in the subject.

[0011] In some embodiments, the present invention includes the use of a non-naturally occurring melanocortin analogue to maintain or increase the weight of a subject before, during, and / or after administration of an anticancer agent. This use includes administering the non-naturally occurring melanocortin analogue to the subject, wherein the subject's weight is maintained or increased by preventing or reducing one or more side effects associated with the anticancer agent, the one or more side effects being selected from the group consisting of: anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, and loss of appetite.

[0012] In some embodiments, the subject experienced a weight gain of at least about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 225%, 250%, 275%, 300%, 350%, 400%, 450%, or 500% compared to baseline or control.

[0013] In some embodiments, the present invention includes a method for maintaining or increasing muscle mass, fat mass, or heart mass of a subject before, during, and / or after administration of an anticancer agent, the method comprising administering to the subject a non-naturally occurring melanocortin analogue.

[0014] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues to maintain or increase muscle mass, fat mass, or heart mass in a subject before, during, and / or after administration of an anticancer agent.

[0015] In some embodiments, the subject experienced an increase in muscle mass, fat mass, or heart mass of at least about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% compared to baseline or control.

[0016] In some embodiments, the present invention includes a method for maintaining or increasing bone mineral density in a subject before, during, and / or after administration of an anticancer agent, the method comprising administering to the subject a non-naturally occurring melanocortin analogue.

[0017] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues to maintain or increase bone mineral density in subjects before, during, and / or after administration of anticancer agents.

[0018] In some embodiments, the subject experienced an increase in bone mineral density of at least about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% compared to baseline or control.

[0019] In some embodiments, the present invention includes a method for increasing or maintaining a subject’s Functional Assessment of Anorexia / Cachexia Therapy (FAACT) score before, during and / or after administration of an anticancer agent, the method comprising administering to the subject a non-natural melanocorticoid analogue.

[0020] In some embodiments, the present invention includes the use of non-naturally occurring melanocorticoid analogues to maintain or increase the functional assessment of anorexia / cachexia therapy (FAACT) scores of subjects before, during, and / or after administration of anticancer agents.

[0021] In some embodiments, the subject experiences an increase of at least 1, 2, 3, 4, or 5 points in the FAACT score compared to baseline or control.

[0022] In some embodiments, the present invention includes a method for stimulating the appetite of a subject or reducing loss of appetite induced by an anticancer agent in a subject, the method comprising administering to the subject a non-naturally occurring melanocortin analogue before, during and / or after administration of the anticancer agent.

[0023] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues to stimulate appetite in subjects or reduce anorexia induced by anticancer agents in subjects.

[0024] In some embodiments, the subject experienced an increased appetite compared to a baseline control, as measured by an increase in food intake of approximately 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1200, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000 or more calories.

[0025] In some embodiments, the present invention includes a method for preventing, reducing, or reversing weight loss induced by an anticancer agent in a subject, the method comprising administering a non-naturally occurring melanocortin analog to the subject before, during, and / or after administration of the anticancer agent.

[0026] In some embodiments, the present invention includes a method for treating, preventing, or reducing one or more side effects associated with an anticancer agent in a subject who is unresponsive to antiemetic treatment, the method comprising administering to the subject a non-naturally occurring melanocortin analogue before, during, and / or after administration of the anticancer agent, wherein the one or more side effects are selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

[0027] In some embodiments, the present invention includes a method for treating, preventing, or reducing one or more side effects associated with an anticancer agent in a subject who is unresponsive to a nutritional intervention, the method comprising administering to the subject a non-naturally occurring melanocortin analogue before, during, and / or after administration of the anticancer agent, wherein the one or more side effects are selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

[0028] In some embodiments, the present invention includes a method for preventing or reducing anticancer agent-induced side effects in a subject with cancer, the method comprising administering to the subject: the anticancer agent; and a non-naturally occurring melanocortin analogue.

[0029] In some embodiments, the present invention includes a method for treating, preventing, or reducing iatrogenic injury caused by an anticancer agent in a subject with cancer, the method comprising administering to the subject: the anticancer agent; and a non-naturally occurring melanocortin analogue.

[0030] In some embodiments, the present invention includes a method for reducing, maintaining, or improving the Eastern Cooperative Oncology Group (ECOG) and / or Karnofsky Performance Status (KPS) scores of a subject with cancer relative to baseline or control, the method comprising administering an anticancer agent and a non-naturally occurring melanocortin analogue to the subject.

[0031] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues for the prevention, reduction, or reversal of weight loss induced by anticancer agents in subjects.

[0032] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues for the treatment, prevention, or reduction of one or more side effects associated with anticancer agents in subjects unresponsive to antiemetic treatment, the one or more side effects being selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

[0033] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues for the treatment, prevention, or reduction of one or more side effects associated with anticancer agents in subjects who are unresponsive to nutritional interventions, the one or more side effects being selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

[0034] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues for the prevention or reduction of anticancer agent-induced side effects in subjects with cancer.

[0035] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues for the treatment, prevention, or reduction of iatrogenic injury caused by anticancer agents in subjects with cancer.

[0036] In some embodiments, the present invention includes the use of a non-naturally occurring melanocortin analogue, relative to a baseline or control, before, during, and / or after administration of an anticancer agent, to prevent a reduction, maintain, or improve the ECOG and / or KPS scores of subjects with cancer.

[0037] In some embodiments, the subject experienced a reduction of approximately 1, 2, or 3 in ECOG fitness scores compared to baseline or control.

[0038] In some embodiments, the subject experienced an increase in KPS score of approximately 100, 90, 80, 70, 60, 50, 40, or 30 compared to baseline or control.

[0039] In some embodiments, the present invention includes a method for reducing, maintaining, or improving overall survival (OS) or progression-free survival (PFS) relative to baseline or control in a subject with cancer, the method comprising administering an anticancer agent and a non-naturally occurring melanocortin analogue to the subject.

[0040] In some embodiments, the present invention includes the use of a non-naturally occurring melanocortin analogue, relative to a baseline or control, before, during, and / or after administration of an anticancer agent, to prevent a reduction, maintenance, or improvement of OS or PFS in subjects with cancer.

[0041] In some embodiments, the subject experienced an increase in OS or PFS of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

[0042] In some embodiments, the present invention includes a method for reducing the time to cancer treatment failure in a subject with cancer relative to a baseline or control, the method comprising administering an anticancer agent and a non-naturally occurring melanocorticoid analog to the subject.

[0043] In some embodiments, the present invention includes a method for increasing or maintaining a subject's body mass index (BMI) relative to a baseline or control, the method comprising administering an anticancer agent and a non-naturally occurring melanocorticoid analog to the subject.

[0044] In some embodiments, the present invention includes the use of a non-naturally occurring analogue, relative to a baseline or control, before, during, and / or after administration of an anticancer agent, to reduce the time to cancer treatment failure in subjects with cancer.

[0045] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues relative to baseline or control for increasing or maintaining a subject's BMI before, during, and / or after administration of an anticancer agent.

[0046] In some embodiments, the subject experienced a BMI increase of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 points compared to baseline or control.

[0047] In some embodiments, the subject experienced a sustained increase in BMI of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

[0048] In some embodiments, the present invention includes a method for reducing the levels of pro-inflammatory transcripts or proteins in a subject with cancer relative to a baseline or control, the method comprising administering an anticancer agent and a non-naturally occurring melanocortin analogue to the subject.

[0049] In some embodiments, the present invention includes the use of non-naturally occurring melanocortin analogues, relative to baseline or control, before, during, and / or after administration of an anticancer agent, to reduce the levels of pro-inflammatory transcripts or proteins in subjects with cancer.

[0050] In some embodiments, the subject experienced a reduction in inflammatory transcript levels of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

[0051] In some embodiments, the subject experienced a reduction in inflammatory protein levels of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

[0052] In some embodiments, the pro-inflammatory transcript is a transcript selected from the group consisting of: IL1 transcript, IL6 transcript, IL1R1 transcript, TNFα transcript, selectin P transcript, cytokine transcript, and chemokine transcript.

[0053] In some embodiments, the pro-inflammatory protein is a protein selected from the group consisting of: IL1 protein, IL6 protein, IL1R1 protein, TNFα protein, selectin P protein, cytokine protein, and chemokine protein.

[0054] In some embodiments, the method or use maintains or increases the subject's lean body mass, fat mass, and / or body weight relative to a baseline or control.

[0055] In some embodiments, the method or use maintains or increases the subject's lean body mass, fat mass, and / or body weight relative to a baseline or control.

[0056] In some embodiments, non-responsiveness to antiemetic treatment further includes insufficient clinical and / or therapeutic weight gain, muscle mass gain, fat mass gain, appetite gain, and / or food intake gain in the subject.

[0057] In some embodiments, the nutritional intervention further includes nutritional supplementation.

[0058] In some embodiments, iatrogenic injury is selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

[0059] In some embodiments, improvement, maintenance, or prevention of reduction in ECOG and / or KPS scores is achieved by inhibiting or reducing the subject's anorexia, weight loss, muscle mass loss, fat mass loss, emaciation, decreased appetite, and / or loss of appetite.

[0060] In some embodiments, the subject has cancer.

[0061] In some embodiments, the anticancer agent includes chemotherapy.

[0062] In some embodiments, the method or use reduces chemotherapy-induced weight loss and / or wasting in the subject, and increases the subject's lean body mass and body weight, relative to baseline or control.

[0063] In some embodiments, the method or use maintains or increases the subject's weight before, during, or after the administration of the chemotherapy, and wherein the method reduces the subject's weight loss and / or emaciation relative to a baseline or control.

[0064] In some embodiments, this anorexia is associated with weight loss.

[0065] In some embodiments, the subject has not previously received anticancer drugs.

[0066] In some embodiments, the subject has previously received anticancer drugs.

[0067] In some embodiments, the subject receives an anticancer agent.

[0068] In some embodiments, administration of the non-natural melanocortin analogue enhances tolerance to the anticancer agent.

[0069] In some embodiments, the enhanced tolerability relative to baseline or control results in a higher dose, increased frequency of administration, and / or longer duration of administration of the anticancer agent, wherein the baseline or control is the subject prior to administration of the non-naturally occurring melanocortin analogue and / or a subject currently receiving or having received the anticancer agent but not the non-naturally occurring melanocortin analogue.

[0070] In some embodiments, the anticancer agent includes a chemotherapy comprising at least two chemotherapeutic agents, and wherein enhanced tolerance leads to administration of a second chemotherapeutic agent to the subject during or after administration of the first chemotherapeutic agent.

[0071] In some embodiments, administration of the non-natural melanocorticoid analogue, relative to a baseline or control, prevents or reduces downward adjustments to the dosing regimen of the anticancer agent.

[0072] In some embodiments, the downward adjustment includes a reduced dose, a reduced frequency of administration, and / or a shortened duration of administration compared to a baseline or control, wherein the baseline or control is the subject prior to administration of the non-naturally occurring melanocortin analogue and / or a subject currently receiving or having received the anticancer agent but not the non-naturally occurring melanocortin analogue.

[0073] In some embodiments, subjects experienced loss of appetite, decreased appetite, reduced food consumption, and / or weight loss prior to administration of a non-naturally occurring melanocorticoid analogue.

[0074] In some embodiments, the loss of appetite, decreased appetite, reduced food consumption, and / or weight loss are caused by cancer.

[0075] In some embodiments, the loss of appetite, decreased appetite, reduced food consumption, and / or weight loss are caused by anticancer agents.

[0076] In some embodiments, the subject is receiving or has received antinausea medication.

[0077] In some embodiments, the antiemetic is cannabis, medroxyprogesterone acetate, growth hormone, or dronabinol.

[0078] In some embodiments, the non-natural melanocortin analogue and the anticancer agent are administered in parallel.

[0079] In some embodiments, the non-natural melanocortin analogue is applied before and / or after the application of the anticancer agent.

[0080] In some embodiments, the administration of this non-natural melanocortin analogue treats, prevents, or reduces one or more side effects associated with anticancer agents in a subject.

[0081] In some embodiments, relative to baseline or control, administration of the non-naturally occurring melanocortin analogue maintains or increases the subject's weight by preventing or reducing anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, and / or loss of appetite.

[0082] In some embodiments, relative to baseline or control, administration of the non-naturally occurring melanocortin analogue maintains or increases the subject’s weight by preventing or reducing one or more side effects selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

[0083] In some embodiments, relative to baseline or control, administration of the non-naturally occurring melanocortin analogue stimulates the subject's appetite or reduces the subject's anorexia induced by the anticancer agent.

[0084] In some embodiments, relative to baseline or control, administration of the non-naturally occurring melanocortin analogue prevents, reduces, or reverses the subject's anticancer agent-induced weight loss.

[0085] In some embodiments, relative to a baseline or control, the non-naturally occurring melanocorticoid analogue is administered to treat, prevent, or reduce one or more side effects in subjects who are clinically and / or therapeutically unresponsive to antiemetic treatment.

[0086] In some embodiments, relative to a baseline or control, the non-naturally occurring melanocorticoid analogue is administered to treat, prevent, or reduce one or more side effects in subjects who are clinically and / or therapeutically unresponsive to nutritional interventions.

[0087] In some embodiments, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue prevents or reduces the subject's anticancer agent-induced side effects.

[0088] In some embodiments, the non-naturally occurring melanocorticoid analogue is administered to treat, prevent, or reduce the iatrogenic injury caused by the anticancer agent in the subject, relative to a baseline or control.

[0089] In some embodiments, relative to baseline or control, administration of the non-naturally occurring melanocorticoid analogue prevents, maintains, or improves the subject's ECOG and / or KPS scores.

[0090] In some embodiments, prior to administration of the non-natural melanocorticoid analogue and / or the anticancer agent, the subject’s weight and / or body mass decreased by no more than 5% relative to baseline.

[0091] In some embodiments, prior to administration of the non-natural melanocorticoid analogue and / or the anticancer agent, the subject’s mass and / or weight reduction relative to baseline does not exceed 10%.

[0092] In some embodiments, the subject’s ECOG score was 1 or higher prior to administration of the non-natural melanocorticoid analog and / or the anticancer agent.

[0093] In some embodiments, the subject’s ECOG score was 2 or higher prior to administration of the non-natural melanocorticoid analog and / or the anticancer agent.

[0094] In some embodiments, the method reduces the subject's ECOG scale relative to baseline or control.

[0095] In some embodiments, the subject’s KPS score does not exceed 70 prior to administration of the non-natural melanocorticoid analog and / or the anticancer agent.

[0096] In some embodiments, the subject’s KPS score does not exceed 50 prior to administration of the non-natural melanocorticoid analog and / or the anticancer agent.

[0097] In some embodiments, the method or use increases the cumulative mass of the subject relative to a baseline or control.

[0098] In some embodiments, the method or use reduces the subject's cumulative quality loss rate relative to a baseline or control.

[0099] In some embodiments, the method or use increases the subject's net weight gain relative to a baseline or control.

[0100] In some embodiments, the net weight gain is the weight change between two or more time points.

[0101] In some embodiments, the net weight gain is the weight change between the start and end of treatment with the non-naturally occurring melanocorticoid analog or the anticancer agent.

[0102] In some embodiments, the two or more time points include an intermediate time point.

[0103] In some embodiments, the method or use increases the subject’s cumulative food intake relative to a baseline or control.

[0104] In some embodiments, the cumulative food intake is the total food intake between two or more time points.

[0105] In some embodiments, the cumulative food intake is the cumulative food intake between the start and end of treatment with the non-natural melanocorticoid analogue or the anticancer agent.

[0106] In some embodiments, the two or more time points include an intermediate time point.

[0107] In some embodiments, the method or use increases the subject's BMI relative to a baseline or control.

[0108] In some embodiments, the increase in BMI is a change in BMI between two or more time points.

[0109] In some embodiments, the increase in BMI is the change in BMI between the start and end of treatment with the non-naturally occurring melanocorticoid analog or the anticancer agent.

[0110] In some embodiments, the two or more time points include an intermediate time point.

[0111] In some embodiments, the non-natural melanocortin analogue is administered to the subject based on the subject's BMI at the time of administration.

[0112] In some embodiments, the non-natural melanocortin analogue is administered to the subject in two or more doses based on the subject's BMI at the time of each administration.

[0113] In some embodiments, the two or more doses are adjusted in reverse based on the subject’s BMI at the time of each administration.

[0114] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence according to formula (I), X 1 X 2 X 3 R 1 R 2 R 3 R 4 R 5 R 6 R 7 R 8 R 9 R 10 R 11 R 12 R13 R 14 R 15 R 16 R 17 R 18 R 19 R 20 Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 (I) in: R 1 The group consisting of the following items is absent or selected: cysteine, norepinephrine (Nle), acetylated norepinephrine (Ac-Nle). trans -4-guanidino-proline ( trans Pro(guan)), Cis -4-guanidino-proline ( Cis Pro(guan)), acetylation trans -4-Guidino-proline (Ac- trans Pro(guan)), acetylation Cis -4-Guidino-proline (Ac- Cis Pro(guan)), tyrosine, D-tyrosine, dimethyltyrosine (Dmt), aspartic acid, glutaric acid, leucine, isoleucine, valine, normal valine (Nva), alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, asparagine, and acetylated glutamic acid; R 2 The group consisting of the following items is absent or selected: proline, histidine, D-hydroxyproline (dHyp). trans Pro(guan), Cis Pro(guan), aspartic acid, glutamic acid, glycine, lysine, alanine, D-alanine, cysteine, leucine, arginine, succinic acid, glutaric acid, methionine, and phenylalanine; R 3 The following groups are not present or are selected: histidine, L-proline, trans Pro(guan), CisPro(guan), D-valine, glutamic acid, tryptophanyl arginine (Trp-Arg), glycine, D-leucine, D-isoleucine, tryptophan, arginine, 4-amino-1,2,4,5-tetrahydro-2-benzozazepine-3-one (Aba), 7-amino-7,8-dihydro-4H-(1,2,3)triazol-(1,5-a)(1,4)diazepine-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydroazazepine (4,3) -b Indole-3 ( 2H )-ketone (Aia), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), and indoline-2-carboxylic acid (Ioc). R 4 Select the group consisting of the following: histidine, D-phenylalanine, L-phenylalanine, D-Nal(2'), aspartic acid, dBip, glycine, proline, cysteine, p-chloro-D-phenylalanine (p(Cl)dPhe), p-iodo-D-phenylalanine (p(I)dPhe), p-fluoro-D-phenylalanine (p(F)dPhe), and p-trifluoromethyl-D-phenylalanine (p(CF3)dPhe); R 5 The following groups are not present or are selected: arginine, high arginine, proline, trans Pro(guan), Cis Pro(guan), Pip, Nip, Tic, Phg, Sar, Azt, phenylalanine, D-Nal(2'), D-histidine, D-alanine, D-aspartic acid, D-glutamic acid, cysteine ​​and p(I)dPhe; R 6 The group consisting of the following items is absent or selected: L-tryptophan, D-phenylalanine, D-Nal(2'), L-Nal(2'), Tic, Bip, arginine, D-histidine, cysteine, D-Nal(1'), Aba, Ata, D-tyrosine, Pen, dPen and D-alanine; R 7 The following groups are not present or are selected: glycine, aspartic acid, glutamic acid, cysteine, lysine, ornithine, 2,3-diamino-propionic acid (Dap), methionine, proline, tryptophan, D-Nal(2') and tetrahydro-isoquinoline-3-carboxylic acid (Tic). R 8 It may be absent or contain lysine; R 9 To R 20 It does not exist; X 1The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, D-alanine, L-alanine, β-alanine, D-arginine, L-arginine, D-valine, L-valine, D-leucine, L-leucine, D-isoleucine, L-isoleucine, n-valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, acetylated D-arginine, acetylated L-arginine, acetylated D-valine, and acetylated n-leucine; X 2 It may be absent or contain D-proline; X 3 It does not exist; Y 1 The group consisting of the following is absent or selected: D-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and D-proline; Y 2 The group consisting of the following is absent or selected: D-proline, L-proline, Hyp, D-valine, L-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and glycine; Y 3 The group consisting of the following is absent or selected: D-lysine, L-lysine, D-proline, L-proline, D-valine, and L-valine; Y 4 It is absent or is either D-aspartic acid or aspartic acid; Y 5 To Y 8 It does not exist; This non-natural melanocortin analogue is optionally cyclized via a portion selected from the group consisting of: When R 1 For cysteine ​​and R 7 When it is cysteine, R 1 With R 7 disulfide bonds between them; When R 1 It is leucine and R 7 When it is glutamic acid, R 1 With R 7 The lactam bridge between them; When R 1 Or R 2 It is glutamic acid or aspartic acid and R 7 When it is lysine, Dap, or ornithine, R 1 Or R 2 With R 7 Side-chain lactam bridges between them; When R 2 For lysine and R7 When it is glutamic acid or aspartic acid, R 2 With R 7 Side-chain lactam bridges between them; When R 1 Or R 2 It is either glutamic acid or aspartic acid, R 8 For lysine and R 7 When it is proline, glycine, or tryptophan, R 1 Or R 2 With R 8 Side-chain lactam bridges between them; The conditions are: When R 2 When it is dAsp, then R 7 Not for dLys; When R 2 To R 4 When R is Asp-His-dNal(2'), Asp-Pro-dNal(2'), or Asp-Pro-dPhe, then 5 To R 7 Not Arg-Trp-Lys; When Y 1 For dPro, Y 2 For dVal and Y 3 To Y 8 If it does not exist, then R 4 Not dNal(2') or R 4 It is dNal(2') and the C-terminus is not modified; When R 3 For Aba, Ata, or Aia, R 6 For Aia, or R 7 When it is Orn, then R 4 Not dNal(2'), or R 4 For dNal(2') and R 5 Not for Arg; When R 4 When R is p(Cl)dPhe, then 3 Not Pro or His; When R 4 When the value is p(I)dPhe, this non-natural melanocortin analogue is obtained through R. 1 With R 7 The side-chain lactam bridged cyclization between them, and R 2 and R 3 At least one of them is Pro; When Y 2 To Y 4 If it does not exist, then Y 1It is absent or contains ortholeucine; When R 2 For Pro or Y 2 When it is Hyp, then R 3 Not for Pro; When R 3 R 5 Or R 6 If it does not exist, then this non-natural melanocortin analogue is obtained through R. 1 With R 7 The cyclization of lactams between them, or X 1 To X 2 It exists and is Ac-dVal-dPro; When R 2 To R 7 When it is Asp-Pro-dNal(2')-Arg-Trp-Lys (SEQ ID NO: 526) or Cys-Pro-dNal(2')-Arg-Trp-Cys (SEQ ID NO: 527), then R 1 Not Ac-Nle or Y 1 To Y 2 Not dVal-dPro, dVal-dVal, or dPro-dPro; and When this non-natural melanocortin analogue is administered via R 2 With R 8 When the lactam bridge between them is cyclized, then R 3 Not His or Y 1 Not dVal.

[0115] In some embodiments, the non-natural melanocortin analogue contains the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2.

[0116] In some embodiments, the chemotherapy includes at least one chemotherapeutic agent.

[0117] In some embodiments, the at least one chemotherapeutic agent includes one or more chemotherapeutic agents selected from the group consisting of platinum coordination complexes, antimetabolites, tubulin binders or plant alkaloids, alkylated antitumor agents and cytotoxic antibiotics.

[0118] In some embodiments, the at least one chemotherapeutic agent comprises a platinum coordination complex.

[0119] In some embodiments, the at least one chemotherapeutic agent comprises an antimetabolite.

[0120] In some embodiments, the at least one chemotherapeutic agent comprises a tubulin binder or a plant alkaloid.

[0121] In some embodiments, at least one chemotherapeutic agent includes an alkylated antitumor agent.

[0122] In some embodiments, at least one chemotherapeutic agent includes a cytotoxic antibiotic.

[0123] In some embodiments, the platinum coordination complex is carboplatin and / or cisplatin.

[0124] In some embodiments, the antimetabolite is at least one selected from the group consisting of: 5-fluorouracil (5-FU), 6-mercaptopurine, azacitidine, capecitabine, flufarabine, cytarabine, fluorouridine, fludarabine, gemcitabine, methotrexate, pemetrexed, pentostatin, pralatrexate, trifluorouridine, and tipyrimidine.

[0125] In some embodiments, the tubulin binder or plant alkaloid is at least one selected from the group consisting of: vincristine, vinblastine, vinorelbine, paclitaxel, docetaxel, etoposide, teniposide, irinotecan, and topotecan.

[0126] In some embodiments, the alkylated antitumor agent is at least one selected from the group consisting of: hexamethylmelamine, busulfan, carmustine, cyclophosphamide, dacarbazine, ifosfamide, lomustine, melphalan, temozolomide, and trabectedin.

[0127] In some embodiments, the cytotoxic antibiotic is at least one selected from the group consisting of: doxorubicin, doxorubicin, liposomal doxorubicin, epirubicin, idarubicin, and pentorubicin.

[0128] In some embodiments, the platinum coordination complex is cisplatin.

[0129] In some embodiments, the antimetabolite is 5-fluorouracil (5-FU).

[0130] In some embodiments, the tubulin binder or the plant alkaloid is vincristine.

[0131] In some embodiments, the alkylated antitumor agent is cyclophosphamide.

[0132] In some embodiments, the cancer is at least one selected from the group consisting of: bone cancer, testicular cancer, gastric cancer, sarcoma, lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, head and neck cancer, squamous cell head and neck cancer, thymic cancer, epithelial cancer, salivary gland cancer, liver cancer, gastric cancer, thyroid cancer, lung cancer, ovarian cancer, breast cancer, prostate cancer, esophageal cancer, pancreatic cancer, glioma, leukemia, multiple myeloma, renal cell carcinoma, bladder cancer, cervical cancer, choriocarcinoma, colorectal cancer, oral cancer, skin cancer, and melanoma.

[0133] In some embodiments, the cancer is at least one selected from the group consisting of: bone cancer, lung cancer, testicular cancer, breast cancer, prostate cancer, colorectal cancer, non-Hodgkin's lymphoma, ovarian cancer, cervical cancer, bladder cancer, and head and neck cancer.

[0134] In some embodiments, the cancer is breast cancer, and the anticancer agent is at least one selected from the group consisting of: anthracyclines, cyclophosphamide, epirubicin, fluorouracil, methotrexate, taxane, and docetaxel.

[0135] In some embodiments, the anthracycline is doxorubicin.

[0136] In some embodiments, the taxane is paclitaxel.

[0137] In some embodiments, the cancer is lung cancer, and the anticancer agent is at least one selected from the group consisting of: cisplatin, carboplatin, paclitaxel, albumin-bound paclitaxel, docetaxel, gemcitabine, vinorelbine, etoposide, and pemetrexed.

[0138] In some embodiments, the cancer is prostate cancer, and the anticancer agent is at least one selected from the group consisting of: docetaxel, cabazitaxel, mitoxantrone, and estradiol.

[0139] In some embodiments, the cancer is colorectal cancer, and the anticancer agent is at least one selected from the group consisting of: 5-FU, capecitabine, irinotecan, oxaliplatin, trifluorouridine, and tipyrimidine.

[0140] In some embodiments, the cancer is colorectal cancer, the subject receives radiation therapy, and the chemotherapy is at least one of the following: cisplatin, cisplatin plus 5-FU, and mitomycin plus 5-FU.

[0141] In some embodiments, the cancer is colorectal cancer, the subject is not receiving radiation therapy, and the chemotherapy is at least one of the following: gemcitabine plus cisplatin, methotrexate, vincristine, doxorubicin plus cisplatin, cisplatin, methotrexate plus vincristine, and gemcitabine plus paclitaxel.

[0142] In some embodiments, the cancer is melanoma, and the anticancer agent is dacarbazine and / or temozolomide.

[0143] In some embodiments, the cancer is non-Hodgkin's lymphoma, and the anticancer agent is at least one selected from the group consisting of: cyclophosphamide, chlorambucil, bendamustine, ifosfamide, prednisone, dexamethasone, cisplatin, carboplatin, oxaliplatin, fludarabine, pentostatin, cladribine (2-CdA), cytarabine (ara-C), gemcitabine, methotrexate, pralatrexate, doxorubicin, liposomal doxorubicin, hydroxydaunorubicin, vincristine, mitoxantrone, etoposide, and bleomycin.

[0144] In some embodiments, the method or use does not reduce the efficacy of the anticancer agent.

[0145] In some embodiments, the subject with cancer has previously undergone treatment with the anticancer agent.

[0146] In some embodiments, the subject has previously experienced one or more adverse side effects while being treated with the anticancer agent, wherein the adverse side effects are selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, and decreased or absent appetite.

[0147] In some embodiments, the subject is a human being.

[0148] In some embodiments, the subjects are animals.

[0149] In some embodiments, the muscle mass loss is cardiac muscle mass loss, skeletal muscle mass loss, or both.

[0150] In some embodiments, the loss of myocardial mass is determined by measuring changes in heart weight.

[0151] In some embodiments, the loss of skeletal muscle mass is determined by measuring changes in the weight of the gastrocnemius muscle tissue.

[0152] In some embodiments, anorexia is determined by daily food intake, daily food consumption, and / or weekly food intake.

[0153] In some embodiments, the daily food intake is determined by the total calories (kcal) consumed in a day or the mass (grams or kilograms) of food consumed in a day.

[0154] In some embodiments, the daily food consumption is determined by the daily food intake normalized relative to the subject's daily body weight.

[0155] In some embodiments, the weekly food intake is determined by the total calories (kcal) consumed per day or the mass (grams or kilograms) of food consumed per week.

[0156] In some embodiments, the weight loss is determined by daily weight and / or daily weight gain.

[0157] In some embodiments, the subject treated with the method has a fat mass that is at least 10% to 100% greater than the baseline or control, and the baseline or control is the subject before administration of the non-naturally occurring melanocortin analogue and / or the subject who is receiving or has received the anticancer agent but has not received the non-naturally occurring melanocortin analogue.

[0158] In some embodiments, the heart weight of the subject treated with the method is at least 0.1% to 10% larger than that of the baseline or control, and the baseline or control is the subject before administration of the non-naturally occurring melanocortin analogue and / or the subject who is receiving or has received the anticancer agent but has not received the non-naturally occurring melanocortin analogue.

[0159] In some embodiments, the weight of the gastrocnemius muscle tissue in the subject treated by the method is at least 0.1% to 10% greater than that of the baseline or control, and the baseline or control is the subject before administration of the non-naturally occurring melanocortin analogue and / or the subject who is receiving or has received the anticancer agent but has not received the non-naturally occurring melanocortin analogue.

[0160] In some embodiments, the daily food intake of the subject treated by the method is at least 5% to 50% greater than that of the baseline or control, and the baseline or control is the subject before administration of the non-naturally occurring melanocortin analogue and / or the subject who is receiving or has received the anticancer agent but has not received the non-naturally occurring melanocortin analogue.

[0161] In some embodiments, after administration of the non-natural melanocortin analogue, the subject’s appetite increased by at least 10% to 200%.

[0162] In some embodiments, after administration of the non-natural melanocortin analogue, the subject’s appetite increased by at least 25% to 100%.

[0163] In some embodiments, appetite increases for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years during the period of administration.

[0164] In some embodiments, during the administration period, appetite increases for at least 1 day, 5 days, 7 days, 14 days, 21 days, 28 days, 35 days, 40 days, 45 days, 50 days, 60 days, 75 days, 90 days, 100 days, 110 days, or 120 days.

[0165] In some embodiments, the increased appetite is maintained for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 3 months, 6 months, 1 year, or 5 years after discontinuation of administration.

[0166] In some embodiments, appetite is assessed using a scale that measures food cravings, hunger, and / or satiety.

[0167] In some embodiments, the appetite is assessed between meals.

[0168] In some embodiments, the subject includes two or more subjects, and the appetite is the average appetite of the two or more subjects.

[0169] In some embodiments, anorexia is determined by food consumption.

[0170] In some embodiments, the non-natural melanocortin analogue is present in the pharmaceutical composition.

[0171] In some embodiments, the pharmaceutical composition further comprises a pharmaceutical salt.

[0172] In some embodiments, the pharmaceutical composition further comprises a pharmaceutical carrier.

[0173] In some embodiments, the non-naturally occurring melanocorticoid analogue is present in the pharmaceutical composition at a concentration of 0.1 mg / mL to 500 mg / mL relative to the total volume of the pharmaceutical composition.

[0174] In some embodiments, the non-naturally occurring melanocorticoid analogue is present in the pharmaceutical composition at a concentration of about 50 mg / mL relative to the total volume of the pharmaceutical composition.

[0175] In some embodiments, the non-natural melanocorticoid analogue is administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intravenous, intranasal, or oral administration.

[0176] In some embodiments, the pharmaceutical composition comprising the non-naturally occurring melanocorticoid analogue is administered parenterally to the subject.

[0177] In some embodiments, the pharmaceutical composition comprising the non-naturally occurring melanocortin analogue is administered subcutaneously to the subject.

[0178] In some embodiments, the non-natural melanocortin analog crosses the subject's blood-brain barrier.

[0179] In some embodiments, the pharmaceutical carrier comprises water.

[0180] In some embodiments, the non-natural melanocortin analogue is administered to the subject before or after a meal.

[0181] In some embodiments, the non-natural melanocortin analogue is administered to the subject with a meal.

[0182] In some embodiments, a therapeutically effective amount of the non-naturally occurring melanocortin analogue is administered, wherein the therapeutically effective amount of the non-naturally occurring melanocortin analogue is from 0.001 mg / kg to 25 mg / kg, depending on the subject's weight.

[0183] In some embodiments, the therapeutically effective dose of the non-naturally occurring melanocortin analogue is 0.5 mg / kg to 10 mg / kg, depending on the subject's weight.

[0184] In some embodiments, the non-natural melanocorticoid analogue is administered at least once daily in an amount ranging from 0.001 mg / kg to 25 mg / kg, depending on the subject's weight.

[0185] In some embodiments, the non-natural melanocorticoid analogue is administered at least once daily in an amount ranging from about 0.5 mg / kg to about 10 mg / kg, depending on the subject's weight.

[0186] In some embodiments, the non-natural melanocortin analogue is administered to the subject for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

[0187] In some embodiments, the non-natural melanocortin analogue is administered to the subject for 1, 5, 7, 14, 21, 28, 35, 40, 45, 50, 60, 75, 90, 100, 110, or 120 days.

[0188] In some embodiments, the anticancer agent and the non-natural melanocorticoid analogue are administered simultaneously as a single composition.

[0189] In some embodiments, the non-naturally occurring melanocortin analogue is present in the single composition at a concentration of 0.1 mg / mL to 500 mg / mL relative to the total volume of the single composition.

[0190] In some embodiments, the non-naturally occurring melanocortin analogue is present in the single composition at a concentration of about 10 mg / mL, about 20 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, or about 60 mg / mL relative to the total volume of the single composition.

[0191] In some embodiments, the non-naturally occurring melanocortin analogue is present in the single composition at a concentration of about 50 mg / mL relative to the total volume of the single composition.

[0192] In some embodiments, the non-natural melanocorticoid analogue is present in the single composition at a dose of about 5 mg to about 500 mg in a dose volume of about 1 mL to 20 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

[0193] In some embodiments, the non-natural melanocorticoid analogue is present in the single composition at a dose of about 50 mg to about 100 mg in a dose volume of about 2 mL to 10 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

[0194] In some embodiments, the non-natural melanocorticoid analogue is present in the single composition at a dose of about 75 mg in a dose volume of about 5 mL, and the application is performed once, twice, three times, four times, five times, or ten times daily.

[0195] In some embodiments, the application is performed once daily.

[0196] In some embodiments, the anticancer agent is present in a first pharmaceutical composition; and the non-natural melanocortin analog is present in a second pharmaceutical composition.

[0197] In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are different and are administered sequentially.

[0198] In some embodiments, the first pharmaceutical composition and the second pharmaceutical composition are different and are administered simultaneously but separately.

[0199] In some embodiments, the second pharmaceutical composition is administered subcutaneously.

[0200] In some embodiments, the anticancer agent comprises chemotherapy, and the chemotherapy is present in the first pharmaceutical composition at a concentration of 0.001 mg / mL to 1,000 mg / mL relative to the total volume of the first pharmaceutical composition.

[0201] In some embodiments, the non-naturally occurring melanocorticoid analogue is present in the second pharmaceutical composition at a concentration of 0.1 mg / mL to 500 mg / mL relative to the total volume of the second pharmaceutical composition.

[0202] In some embodiments, the non-naturally occurring melanocorticoid analogue is present in the second pharmaceutical composition at a concentration of about 10 mg / mL, about 20 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, or about 60 mg / mL relative to the total volume of the second pharmaceutical composition.

[0203] In some embodiments, the non-naturally occurring melanocorticoid analogue is present in the second pharmaceutical composition at a concentration of about 50 mg / mL relative to the total volume of the second pharmaceutical composition.

[0204] In some embodiments, the non-natural melanocorticoid analogue is present in the second pharmaceutical composition at a dose of about 5 mg to about 500 mg in a dose volume of about 1 mL to 20 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

[0205] In some embodiments, the non-natural melanocorticoid analogue is present in the second pharmaceutical composition at a dose of about 50 mg to about 100 mg in a dose volume of about 2 mL to 10 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

[0206] In some embodiments, the non-natural melanocorticoid analogue is present in the second pharmaceutical composition at a dose of about 75 mg in a dose volume of about 5 mL, and the administration is performed once, twice, three times, four times, five times, or ten times daily. Attached Figure Description

[0207] Figure 1A This is a graph depicting the daily food intake of Sprague Dawley rats in a chemotherapy dose-response study. The graph compares the daily food intake of rats treated with saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5) for 21 consecutive days. Following the second cycle of chemotherapy, death was observed in rats treated with high doses of cisplatin (Group 3, 5 mg / kg / week cisplatin) or 5-FU (Group 5, 125 mg / kg / week 5-FU). Therefore, the third cycle of chemotherapy was discontinued to ensure survival in the two high-dose groups.

[0208] Figure 1B This is a graph depicting the daily food consumption of Sprague Dawley rats in a chemotherapy dose-response study. The graph compares the daily food consumption (i.e., daily food intake normalized relative to daily body weight) of rats treated for 21 days with saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5). Following the second cycle of chemotherapy, death was observed in rats treated with high doses of cisplatin (Group 3, 5 mg / kg / week cisplatin) or 5-FU (Group 5, 125 mg / kg / week 5-FU). Therefore, the third cycle of chemotherapy was discontinued to ensure survival in the two high-dose groups.

[0209] Figure 1C This is a graph depicting the daily body weight of Sprague Dawley rats in a chemotherapy dose-response study. The graph compares the daily body weight of rats treated for 21 days with saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5). Following the second cycle of chemotherapy, death was observed in rats treated with high doses of cisplatin (Group 3, 5 mg / kg / week cisplatin) or 5-FU (Group 5, 125 mg / kg / week 5-FU). Therefore, the third cycle of chemotherapy was discontinued to ensure survival in the two high-dose groups.

[0210] Figure 1D This is a graph depicting the daily weight gain in Sprague Dawley rats in a chemotherapy dose-response study. The graph compares the daily weight gain (initial %) of rats treated with saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5) for 21 consecutive days. Following the second cycle of chemotherapy, death was observed in rats treated with high doses of cisplatin (Group 3, 5 mg / kg / week cisplatin) or 5-FU (Group 5, 125 mg / kg / week 5-FU). Therefore, the third cycle of chemotherapy was discontinued to ensure survival in the two high-dose groups.

[0211] Figure 2AThis is a graph depicting the locomotor activity of Sprague Dawley rats during the dark period in a chemotherapy dose-response study. The graph compares the locomotor activity of rats administered saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5) for 21 consecutive days during the dark period. Locomotor activity was monitored from 5 days prior to administration until 21 days after the initial dose. Following the second cycle of chemotherapy, death was observed in rats treated with high doses of cisplatin (Group 3, 5 mg / kg / week cisplatin) or 5-FU (Group 5, 125 mg / kg / week 5-FU). Therefore, the third cycle of chemotherapy was discontinued to ensure survival in the two high-dose groups.

[0212] Figure 2B This is a graph depicting the photoperiodic kinetic activity of Sprague Dawley rats in a chemotherapy dose-response study. The graph compares the photoperiodic kinetic activity of rats administered saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5) for 21 consecutive days. Photoperiodic kinetic activity was monitored from 5 days before administration until 21 days after the initial dose. Following the second cycle of chemotherapy, death was observed in rats treated with high doses of cisplatin (Group 3, 5 mg / kg / week cisplatin) or 5-FU (Group 5, 125 mg / kg / week 5-FU). Therefore, the third cycle of chemotherapy was discontinued to ensure survival in the two high-dose groups.

[0213] Figure 2C This is a graph depicting the motor activity (baseline %) during the dark period in Sprague Dawley rats in a chemotherapy dose-response study. The graph compares the motor activity (baseline %) during the dark period in rats administered saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5) for 21 consecutive days. Motor activity during the dark period was monitored from 5 days before administration until 21 days after the initial dose. Following the second cycle of chemotherapy, death was observed in rats treated with high doses of cisplatin (Group 3, 5 mg / kg / week cisplatin) or 5-FU (Group 5, 125 mg / kg / week 5-FU). Therefore, the third cycle of chemotherapy was discontinued to ensure survival in the two high-dose groups.

[0214] Figure 2DThis is a graph depicting the photoperiodic motor activity (baseline %) of Sprague Dawley rats in a chemotherapy dose-response study. The graph compares the photoperiodic motor activity (baseline %) of rats administered saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5) for 21 consecutive days. Photoperiodic motor activity was monitored from 5 days prior to administration until 21 days after the initial dose. Following the second cycle of chemotherapy, death was observed in rats treated with high doses of cisplatin (Group 3, 5 mg / kg / week cisplatin) or 5-FU (Group 5, 125 mg / kg / week 5-FU). Therefore, the third cycle of chemotherapy was discontinued to ensure survival in the two high-dose groups.

[0215] Figure 3 This is a bar chart depicting changes in fat mass, lean body mass, and total water content in Sprague Dawley rats following a chemotherapy dose-response study. The chart compares changes in fat mass, lean body mass, and total water content in rats after 21 days of treatment with saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5), respectively.

[0216] Figure 4 This is a bar chart showing serum GDF-15 (growth differentiation factor-15) concentrations in Sprague Dawley rats after a dose-response study of chemotherapy. The chart compares serum GDF-15 concentrations in rats after 21 days of treatment with saline (Group 1), 2.5 mg / kg / week cisplatin (Group 2), 5 mg / kg / week cisplatin (Group 3), 62.5 mg / kg / week 5-FU (Group 4), and 125 mg / kg / week 5-FU (Group 5), respectively.

[0217] Figure 5 This is a diagram illustrating the research design of one or more compositions using the technology of this invention.

[0218] Figure 6A This is a graph showing the daily food intake of Sprague Dawley rats in a combination therapy study. The graph compares the daily food intake of rats treated with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001 <.0001.

[0219] Figure 6B This is a graph showing the daily food intake of Sprague Dawley rats in a combination therapy study. The graph compares the daily food intake of rats treated with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0220] Figure 6C This is a graph depicting the daily food consumption of Sprague Dawley rats in a combination therapy study. The graph compares the daily food consumption (i.e., daily food intake normalized relative to daily body weight) of rats treated for 21 days with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3). The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0221] Figure 6DThis figure depicts the daily food consumption of Sprague Dawley rats in a combination therapy study. The figure compares the daily food consumption (i.e., daily food intake normalized relative to daily body weight) of rats treated with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0222] Figure 7A This is a graph showing the cumulative food intake of Sprague Dawley rats in a combination therapy study. The graph compares the cumulative food intake of rats treated with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0223] Figure 7B This is a graph showing the cumulative food intake of Sprague Dawley rats in a combination therapy study. The graph compares the cumulative food intake of rats treated with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0224] Figure 7C This is a graph showing the weekly food intake of Sprague Dawley rats in a combination therapy study. The graph compares the weekly food intake of rats treated with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 21 days.

[0225] Figure 7D This is a graph showing the weekly food intake of Sprague Dawley rats in a combination therapy study. The graph compares the weekly food intake of rats treated with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3) for 21 consecutive days.

[0226] Figure 8A This is a graph showing the daily food intake of Sprague Dawley rats in a combination therapy study. The graph compares the daily food intake of rats treated with 65 mg / kg / week cyclophosphamide plus saline (Group 1), 65 mg / kg / week cyclophosphamide plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0227] Figure 8B This is a graph showing the cumulative food intake of Sprague Dawley rats in a combination therapy study. The graph compares the cumulative food intake of rats treated with 65 mg / kg / week cyclophosphamide plus saline (Group 1), 65 mg / kg / week cyclophosphamide plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0228] Figure 9A This is a graph showing the daily food intake of Sprague Dawley rats in a combination therapy study. The graph compares the daily food intake of rats treated with 0.27 mg / kg / week vincristine plus saline (Group 1), 0.27 mg / kg / week vincristine plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0229] Figure 9B This is a graph showing the cumulative food intake of Sprague Dawley rats in a combination therapy study. The graph compares the cumulative food intake of rats treated with 0.27 mg / kg / week vincristine plus saline (Group 1), 0.27 mg / kg / week vincristine plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0230] Figure 10AThis is a graph showing the daily food intake of Sprague Dawley rats in a combination therapy study. The graph compares the daily food intake of rats administered cisplatin, saline, and IgG (Group 1); cisplatin plus saline plus an anti-GDF-15 monoclonal antibody (mAb) containing the Fab region of human ponsegromab (Group 2); and cisplatin plus 3 mg / kg / day TCMCB07 plus anti-GDF-15 mAb (Group 3). Cisplatin was administered at 5 mg / kg on day 0, 3 mg / kg on day 7, and 3 mg / kg on day 14. The significance threshold was [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0231] Figure 10B This is a graph depicting the weekly food intake of Sprague Dawley rats in a combination therapy study. The graph compares the weekly food intake of rats treated with cisplatin plus saline plus IgG (IgG (Group 1)), cisplatin plus saline plus anti-GDF-15 mAb (Group 2), and cisplatin plus 3 mg / kg / day TCMCB07 plus GDF15 and anti-GDF-15 mAb (Group 3). Cisplatin was administered at 5 mg / kg on day 0, 3 mg / kg on day 7, and 3 mg / kg on day 14. The significance threshold was [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0232] Figure 10C This is a graph showing the cumulative food intake of Sprague Dawley rats in a combination therapy study. The graph compares the cumulative food intake of rats treated with cisplatin plus saline plus IgG (Group 1), cisplatin plus saline plus anti-GDF-15 mAb (Group 2), and cisplatin plus 3 mg / kg / day TCMCB07 plus anti-GDF-15 mAb (Group 3). Cisplatin was administered at 5 mg / kg on day 0, 3 mg / kg on day 7, and 3 mg / kg on day 14. The significance threshold was [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0233] Figure 10D This graph depicts the total food intake of Sprague Dawley rats in a combination therapy study over 21 days. The graph compares the total food intake of rats treated with cisplatin plus saline plus IgG (Group 1), cisplatin plus saline plus anti-GDF-15 mAb (Group 2), and cisplatin plus 3 mg / kg / day TCMCB07 plus anti-GDF-15 mAb (Group 3). Cisplatin was administered at 5 mg / kg on day 0, 3 mg / kg on day 7, and 3 mg / kg on day 14. The significance threshold was [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0234] Figure 11A This is a graph showing the daily body weight of Sprague Dawley rats in a combination therapy study. The graph compares the daily body weight of rats treated with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0235] Figure 11BThis is a graph showing the daily body weight of Sprague Dawley rats in a combination therapy study. The graph compares the daily body weight of rats treated with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0236] Figure 11C This is a graph showing the daily weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the daily weight gain (initial %) of rats treated with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 21 days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0237] Figure 11D This is a graph showing the daily weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the daily weight gain (initial %) of rats treated with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3) for 21 days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0238] Figure 11E This is a graph showing the daily body weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the daily body weight gain (day 0%) in rats treated with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3). Daily body weight gain from day -10 to day 21 is shown, where day 0 indicates the start of cisplatin administration. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0239] Figure 12A This is a graph showing the cumulative weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the cumulative weight gain (initial %) of rats treated with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 21 days.

[0240] Figure 12B This is a graph showing the cumulative weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the cumulative weight gain (initial %) of rats treated with 70 mg / kg / week 5-FU plus saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 21 days.

[0241] Figure 13A This is a graph showing the daily weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the daily weight gain of rats treated with 65 mg / kg / week cyclophosphamide plus saline (Group 1), 65 mg / kg / week cyclophosphamide plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0242] Figure 13B This is a graph showing the daily body weight changes in Sprague Dawley rats in a combination therapy study. The graph compares the daily body weight gain (initial %) of rats treated with 65 mg / kg / week cyclophosphamide plus saline (Group 1), 65 mg / kg / week cyclophosphamide plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0243] Figure 14A This is a graph showing the daily weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the daily weight gain of rats treated with 0.27 mg / kg / week vincristine plus saline (Group 1), 0.27 mg / kg / week vincristine plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0244] Figure 14B This is a graph showing the daily body weight changes in Sprague Dawley rats in a combination therapy study. The graph compares the daily body weight gain (initial %) of rats treated with 0.27 mg / kg / week vincristine plus saline (Group 1), 0.27 mg / kg / week vincristine plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0245] Figure 15A This is a graph showing the daily weight gain of Sprague Dawley rats in a combination therapy study. The graph compares the daily weight gain of rats treated with cisplatin plus saline plus IgG (Group 1), cisplatin plus saline plus anti-GDF-15 mAb (Group 2), and cisplatin plus 3 mg / kg / day TCMCB07 anti-GDF-15 mAb (Group 3). Cisplatin was administered at 5 mg / kg on day 0, 3 mg / kg on day 7, and 3 mg / kg on day 14. The significance threshold was [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0246] Figure 15B This is a graph showing the cumulative weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the initial percentage change in body weight (%) in rats treated with cisplatin plus saline (Group 1), cisplatin plus saline plus anti-GDF-15 mAb (Group 2), and cisplatin plus 3 mg / kg / day TCMCB07 plus anti-GDF-15 mAb (Group 3). Cisplatin was administered at 5 mg / kg on day 0, 3 mg / kg on day 7, and 3 mg / kg on day 14. The significance threshold was [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0247] Figure 15CThis is a graph showing the daily weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the daily weight change (initial %) in rats treated with cisplatin plus saline plus IgG (Group 1), cisplatin plus saline plus anti-GDF-15 mAb (Group 2), and cisplatin plus 3 mg / kg / day TCMCB07 plus anti-GDF-15 mAb (Group 3). Cisplatin was administered at 5 mg / kg on day 0, 3 mg / kg on day 7, and 3 mg / kg on day 14. The significance threshold was [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0248] Figure 15D This is a graph showing the total body weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the net body weight gain (baseline %) in rats treated with cisplatin plus saline plus IgG (Group 1), cisplatin plus saline plus anti-GDF-15 mAb (Group 2), and cisplatin plus 3 mg / kg / day TCMCB07 plus anti-GDF-15 mAb (Group 3) (Figure 10). Cisplatin was administered at 5 mg / kg on day 0, 3 mg / kg on day 7, and 3 mg / kg on day 14. The significance threshold was [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0249] Figure 16A This is a graph showing the daily body weight of Sprague Dawley rats in a combination therapy study. The graph compares the daily body weight of rats treated with 2 mg / kg / week doxorubicin plus saline (Group 1), 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 21 days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0250] Figure 16B This is a graph showing the daily weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the daily weight gain (initial %) of rats treated with 2 mg / kg / week doxorubicin plus saline (Group 1), 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 21 days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0251] Figure 16C This is a graph showing the daily body weight of Sprague Dawley rats in a combination therapy study. The graph compares the daily body weight of rats treated with 2 mg / kg / week doxorubicin plus saline (Group 1), 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 63 days. Administration was performed on days 0, 7, 14, 21, 28, and 35.

[0252] Figure 16D This is a graph showing the daily weight gain in Sprague Dawley rats in a combination therapy study. The graph compares the daily weight gain (initial %) in rats treated with 2 mg / kg / week doxorubicin plus saline (Group 1), 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3) for 63 days. Administration was performed on days 0, 7, 14, 21, 28, and 35.

[0253] Figure 17A This is a bar chart depicting the heart weight of Sprague Dawley rats after combination therapy. The chart compares the heart weight of rats after 21 days of treatment with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3).

[0254] Figure 17B This is a bar chart depicting the heart weight of Sprague Dawley rats after combination therapy. The chart compares the heart weight of rats after 21 days of treatment with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3).

[0255] Figure 17C This is a bar chart depicting the gastrocnemius muscle weight of Sprague Dawley rats after combination therapy. The chart compares the gastrocnemius muscle weight of rats after 21 days of treatment with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3).

[0256] Figure 17D This is a bar chart depicting the gastrocnemius muscle weight of Sprague Dawley rats after combination therapy. The chart compares the gastrocnemius muscle weight of rats after 21 days of treatment with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3).

[0257] Figure 17E This is a bar chart depicting spleen weight in Sprague Dawley rats after combination therapy. The chart compares spleen weight in rats after 21 days of treatment with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3).

[0258] Figure 17F This is a bar chart depicting spleen weight in Sprague Dawley rats after combination therapy. The chart compares spleen weight in rats after 21 days of treatment with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3).

[0259] Figure 18AThis is a bar chart depicting the heart weight of Sprague Dawley rats after combination therapy. The chart compares the heart weight of rats treated with 65 mg / kg / week cyclophosphamide plus saline (Group 1), 65 mg / kg / week cyclophosphamide plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0260] Figure 18B This is a bar chart depicting the gastrocnemius muscle weight of Sprague Dawley rats after combination therapy. The chart compares the gastrocnemius muscle weight of rats treated with 65 mg / kg / week cyclophosphamide plus saline (Group 1), 65 mg / kg / week cyclophosphamide plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0261] Figure 19A This is a bar chart depicting the heart weight of Sprague Dawley rats after combination therapy. The chart compares the heart weight of rats treated with 0.27 mg / kg / week vincristine with saline (Group 1), 0.27 mg / kg / week vincristine with 3 mg / kg / day TCMCB07 (Group 2), saline with saline (Group 3), and saline with 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0262] Figure 19B This is a bar chart depicting the gastrocnemius muscle weight of Sprague Dawley rats after combination therapy. The chart compares the gastrocnemius muscle weight of rats treated with 0.27 mg / kg / week vincristine with saline (Group 1), 0.27 mg / kg / week vincristine with 3 mg / kg / day TCMCB07 (Group 2), saline with saline (Group 3), and saline with 3 mg / kg / day TCMCB07 (Group 4) for 21 consecutive days. The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0263] Figure 20A This is a bar chart depicting the increase in adipose mass in Sprague Dawley rats after combination therapy. The chart compares the increase in adipose mass in rats after 21 days of treatment with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3).

[0264] Figure 20B This is a bar chart depicting the increase in adipose mass in Sprague Dawley rats after combination therapy. The chart compares the increase in adipose mass in rats after 21 days of treatment with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3).

[0265] Figure 20C This is a bar chart depicting the increase in lean body mass in Sprague Dawley rats after combination therapy. The chart compares the increase in lean body mass in rats after 21 days of treatment with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3).

[0266] Figure 20DThis is a bar chart depicting the increase in lean body mass in Sprague Dawley rats after combination therapy. The chart compares the increase in lean body mass in rats after 21 days of treatment with 70 mg / kg / week 5-FU plus saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3).

[0267] Figure 21A This is a bar chart depicting the fat mass of Sprague Dawley rats after combination therapy. The chart compares the fat mass of rats before and after 21 days of treatment with 65 mg / kg / week cyclophosphamide plus saline (Group 1), 65 mg / kg / week cyclophosphamide plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4). The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0268] Figure 21B This is a bar chart depicting the increase in adipose mass in Sprague Dawley rats after combination therapy. The chart compares the initial percentage increase in adipose mass after 21 days of treatment with 65 mg / kg / week cyclophosphamide plus saline (Group 1), 65 mg / kg / week cyclophosphamide plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4). The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0269] Figure 21CThis is a bar chart depicting lean body mass in Sprague Dawley rats after combination therapy. The chart compares lean body mass before and after 21 days of treatment with 65 mg / kg / week cyclophosphamide plus saline (Group 1), 65 mg / kg / week cyclophosphamide plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4). The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0270] Figure 21D This is a bar chart depicting the increase in lean body mass in Sprague Dawley rats after combination therapy. The chart compares the initial percentage increase in lean body mass (%) after 21 days of administration of 65 mg / kg / week cyclophosphamide with saline (Group 1), 65 mg / kg / week cyclophosphamide with 3 mg / kg / day TCMCB07 (Group 2), saline with saline (Group 3), and saline with 3 mg / kg / day TCMCB07 (Group 4). The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0271] Figure 22A This is a bar chart depicting the fat mass of Sprague Dawley rats after combination therapy. The chart compares the fat mass of rats before and after 21 days of treatment with 0.27 mg / kg / week vincristine plus saline (Group 1), 0.27 mg / kg / week vincristine plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4). The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0272] Figure 22B This is a bar chart depicting the increase in adipose mass in Sprague Dawley rats after combination therapy. The chart compares the initial percentage increase in adipose mass after 21 days of treatment with 0.27 mg / kg / week vincristine plus saline (Group 1), 0.27 mg / kg / week vincristine plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4). The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0273] Figure 22C This is a bar chart depicting lean body mass in Sprague Dawley rats after combination therapy. The chart compares lean body mass in rats before and after 21 days of treatment with 0.27 mg / kg / week vincristine plus saline (Group 1), 0.27 mg / kg / week vincristine plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4). The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0274] Figure 22DThis is a bar chart depicting the increase in lean body mass in Sprague Dawley rats after combination therapy. The chart compares the initial percentage increase in lean body mass (%) after 21 days of treatment with 0.27 mg / kg / week vincristine plus saline (Group 1), 0.27 mg / kg / week vincristine plus 3 mg / kg / day TCMCB07 (Group 2), saline plus saline (Group 3), and saline plus 3 mg / kg / day TCMCB07 (Group 4). The significance threshold is [value missing]. (or #, &) <.05, <.01, <.001, <.0001.

[0275] Figure 23A This figure depicts the locomotor activity of Sprague Dawley rats during the dark period in combination therapy. The figure compares the locomotor activity of rats administered 2.5 mg / kg / week cisplatin with saline (Group 1), 2.5 mg / kg / week cisplatin with 3 mg / kg / day TCMCB07 (Group 2), and saline with saline (Group 3) for 21 consecutive days during the dark period. Locomotor activity was monitored from 4 days before administration until 21 days after the initial dose.

[0276] Figure 23B This is a graph depicting the locomotor activity of Sprague Dawley rats during the dark period in combination therapy. The graph compares the locomotor activity of rats administered 70 mg / kg / week 5-FU with saline (Group 1), 70 mg / kg / week 5-FU with 3 mg / kg / day TCMCB07 (Group 2), and saline with saline (Group 3) for 21 consecutive days during the dark period. Locomotor activity was monitored from 4 days before administration until 21 days after the initial dose.

[0277] Figure 23C This is a graph depicting the motor activity (baseline %) during the dark period in Sprague Dawley rats under combination therapy. The graph compares the motor activity (baseline %) during the dark period in rats administered 2.5 mg / kg / week cisplatin with saline (Group 1) and 2.5 mg / kg / week cisplatin with 3 mg / kg / day TCMCB07 (Group 2) for 21 days. Motor activity during the dark period was monitored from 4 days before administration until 21 days after the initial dose.

[0278] Figure 23DThis is a graph depicting the motor activity (baseline %) during the dark period in Sprague Dawley rats under combination therapy. The graph compares the motor activity (baseline %) during the dark period in rats administered 70 mg / kg / week 5-FU with saline (Group 1) and 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2) for 21 days. Motor activity during the dark period was monitored from 4 days before administration until 21 days after the initial dose.

[0279] Figure 24A This is a graph depicting the motor activity during the photoperiod in Sprague Dawley rats under combination therapy. The graph compares the motor activity during the photoperiod in rats administered 2.5 mg / kg / week cisplatin with saline (Group 1), 2.5 mg / kg / week cisplatin with 3 mg / kg / day TCMCB07 (Group 2), and saline with saline (Group 3) for 21 consecutive days. Motor activity during the photoperiod was monitored from 4 days before administration until 21 days after the initial dose.

[0280] Figure 24B This is a graph depicting the motor activity of Sprague Dawley rats during the photoperiod under combination therapy. The graph compares the motor activity during the darkperiod of rats administered 70 mg / kg / week 5-FU with saline (Group 1), 70 mg / kg / week 5-FU with 3 mg / kg / day TCMCB07 (Group 2), and saline with saline (Group 3) for 21 consecutive days. Motor activity during the darkperiod was monitored from 4 days prior to administration until 21 days after the initial dose.

[0281] Figure 24C This is a graph depicting the photodynamic motor activity (baseline %) of Sprague Dawley rats under combination therapy. The graph compares the photodynamic motor activity (baseline %) of rats administered 2.5 mg / kg / week cisplatin with saline (Group 1) and 2.5 mg / kg / week cisplatin with 3 mg / kg / day TCMCB07 (Group 2) for 21 days. Photodynamic motor activity was monitored from 4 days prior to administration until 21 days after the initial dose.

[0282] Figure 24D This is a graph depicting the photoperiodic motor activity (baseline %) in Sprague Dawley rats under combination therapy. The graph compares the photoperiodic motor activity (baseline %) of rats administered 70 mg / kg / week 5-FU with saline (Group 1) and 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2) for 21 days. Photoperiodic motor activity was monitored from 4 days prior to administration until 21 days after the initial dose.

[0283] Figure 25AThis is a bar chart depicting the white blood cell counts (total white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) in Sprague Dawley rats after combination therapy. The chart compares the white blood cell counts (total white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) in rats after 21 days of treatment with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3), respectively.

[0284] Figure 25B This is a bar chart depicting the white blood cell counts (total white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) in Sprague Dawley rats after combination therapy. The chart compares the white blood cell counts (total white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, and basophils) in rats after 21 days of treatment with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3), respectively.

[0285] Figure 25C This is a bar chart depicting the white blood cell ratios of neutrophils, lymphocytes, monocytes, eosinophils, and basophils in Sprague Dawley rats after combination therapy. The chart compares the white blood cell ratios of neutrophils, lymphocytes, monocytes, eosinophils, and basophils in rats after 21 days of treatment with cisplatin plus saline (Group 1), cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3), respectively.

[0286] Figure 25D This is a bar chart depicting the white blood cell ratios of neutrophils, lymphocytes, monocytes, eosinophils, and basophils in Sprague Dawley rats after combination therapy. The chart compares the white blood cell ratios of neutrophils, lymphocytes, monocytes, eosinophils, and basophils in rats after 21 days of treatment with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3), respectively.

[0287] Figure 26AThis is a bar chart depicting the red blood cell (RBC, Hb, HCT, MCV, MCH, and MCHC) counts in Sprague Dawley rats after combination therapy. The chart compares the red blood cell (RBC, Hb, HCT, MCV, MCH, and MCHC) counts in rats after 21 days of treatment with cisplatin plus saline (Group 1), cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3), respectively.

[0288] Figure 26B This is a bar chart depicting the red blood cell (RBC, Hb, HCT, MCV, MCH, and MCHC) counts in Sprague Dawley rats after combination therapy. The chart compares the red blood cell (RBC, Hb, HCT, MCV, MCH, and MCHC) counts in rats after 21 days of treatment with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3).

[0289] Figure 26C This is a bar chart depicting platelet concentrations in Sprague Dawley rats after combination therapy. The chart compares platelet concentrations in rats after 21 days of treatment with 2.5 mg / kg / week cisplatin plus saline (Group 1), 2.5 mg / kg / week cisplatin plus 3 mg / kg / day TCMCB07 (Group 2), and saline plus saline (Group 3).

[0290] Figure 26D This is a bar chart depicting platelet concentrations in Sprague Dawley rats after combination therapy. The chart compares platelet concentrations in rats after 21 days of treatment with 70 mg / kg / week 5-FU in saline (Group 1), 70 mg / kg / week 5-FU plus 3 mg / kg / day TCMCB07 (Group 2), and saline in saline (Group 3).

[0291] Figure 27AThis is a bar chart depicting the change in total body weight (as a percentage of baseline) after 7 days of combination therapy in a Sprague Dawley rat model of doxorubicin chemotherapy. The chart compares the total body weight gain (as a percentage of baseline) of rats after 7 days of administration of saline-mediated (Group 1), 2 mg / kg / week doxorubicin (DOX) plus saline (Group 2), and 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 3), respectively. For Groups 1, 2, and 3, N=10, 16, and 12 rats, respectively. DOX was administered via intraperitoneal injection, and TCMCB07 was administered via subcutaneous injection. The significance threshold was [value missing]. <.05, <.01, <.001, <.0001.

[0292] Figure 27B This is a bar chart depicting the change in total body weight (as a percentage of baseline) after 14 days of combination therapy in a Sprague Dawley rat model of doxorubicin chemotherapy. The chart compares the increase in total body weight (as a percentage of baseline) in rats after 14 days of administration of saline-mediated (Group 1), 2 mg / kg / week doxorubicin plus saline (Group 2), and 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 3), respectively. For Groups 1, 2, and 3, N=10, 16, and 12 rats, respectively. DOX was administered via intraperitoneal injection, and TCMCB07 was administered via subcutaneous injection. The significance threshold was [value missing]. <.05, <.01, <.001, <.0001.

[0293] Figure 27CThis is a bar chart depicting the change in total body weight (as a percentage of baseline) after 21 days of combination therapy in a Sprague Dawley rat model of doxorubicin chemotherapy. The chart compares the total body weight gain (as a percentage of baseline) of rats after 21 days of administration of saline-mediated (Group 1), 2 mg / kg / week doxorubicin plus saline (Group 2), and 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 3), respectively. For Groups 1, 2, and 3, N=10, 16, and 12 rats, respectively. DOX was administered via intraperitoneal injection, and TCMCB07 was administered via subcutaneous injection.

[0294] Figure 27D This is a bar chart depicting the change in total body weight (as a percentage of baseline) after 28 days of combination therapy in a Sprague Dawley rat model of doxorubicin chemotherapy. The chart compares the total body weight gain (as a percentage of baseline) of rats after 28 days of administration of saline-mediated (Group 1), 2 mg / kg / week doxorubicin plus saline (Group 2), and 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 3), respectively. For Groups 1, 2, and 3, N=10, 16, and 12 rats, respectively. DOX was administered via intraperitoneal injection, and TCMCB07 was administered via subcutaneous injection. The significance threshold was [value missing]. <.05, <.01, <.001, <.0001.

[0295] Figure 28A This is a graph depicting daily body weight following combination therapy in the Sprague Dawley rat model of doxorubicin chemotherapy. The graph compares the daily body weight of rats administered saline medium (Group 1), 2 mg / kg / week doxorubicin plus saline (Group 2), and 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 3) for 17 days.

[0296] Figure 28BThis is a graph depicting daily body weight following combination therapy in the Sprague Dawley rat model of doxorubicin chemotherapy. The graph compares the daily body weight of rats administered saline medium (Group 1), 2 mg / kg / week doxorubicin plus saline (Group 2), and 2 mg / kg / week doxorubicin plus 3 mg / kg / day TCMCB07 (Group 3) for 26 days. N = 12 rats / group. TCMCB07 was administered subcutaneously.

[0297] Figures 29A to 29C This figure is from a post-treatment study in the Sprague Dawley rat model (TCMCB07 after cisplatin administration). Rats were administered cisplatin plus TCMCB07 followed by saline mediator (Group 1), cisplatin plus TCMCB07 followed by treatment followed by TCMCB07 (Group 2), cisplatin followed by saline mediator (Group 3), and cisplatin followed by treatment followed by TCMCB07 (Group 4). N = 10 rats / group. Figure 29A It describes the daily weight. Figure 29B The weight gain (initial %) was depicted. Figure 29C Daily cumulative food intake (g) was depicted. TCMCB07 was administered subcutaneously.

[0298] Figures 30A to 30YY Embodiments of the present invention are illustrated, showing the percentage activation of the melanocortin 3 receptor (MC3R), as measured by cAMP levels, after stimulation with a non-naturally occurring melanocortin analogue. Exemplary non-naturally occurring melanocortin analogues include HS024 (TFA) (… Figure 30A ;SEQ ID NO: 525), E1 ( Figure 30B ;SEQ ID NO:15), E2 ( Figure 30C ;SEQ ID NO: 16), E3 ( Figure 30D ;SEQ ID NO: 17), E4 ( Figure 30E ;SEQ ID NO: 18), E5 ( Figure 30F ;SEQ ID NO: 19), E6 ( Figure 30G ;SEQ ID NO: 20), E7 ( Figure 30H ;SEQ ID NO: 21), E8 ( Figure 30I ;SEQ ID NO: 22), E9 ( Figure 30J ;SEQ ID NO: 23), E10 ( Figure 30K ;SEQ ID NO: 24), E11 ( Figure 30L ;SEQ ID NO: 25), E12 ( Figure 30M ;SEQ ID NO: 26), E13 ( Figure 30N ;SEQ ID NO: 27)、E14( Figure 30O ;SEQ ID NO: 28)、E15( Figure 30P ;SEQ ID NO: 29)、E16( Figure 30Q ;SEQ ID NO: 30)、E17( Figure 30R ;SEQ ID NO: 31)、E18( Figure 30S ;SEQ ID NO: 32)、E19( Figure 30T ;SEQ ID NO: 35)、E20( Figure 30U ;SEQ ID NO: 36)、E21( Figure 30V ;SEQ ID NO: 37)、F1( Figure 30W ;SEQ ID NO: 40)、F2( Figure 30X ;SEQ ID NO: 41)、F3( Figure 30Y ;SEQ ID NO: 42)、F4( Figure 30Z ;SEQ ID NO: 43)、F5( Figure 30AA ;SEQID NO: 44)、F6( Figure 30BB ;SEQ ID NO: 50)、F7( Figure 30CC ;SEQ ID NO: 51)、F8( Figure 30DD ;SEQ IDNO: 52)、F9( Figure 30EE ;SEQ ID NO: 53)、F10( Figure 30FF ;SEQ ID NO: 54)、F11( Figure 30GG ;SEQ IDNO: 55)、F12( Figure 30HH ;SEQ ID NO: 56)、F13( Figure 30II ;SEQ ID NO: 57)、F14( Figure 30JJ ;SEQ IDNO: 58)、F15( Figure 30KK ;SEQ ID NO: 59)、F16( Figure 30LL ;SEQ ID NO: 60)、F17( Figure 30MM ;SEQ IDNO: 61)、F18( Figure 30NN ;SEQ ID NO: 62)、F19( Figure 3000 ;SEQ ID NO: 63)、F20( Figure 30PP ;SEQ IDNO: 64)、F21( Figure 30 QQ ;SEQ ID NO: 65)、F22( Figure 30RR;SEQ ID NO: 45), F23 ( Figure 30SS ;SEQ IDNO: 46), F24 ( Figure 30TT ;SEQ ID NO: 47), F25 ( Figure 30UU ;SEQ ID NO: 48), F26 ( Figure 30VV ;SEQ IDNO: 49), F28 ( Figure 30WW ;SEQ ID NO: 67), F29 ( Figure 30XX ;SEQ ID NO: 68) and F30 ( Figure 30YY ;SEQ ID NO: 69).

[0299] Figures 31A to 3100 Embodiments of the present invention are illustrated, showing the percentage of MC3R activation, as measured by cAMP levels, after stimulation with a non-naturally occurring melanocortin analogue. Exemplary non-naturally occurring melanocortin analogues include G5 (…). Figure 31A ;SEQ ID NO: 77), G6 ( Figure 31B ;SEQ ID NO: 78), G7 ( Figure 31C ;SEQ ID NO: 75), G8 ( Figure 31D ;SEQ ID NO: 74), G9 ( Figure 31E ;SEQ ID NO: 79), G10 ( Figure 31F ; SEQ ID NO: 80), G11 ( Figure 31G ; SEQ ID NO: 81), G12 ( Figure 31H ;SEQ IDNO: 82), G13 ( Figure 31I ; SEQ ID NO: 83), G15 ( Figure 31J ; SEQ ID NO: 85), G17 ( Figure 31K ;SEQ IDNO: 211), G18 ( Figure 31L ;SEQ ID NO: 212), G19 ( Figure 31M ;SEQ ID NO: 213), G 20 ( Figure 31N ;SEQ ID NO: 214), H1 ( Figure 31O ; SEQ ID NO: 97), H2 ( Figure 31P ; SEQ ID NO: 98), H3 ( Figure 31Q ;SEQ IDNO: 99), H4 ( Figure 31R ; SEQ ID NO: 100), H5 ( Figure 31S ; SEQ ID NO: 101), H6 ( Figure 31T ;SEQ ID NO:102), H7 ( Figure 31U ; SEQ ID NO: 103), H8 ( Figure 31V ; SEQ ID NO: 104), H9 ( Figure 31W ;SEQ ID NO:105), H10 ( Figure 31X ; SEQ ID NO: 106), H11 ( Figure 31Y ;SEQ ID NO: 107), H12 ( Figure 31Z ;SEQ ID NO:108), H13 ( Figure 31AA ; SEQ ID NO: 109), H14 ( Figure 31BB ; SEQ ID NO: 110), H15 ( Figure 31CC ;SEQ IDNO: 111), I1 ( Figure 31DD ;SEQ ID NO: 112), I2 ( Figure 31EE ;SEQ ID NO: 113), I3 ( Figure 31FF ;SEQ IDNO: 119), I4 ( Figure 31GG ;SEQ ID NO: 115), I5 ( Figure 31HH ;SEQ ID NO: 120), I6 ( Figure 31II ;SEQ IDNO: 121), I7 ( Figure 31JJ ;SEQ ID NO: 116), I8 ( Figure 31KK ;SEQ ID NO: 117), I9 ( Figure 31LL ;SEQ IDNO: 122), I10 ( Figure 31MM ;SEQ ID NO: 123), I11 ( Figure 31NN ;SEQ ID NO: 118) and I12 ( Figure 3100 (SEQ ID NO: 124).

[0300] Figures 32A to 32ZZ Embodiments of the present invention are illustrated, showing the percentage inhibition of MC3R, as measured by cAMP levels, after stimulation with a non-naturally occurring melanocortin analogue. Exemplary non-naturally occurring melanocortin analogues include J1 (…). Figure 32A ;SEQ ID NO: 126), J4 ( Figure 32B ;SEQ ID NO: 129), J5 ( Figure 32C ; SEQ ID NO: 130), J6 ( Figure 32D ;SEQ ID NO: 131), J7 ( Figure 32E ;SEQ ID NO: 132)、J8( Figure 32F ;SEQ ID NO: 133)、J9( Figure 32G ;SEQ ID NO: 134)、J10( Figure 32H ;SEQ ID NO: 135)、J11( Figure 32I ;SEQ ID NO: 136)、J12( Figure 32J ;SEQ ID NO: 137)、J13( Figure 32K ;SEQ ID NO: 138)、J14( Figure 32L ;SEQ ID NO: 139)、J15( Figure 32M ;SEQ ID NO: 140)、J16( Figure 32N ;SEQ ID NO: 141)、J17( Figure 32O ;SEQ ID NO: 142)、J18( Figure 32P ;SEQ ID NO: 143)、J19( Figure 32Q ;SEQ ID NO: 144)、J20( Figure 32R ;SEQ ID NO: 145)、J21( Figure 32S ;SEQ ID NO:146)、J22( Figure 32T ;SEQ ID NO: 147)、J23( Figure 32U ;SEQ ID NO: 148)、J24( Figure 32V ;SEQ ID NO:149)、J25( Figure 32W ;SEQ ID NO: 150)、J26( Figure 32X ;SEQ ID NO: 151)、J27( Figure 32Y ;SEQ ID NO:152)、J28( Figure 32Z ;SEQ ID NO: 153)、J29( Figure 32AA ;SEQ ID NO: 154)、J30( Figure 32BB ;SEQ IDNO: 155)、J31( Figure 32CC ;SEQ ID NO: 156)、J32( Figure 32DD ;SEQ ID NO: 157)、J33( Figure 32EE ;SEQID NO: 158)、J34( Figure 32FF ;SEQ ID NO: 159)、J35( Figure 32GG ;SEQ ID NO: 160)、J36( Figure 32HH; SEQ ID NO: 161), J37 ( Figure 32II ;SEQ ID NO: 162), J38 ( Figure 32JJ ;SEQ ID NO: 163), J39 ( Figure 32KK ;SEQ ID NO: 164), J40 ( Figure 32LL ;SEQ ID NO: 165), J41 ( Figure 32MM ;SEQ ID NO: 166), J42 ( Figure 32NN ;SEQ ID NO: 167), J43 ( Figure 3200 ;SEQ ID NO: 168), J44 ( Figure 32PP ; SEQ ID NO:169), J45 ( Figure 32 QQ ;SEQ ID NO: 170), J46 ( Figure 32RR ;SEQ ID NO: 171), J47 ( Figure 32SS ;SEQ IDNO: 172), J48 ( Figure 32TT ;SEQ ID NO: 173), J49 ( Figure 32UU ;SEQ ID NO: 174), J60 ( Figure 32VV ;SEQ ID NO: 185), J63 ( Figure 32WW ;SEQ ID NO: 188), J65 ( Figure 32XX ; SEQ ID NO: 190), J68 ( Figure 32YY ;SEQ ID NO: 193) and J69 ( Figure 32ZZ (SEQ ID NO: 194).

[0301] Figures 33A to 33SS Embodiments of the present invention are illustrated, showing the percentage inhibition of MC3R, as measured by cAMP levels, after stimulation with a non-naturally occurring melanocortin analogue. Exemplary non-naturally occurring melanocortin analogues include K2 (…). Figure 33A ; SEQ ID NO: 394), K3 ( Figure 33B ;SEQ ID NO: 396), K4 ( Figure 33C ; SEQ ID NO: 398), K5 ( Figure 33D ;SEQ ID NO: 399), K6 ( Figure 33E ;SEQ ID NO: 392), K7 ( Figure 33F ;SEQ ID NO: 393), K8 ( Figure 33G ;SEQ ID NO: 395), K9 ( Figure 33H ; SEQ ID NO: 397), K10( Figure 33I ; SEQ ID NO: 400), K13( Figure 33J ; SEQ ID NO: 403), K16( Figure 33K ; SEQ ID NO: 376), K17( Figure 33L ; SEQ ID NO: 377), K18( Figure 33M ; SEQ ID NO: 378), K20( Figure 33N ; SEQ ID NO: 380), K23( Figure 330 ; SEQ ID NO: 388), L4( Figure 33P ; SEQ ID NO: 217), M1( Figure 33Q ; SEQ ID NO: 225), M2( Figure 33R ; SEQ ID NO: 234), M3( Figure 33S ; SEQ ID NO: 226), M4( Figure 33T ; SEQ ID NO: 235), M5( Figure 33U ; SEQ ID NO: 227), M6( Figure 33V ; SEQ ID NO: 228), M7( Figure 33W ; SEQ ID NO: 229), M8( Figure 33X ; SEQ ID NO: 230), M9( Figure 33Y ; SEQ ID NO: 231), M11( Figure 33Z ; SEQ ID NO: 233), N1 (Figure AA; SEQ ID NO: 236), N2( Figure 33BB ; SEQ ID NO: 237), N3( Figure 33CC ; SEQ ID NO: 240), N4( Figure 33DD ; SEQ ID NO: 241), N5( Figure 33EE ; SEQ ID NO: 242), N6( Figure 33FF ; SEQ ID NO: 243), N7( Figure 33GG ; SEQ ID NO: 244), N8( Figure 33HH ; SEQ ID NO:245), O1( Figure 33II ; SEQ ID NO: 246), O2( Figure 33JJ ; SEQ ID NO: 247), O3( Figure 33KK ; SEQ ID NO:248), O4( Figure 33LL;SEQ ID NO: 249), O5 ( Figure 33MM ;SEQ ID NO: 250), O6 ( Figure 33NN ;SEQ ID NO:255), O7 ( Figure 3300 ;SEQ ID NO: 256), O9 ( Figure 33PP ;SEQ ID NO: 258), O10 ( Figure 33 QQ ;SEQ IDNO: 259), O11 ( Figure 33RR ;SEQ ID NO: 260) and TCMCB07 ( Figure 33SS ;SEQ ID NO: 3).

[0302] Figures 34A to 34DD Embodiments of the present invention are illustrated, showing the percentage activation of the melanocortin 4 receptor (MC4R) after stimulation with a non-naturally occurring melanocortin analog, as measured by cAMP levels. Exemplary non-naturally occurring melanocortin analogs include HS024 (TFA) (… Figure 34A ;SEQ ID NO: 525), E1 ( Figure 34B ;SEQ ID NO:15), E2 ( Figure 34C ;SEQ ID NO: 16), E3 ( Figure 34D ;SEQ ID NO: 17), E4 ( Figure 34E ;SEQ ID NO: 18), E5 ( Figure 34F ;SEQ ID NO: 19), E6 ( Figure 34G ;SEQ ID NO: 20), E7 ( Figure 34H ;SEQ ID NO: 21), E8 ( Figure 34I ;SEQ ID NO: 22), E9 ( Figure 34J ;SEQ ID NO: 23), E10 ( Figure 34K ;SEQ ID NO: 24), E11 ( Figure 34L ;SEQ ID NO: 25), E12 ( Figure 34M ;SEQ ID NO: 26), E13 ( Figure 34N ;SEQ ID NO: 27), E14 ( Figure 34O ;SEQ ID NO: 28), E15 ( Figure 34P ;SEQ ID NO: 29), E16 ( Figure 34Q ;SEQ ID NO: 30), E17 ( Figure 34R ;SEQ ID NO: 31), E18 ( Figure 34S;SEQ ID NO: 32)、E20( Figure 34T ;SEQ ID NO: 36)、E21( Figure 34U ;SEQ ID NO: 37)、E22( Figure 34V ;SEQ ID NO: 195)、E23( Figure 34W ;SEQ ID NO: 196)、E24( Figure 34X ;SEQ ID NO: 197)、F1( Figure 34Y ;SEQ ID NO: 40)、F2( Figure 34Z ;SEQ ID NO: 41)、F3( Figure 34AA ;SEQ ID NO: 42)、F4( Figure 34BB ;SEQ ID NO: 43)、F5( Figure 34CC ;SEQ ID NO: 44)、F6( Figure 34DD ;SEQ ID NO: 50)、F7( Figure 34EE ;SEQ ID NO: 51)、F8( Figure 34FF ;SEQ ID NO: 52)、F9( Figure 34GG ;SEQ ID NO: 53)、F10( Figure 34HH ;SEQ ID NO: 54)、F11( Figure 34II ;SEQ ID NO: 55)、F12( Figure 34JJ ;SEQ ID NO: 56)、F13( Figure 34KK ;SEQ ID NO: 57)、F14( Figure 34LL ;SEQ ID NO: 58)、F15( Figure 34MM ;SEQ ID NO: 59)、F16( Figure 34NN ;SEQ ID NO: 60)、F17( Figure 3400 ;SEQ ID NO:61)、F18( Figure 34PP ;SEQ ID NO: 62)、F19( Figure 34 QQ ;SEQ ID NO: 63)、F20( Figure 34RR ;SEQ ID NO:64)、F21( Figure 34SS ;SEQ ID NO: 65)、F22( Figure 34TT ;SEQ ID NO: 45)、F23( Figure 34UU ;SEQ ID NO:46)、F24( Figure 34VV ;SEQ ID NO: 47)、F25( Figure 34WW ;SEQ ID NO: 48)、F26( Figure 34XX ;SEQ ID NO:49), F27 ( Figure 34YY ;SEQ ID NO: 66), F28 ( Figure 34ZZ ;SEQ ID NO: 67), F29 ( Figure 34AAA ;SEQ IDNO: 68), F30 ( Figure 34BBB ;SEQ ID NO: 69), F31 ( Figure 34 CCC ;SEQ ID NO: 201) and F32 ( Figure 34DDD (SEQ ID NO: 205).

[0303] Figures 35A to 35ZZ Embodiments of the present invention are illustrated, showing the percentage activation of MC4R, as measured by cAMP levels, after stimulation with a non-naturally occurring melanocortin analogue. Exemplary non-naturally occurring melanocortin analogues include G1 (… Figure 35A ;SEQ ID NO: 71), G2 ( Figure 35B ; SEQ ID NO: 72), G3 ( Figure 35C ;SEQ ID NO:73), G4 ( Figure 35D ;SEQ ID NO: 76), G5 ( Figure 35E ;SEQ ID NO: 77), G6 ( Figure 35F ;SEQ ID NO: 78), G7 ( Figure 35G ;SEQ ID NO: 75), G8 ( Figure 35H ;SEQ ID NO: 74), G9 ( Figure 35I ;SEQ ID NO: 79), G10 ( Figure 35J ; SEQ ID NO: 80), G11 ( Figure 35K ; SEQ ID NO: 81), G12 ( Figure 35L ; SEQ ID NO: 82), G13 ( Figure 35M ; SEQ ID NO: 83), G14 ( Figure 35N ; SEQ ID NO: 84), G15 ( Figure 35O ; SEQ ID NO: 85), G16 ( Figure 35P ; SEQ ID NO: 86), G17 ( Figure 35Q ; SEQ ID NO: 211), G18 ( Figure 35R ;SEQ ID NO: 212), G19 ( Figure 35S ;SEQ ID NO: 213), G20 ( Figure 35T ; SEQ ID NO: 214), G21 ( Figure 35U ;SEQ ID NO: 215)、G22( Figure 35V ;SEQ ID NO: 202)、G23( Figure 35W ;SEQ ID NO: 203)、G24( Figure 35X ;SEQ ID NO:204)、H1( Figure 35Y ;SEQ ID NO: 97)、H2( Figure 35Z ;SEQ ID NO: 98)、H3( Figure 35AA ;SEQ ID NO:99)、H4( Figure 35BB ;SEQ ID NO: 100)、H5( Figure 35CC ;SEQ ID NO: 101)、H6( Figure 35DD ;SEQ ID NO:102)、H7( Figure 35EE ;SEQ ID NO: 103)、H8( Figure 35FF ;SEQ ID NO: 104)、H9( Figure 35GG ;SEQ ID NO:105)、H10( Figure 35HH ;SEQ ID NO: 106)、H11( Figure 35II ;SEQ ID NO: 107)、H12( Figure 35JJ ;SEQ IDNO: 108)、H13( Figure 35KK ;SEQ ID NO: 109)、H14( Figure 35LL ;SEQ ID NO: 110)、H15( Figure 35MM ;SEQID NO: 111)、I1( Figure 35NN ;SEQ ID NO: 112)、I2( Figure 3500 ;SEQ ID NO: 113)、I3( Figure 35PP ;SEQID NO: 119)、I4( Figure 35 QQ ;SEQ ID NO: 115)、I5( Figure 35RR ;SEQ ID NO: 120)、I6( Figure 35SS ;SEQID NO: 121)、I7( Figure 35TT ;SEQ ID NO: 116)、I8( Figure 35UU ;SEQ ID NO: 117)、I9( Figure 35VV ;SEQID NO: 122)、I10( Figure 35WW ;SEQ ID NO: 123)、I11( Figure 35XX ;SEQ ID NO: 118)、I12( Figure 35YY;SEQ ID NO: 124) and I13 ( Figure 35ZZ (SEQ ID NO: 200).

[0304] Figures 36A to 36RRR Embodiments of the present invention are illustrated, showing the percentage inhibition of MC4R, as measured by cAMP levels, after stimulation with a non-naturally occurring melanocortin analogue. Exemplary non-naturally occurring melanocortin analogues include J1 ( Figure 36A ;SEQ ID NO: 126), J2 ( Figure 36B ; SEQ ID NO: 127), J3 ( Figure 36C ;SEQ ID NO:128), J4 ( Figure 36D ;SEQ ID NO: 129), J5 ( Figure 36E ; SEQ ID NO: 130), J6 ( Figure 36F ;SEQ ID NO:131), J7 ( Figure 36G ;SEQ ID NO: 132), J8 ( Figure 36H ;SEQ ID NO: 133), J9 ( Figure 36I ;SEQ ID NO:136), J10 ( Figure 36J ;SEQ ID NO: 135), J11 ( Figure 36K ;SEQ ID NO: 136), J12 ( Figure 36L ;SEQ ID NO:137), J13 ( Figure 36M ;SEQ ID NO: 138), J14 ( Figure 36N ;SEQ ID NO: 139), J15 ( Figure 360 ;SEQ ID NO:140), J16 ( Figure 36P ;SEQ ID NO: 141), J17 ( Figure 36Q ;SEQ ID NO: 142), J18 ( Figure 36R ;SEQ ID NO:143), J19 ( Figure 36S ;SEQ ID NO: 144), J20 ( Figure 36T ;SEQ ID NO: 145), J21 ( Figure 36U ; SEQ ID NO:146), J22 ( Figure 36V ; SEQ ID NO: 147), J23 ( Figure 36W ;SEQ ID NO: 148), J24 ( Figure 36X ;SEQ ID NO:149), J25 ( Figure 36Y;SEQ ID NO: 150)、J26( Figure 36Z ;SEQ ID NO: 151)、J27( Figure 36AA ;SEQ IDNO: 152)、J28( Figure 36BB ;SEQ ID NO: 153)、J29( Figure 36CC ;SEQ ID NO: 154)、J30( Figure 36DD ;SEQID NO: 155)、J31( Figure 36EE ;SEQ ID NO: 156)、J32( Figure 36FF ;SEQ ID NO: 157)、J33( Figure 36GG ;SEQ ID NO: 158)、J34( Figure 36HH ;SEQ ID NO: 159)、J35( Figure 36II ;SEQ ID NO: 160)、J36( Figure 36JJ ;SEQ ID NO: 161)、J37( Figure 36KK ;SEQ ID NO: 126;SEQ ID NO: 162)、J38( Figure 36LL ;SEQID NO: 163)、J39( Figure 36MM ;SEQ ID NO: 164)、J40( Figure 36NN ;SEQ ID NO: 165)、J41( Figure 3600 ;SEQ ID NO: 166)、J42( Figure 36PP ;SEQ ID NO: 167)、J43( Figure 36 QQ ;SEQ ID NO: 168)、J44( Figure 36RR ;SEQ ID NO: 169)、J45( Figure 36SS ;SEQ ID NO: 170)、J46( Figure 36TT ;SEQ ID NO: 171)、J47( Figure 36UU ;SEQ ID NO: 172)、J48( Figure 36VV ;SEQ ID NO: 173)、J49( Figure 36WW ;SEQ ID NO:174)、J50( Figure 36XX ;SEQ ID NO: 175)、J51( Figure 36YY ;SEQ ID NO: 176)、J52( Figure 36ZZ ;SEQ IDNO: 177)、J53( Figure 36AAA ;SEQ ID NO: 178)、J54( Figure 36BBB;SEQ ID NO: 179), J55 ( Figure 36CCC ; SEQ ID NO: 180), J56 ( Figure 36DDD ;SEQ ID NO: 181), J57 ( Figure 36 EEE ;SEQ ID NO: 182), J58 ( Figure 36FFF ;SEQ ID NO: 183), J59 ( Figure 36GGG ;SEQ ID NO: 184), J60 ( Figure 36HHH ;SEQ ID NO:185), J61 ( Figure 36III ; SEQ ID NO: 186), J62 ( Figure 36JJJ ;SEQ ID NO: 187), J63 ( Figure 36KKK ;SEQ ID NO: 188), J64 ( Figure 36LLL ; SEQ ID NO: 189), J65 ( Figure 36MMM ;SEQ ID NO: 190), J66 ( Figure 36NNN ;SEQ ID NO: 191), J67 ( Figure 36OOO ; SEQ ID NO: 192), J68 ( Figure 36 PPP ;SEQ ID NO:193), J69 ( Figure 36 QQQ ;SEQ ID NO: 194) and J70 ( Figure 36RRR (SEQ ID NO: 206).

[0305] Figures 37A to 37GGG Embodiments of the present invention are illustrated, showing the percentage inhibition of MC4R, as measured by cAMP levels, after stimulation with a non-naturally occurring melanocortin analogue. Exemplary non-naturally occurring melanocortin analogues include K1 (…). Figure 37A ; SEQ ID NO: 391), K2 ( Figure 37B ; SEQ ID NO: 394), K3 ( Figure 37C ;SEQ ID NO: 396), K4 ( Figure 37D ; SEQ ID NO: 398), K5 ( Figure 37E ;SEQ ID NO: 399), K6 ( Figure 37F ;SEQ ID NO: 392), K7 ( Figure 37G ;SEQ ID NO: 393), K8 ( Figure 37H ;SEQ ID NO: 395), K9 ( Figure 37I ;SEQ ID NO: 397), K10 ( Figure 37J ;SEQ ID NO: 400)、K11( Figure 37K ;SEQ ID NO: 401)、K12( Figure 37L ;SEQ ID NO: 402)、K13( Figure 37M ;SEQ ID NO: 403)、K14( Figure 37N ;SEQ ID NO: 406)、K15( Figure 37O ;SEQ ID NO: 375)、K16( Figure 37P ;SEQ ID NO: 376)、K17( Figure 37Q ;SEQ ID NO: 377)、K18( Figure 37R ;SEQ ID NO: 378)、K19( Figure 37S ;SEQ ID NO: 379)、K20( Figure 37T ;SEQ ID NO: 380)、K21( Figure 37U ;SEQ ID NO: 381)、K22( Figure 37V ;SEQ ID NO:125)、K23( Figure 37W ;SEQ ID NO: 388)、L1( Figure 37X ;SEQ ID NO: 198)、L2( Figure 37Y ;SEQ ID NO:199)、L3( Figure 37Z ;SEQ ID NO: 216)、L4( Figure 37AA ;SEQ ID NO: 217)、L5( Figure 37BB ;SEQ ID NO:220)、M1( Figure 37CC ;SEQ ID NO: 225)、M2( Figure 37DD ;SEQ ID NO: 234)、M3( Figure 37EE ;SEQ ID NO:226)、M4( Figure 37FF ;SEQ ID NO: 237)、M5( Figure 37GG ;SEQ ID NO: 227)、M6( Figure 37HH ;SEQ ID NO:228)、M7( Figure 37II ;SEQ ID NO: 229)、M8( Figure 37JJ ;SEQ ID NO: 230)、M9( Figure 37KK ;SEQ ID NO:231)、M10( Figure 37LL ;SEQ ID NO: 232)、M11( Figure 37MM ;SEQ ID NO: 233)、N1( Figure 37NN ;SEQ IDNO: 236), N2 ( Figure 3700 ;SEQ ID NO: 237), N3 ( Figure 37PP ;SEQ ID NO: 239), N4 ( Figure 37 QQ ;SEQ IDNO: 241), N5 ( Figure 37RR ;SEQ ID NO: 242), N6 ( Figure 37SS ;SEQ ID NO: 243), N7 ( Figure 37TT ;SEQ IDNO: 244), N8 ( Figure 37UU ;SEQ ID NO: 245), O1 ( Figure 37VV ;SEQ ID NO: 246), O2 ( Figure 37WW ;SEQ IDNO: 247), O3 ( Figure 37XX ;SEQ ID NO: 248), O4 ( Figure 37YY ;SEQ ID NO: 249), O5 ( Figure 37ZZ ;SEQ IDNO: 250), O6 ( Figure 37AAA ;SEQ ID NO: 255), O7 ( Figure 37BBB ;SEQ ID NO: 256), O8 ( Figure 37CCC ;SEQ ID NO: 257), O9 ( Figure 37DDD ;SEQ ID NO: 258), O10 ( Figure 37EEE ;SEQ ID NO: 259), O11 ( Figure 37FFF ;SEQ ID NO: 260) and TCMCB07 ( Figure 37GGG ;SEQ ID NO: 3).

[0306] Figure 38 The expression of pro-inflammatory genes in the hypothalamus of cancer cachexia rats administered TCMCB07 or saline control is shown, measured at mRNA levels.

[0307] Figures 39A to 39C This demonstrates the effects of different concentrations of TCMCB07 on the activation of human (…). Figure 39A ), rats ( Figure 39B ) and dog ( Figure 39C Changes in cAMP levels after melanocortin 1 receptor (MC1R).

[0308] Figure 40 The dosing regimen for administering TCMCB07 in a chronic kidney disease model is shown.

[0309] Figure 41Daily body weight measurements of rats (G2) with chronic kidney disease-induced cachexia and control rats (G1) administered TCMCB07 under three different dosing regimens (G3, G4, and G5) are shown.

[0310] Figures 42A to 42G The invention demonstrates that subcutaneous injection of a non-natural melanocortin analogue improved anorexia, weight loss, and lean mass loss in rats with chronic kidney disease (CKD) cachexia. Figure 42A This describes the design of one or more non-naturally occurring melanocortin analogs in rats using the techniques of this invention. in vivo A diagram of a kidney failure model (5 / 6 nephrectomy model). Figure 42B This is the basis for comparing the application of saline (Neph / saline) or TCMCB07 (Neph / TCMCB07) respectively. Figure 42A of in vivo A graph showing the daily body weight of rats undergoing nephrectomy and sham-operated rats receiving saline (Sham / saline) for 28 consecutive days in a kidney failure model. Figure 42C This is the basis for comparing the application of saline (Neph / saline) or TCMCB07 (Neph / TCMCB07) respectively. Figure 42A of in vivo A graph showing the daily food intake over 28 days in rats with a renal failure model who underwent nephrectomy and rats that underwent sham surgery with saline (Sham / saline). Figure 42D It describes the basis for applying saline (Neph / saline) or TCMCB07 (Neph / TCMCB07) respectively. Figure 42A of in vivo A bar chart showing the increase in fat mass over 28 days in rats with a renal failure model who underwent nephrectomy and rats that underwent sham surgery with saline (Sham / saline). Figure 42E This is a graph showing the weight gain (%, net increase relative to baseline) after nephrectomy and treatment. Figure 42F It is a graph showing the cumulative food intake after treatment. Figure 42G This is a graph showing lean body mass determined by MR before treatment (day 14) and after treatment (day 28), with the increase (%) calculated (net increase relative to baseline normalized). All data for each group are expressed as mean ± SEM. Two-way ANOVA in (42B to 42E), unpaired Student's t-test in (42D and 42G) And # p<0.05, ## p<0.01, and ### p<0.001 and p < 0.0001. Asterisks in (42B and 42C): Neph / saline group compared to Sham / saline group, and red hash marks in (42B and 42C): Neph / TCMCB07 group compared to Neph / saline group.

[0311] Figures 43A to 43F The study demonstrates the effect of continued TCMCB07 treatment in a CKD model after rats reached the equivalence point, where the body weight of rats treated with TCMCB07 was no different from that of sham rats. Figure 43A A schematic diagram of the experimental method is shown. Figure 43B The daily body weight of CKD model rats treated with TCMCB07 and whose administration at the equivalent point changed is shown. Figure 43C The daily weight gain of CKD model rats treated with TCMCB07 and whose administration at the equivalent point resulted in changes compared to day 1 is shown. Figure 43D Weight gain is shown as a percentage of initial body weight in CKD model rats treated with TCMCB07 and whose changes occurred at the point of equivalence, compared to day 1. Figure 43E Weight gain is shown as a percentage of initial body weight in CKD model rats treated with TCMCB07 and whose changes occurred at the point of equivalence, compared to day 14. Figure 43F The cumulative food intake of CKD model rats treated with TCMCB07 and altered at the point of equivalent administration is shown.

[0312] Figures 44A to 44F The body composition of CKD model rats treated with TCMCB07 and altered at the point of equivalent administration is shown. Figure 44A The fat mass was shown; Figure 44B Lean body mass was shown; Figure 44C The fluid mass is shown; Figure 44D It shows increased fat mass; Figure 44E The increased lean body mass was shown; and Figure 44F The increased fluid mass is shown.

[0313] Figures 45A to 45D The tissue weight and length of rats treated with TCMCB07 and whose administration at the equivalent point changed are shown. Figure 45A The heart weight is shown; Figure 45B The weight of the gastrocnemius muscle is shown; Figure 45C The spleen weight was shown; and Figure 45D The body length is shown.

[0314] Figure 46A and 46B Serum creatinine and urea levels are shown in rats treated with TCMCB07 and altered at the equivalent point. Figure 46A Serum creatinine was shown, and Figure 46B Serum blood urea nitrogen (BUN) is shown. Detailed Implementation

[0315] This document describes methods for treating, preventing, or alleviating one or more conditions (including, but not limited to, side effects and iatrogenic injury) associated with anticancer agents (such as chemotherapy agents) in subjects with such needs using non-naturally occurring melanocortin analogs, and methods for treating subjects suffering from one or more such conditions. In some embodiments, the invention includes methods for preventing or alleviating one or more conditions associated with anticancer agents by administering a non-naturally occurring melanocortin analog to a subject with such needs prior to administration of an anticancer agent. In some embodiments, the non-naturally occurring melanocortin analog is administered to the subject after administration of the anticancer agent. In some embodiments, the non-naturally occurring melanocortin analog is administered to the subject concurrently with or during an anticancer agent dosing regimen. In any embodiment of the invention, the subject has cancer, or the subject has other conditions (e.g., non-cancer) that can be treated with anticancer agents (such as, but not limited to, chemotherapy agents).

[0316] Some non-natural melanocortin analogs may bind only to MC3R or MC4R. Other non-natural melanocortin analogs can bind to MC3R with a greater affinity than MC4R, while some non-natural melanocortin analogs can bind to MC4R with a greater affinity than MC3R. Some non-natural melanocortin analogs bind to MC3R with the same or generally similar affinity as MC4R.

[0317] Each non-natural melanocortin analogue may have one or more β-hairpin (β-hairpin) and / or β-turn (β-turn) structures. Rigidly structured amino acids (e.g., Aia, Aba, Ata, Hyp, D-Hyp, Pro, D-Pro, ...) trans Pro(guan) and CisPro(guan) may contribute to the formation of β-hairpins and / or β-turns in peptides. Additionally, D-Met and disulfide bonds (via disulfide cyclization) can induce and / or stabilize β-turn structures in non-natural melanocortin analogs. Pro-Gly and Gly-Gly linkers can also induce and / or stabilize β-turns. Generally, cyclization stabilizes β-turns, while D-amino acids can induce and / or stabilize them. Non-natural melanocortin analogs include D-valine-D-proline (dV-dP) or D-proline-D-valine (dP-dV) as their C-terminus, which can provide enhanced transport and resistance to degradation. Non-natural melanocortin analogs can be linear or optionally cyclized at different positions on the peptide chain via disulfide bridges or lactam bonds. Each non-natural melanocortin analog may contain one or more of the features described above.

[0318] The following description is merely exemplary in nature and is not intended to limit the invention, its application, or its uses. It should be understood that in all the drawings, corresponding reference numerals indicate the same or corresponding parts and features. The description of specific examples shown in various embodiments of the invention is for illustrative purposes only and is not intended to limit the scope of the invention described herein. Furthermore, listing multiple embodiments having said features does not imply exclusion of other embodiments having additional features or other embodiments incorporating different combinations of said features.

[0319] Furthermore, the detailed description of various embodiments herein is referenced to the accompanying drawings, which illustrate various embodiments by way of illustration. While the embodiments have been described in sufficient detail to enable those skilled in the art to practice the invention, it should be understood that other embodiments can be implemented and logical and mechanical changes can be made without departing from the spirit and scope of the invention. Therefore, the specific embodiments described herein are presented for illustrative purposes only and not for limiting purposes. For example, the steps or functions, any methods, systems, or processes described in the specification can be performed in any order and are not limited to the order shown. Furthermore, any step or function may be outsourced to or performed by one or more third parties.

[0320] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. For the purposes of this invention, the following terms are defined.

[0321] The articles “a” and “a kind” in this text refer to one or more grammatical objects of the article (i.e., at least one). For example, “element” means one or more elements.

[0322] The term "about" means a quantity, level, value, number, frequency, percentage, size, volume, weight, or length that varies within a level acceptable in the art. In some embodiments, such variation can be as high as 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of a reference quantity, level, value, number, frequency, percentage, size, volume, weight, or length. When the term "about" is used in conjunction with a numerical range, the term modifies the range by extending the limits above and below the stated numerical value.

[0323] The terms “melanocortin analogue,” “non-naturally occurring melanocortin analogue,” “melanocortin peptide,” “melanocortin receptor peptide,” or “melanocortin” are used interchangeably and refer to melanocortin receptor ligands, which are large molecules containing at least one melanocortin pharmacophore. Melanocortin analogues are typically peptides that bind to melanocortin receptors under physiological conditions. Melanocortin analogues include naturally occurring and non-naturally occurring melanocortin analogues (i.e., “synthetic peptides” or “synthetic analogues”) as well as truncated and / or modified forms of full-length melanocortin proteins or peptides. For example, full-length POMC consists of 241 amino acids before proteolytic cleavage into “subpeptides.” Tissue-specific proteolytic cleavage of POMC yields peptides ranging in size from 13 to 76 amino acids. See Bicknell and Lawry, Encyclopedia of Stress Volume 3, 257-265, Academic Press (2000). As discussed herein, synthetic, non-natural melanocortin analogs with increased melanocortin receptor activity are approximately 7 to 12 amino acids in size. Melanocortin analogs exhibit binding functionality to melanocortin receptors. Binding to melanocortin receptors is inhibitory (antagonistic). In addition to peptides, non-natural melanocortin analogs also include small molecule analogs of melanocortin or its components, consisting of organic compounds, inorganic compounds, or combinations of peptides and small molecules (i.e., peptide mimics) or various combinations thereof. “Non-natural melanocortin analogs” are structurally similar to and / or may be functionally similar to biological melanocortin proteins in their ability to bind to melanocortin receptors. Furthermore, non-natural melanocortin analogs typically contain a pharmacophore: His-Phe-Arg-Trp (SEQ ID NO: 1) or its modified form, or a structural or functional peptide mimic.

[0324] A pharmacophore is the smallest set of amino acid residues required to achieve a physiological effect; or, in the case of a receptor, a small molecule that mimics the structure of the amino acid residues required to bind to and activate the receptor. His-Phe-Arg-Trp (SEQ ID NO: 1) and its analogues are pharmacophores of melanocortin used to regulate physiological effects. Therefore, non-natural melanocortin pharmacophore analogues can be small peptides or organic molecules designed to mimic the appearance or function (including activation or inactivation of receptor activity) of the core sequence peptide of the melanocortin pharmacophore.

[0325] "Enhanced therapeutic activity" refers to the increased melanocortin activity of non-natural melanocortin analogs derivatized at the N-terminus and / or C-terminus. Such derivatization does not necessarily involve a pharmacophore, but it does imply a relative increase in the biological half-life in vivo.

[0326] Melanocortin receptor "antagonists" are naturally occurring substances or manufactured pharmaceutical substances or compositions that can counteract melanocortin receptor-related responses that are typically induced by melanocortin receptor agonists.

[0327] The terms “bind,” “binding,” “complex,” and “complexing” refer to all types of physical and chemical bonding, reaction, compounding, attraction, chelation, etc.

[0328] The “peptide” as described herein may be (a) naturally occurring, (b) produced by chemical synthesis, (c) produced by recombinant DNA technology, (d) produced by biochemical or enzymatic fragmentation of a larger molecule, (e) produced by a combination of the methods listed above (a) to (d), or (f) produced by any other method for producing peptides.

[0329] As used herein, the term "peptide" includes any structure consisting of two or more amino acids, including chemical modifications and derivatives of amino acids. All or part of the amino acids forming a peptide can be naturally occurring amino acids, stereoisomers and modifications of such amino acids, non-protein amino acids, post-translational modified amino acids, enzymatically modified amino acids, constructs or structures designed to mimic amino acids, etc. Therefore, the term "peptide" includes pseudopeptides and peptide mimics, including structures with a non-peptide backbone. The term "peptide" also includes dimers or polymers of peptides. "Manufactured" peptides include peptides produced by chemical synthesis, recombinant DNA technology, biochemical or enzymatic fragmentation of larger molecules, combinations of the foregoing methods, or generally by any other method. The term "peptide" includes peptides containing a variable number of amino acid residues, optionally having non-amino acid residue groups at the N-terminus and C-terminus, such groups particularly including acyl, acetyl, alkenyl, alkyl, N-alkyl, amine, or amide groups.

[0330] By employing chemical synthesis (a useful production method), various amino acids not naturally present in the chain can be introduced, and the N-terminus or C-terminus can be modified, thereby providing improved stability and formulation, resistance to protease degradation, etc.

[0331] An "amino acid" is a molecule containing an amine group, a carboxylic acid group, and a side chain unique to each amino acid. The main elements of amino acids are carbon, hydrogen, oxygen, and nitrogen, and they have the general formula H₂N—CHR—COOH, where R represents a side chain group. Various α-amino acids differ in the side chain portion attached to the α-carbon. The "amino acids" of this invention include known naturally occurring protein amino acids, which are referred to using common three-letter and single-letter abbreviations. See also: General. Non-naturally occurring melanocortin analogs: A User's Guide , GA Grant, editor, WH Freeman & Co., New York (1992), whose teachings are incorporated herein by reference, including the text and tables shown on pages 11–24. As noted above, the term “amino acid” also includes naturally occurring protein amino acids, non-protein amino acids, post-translational modified amino acids, enzymatically synthesized amino acids, derived amino acids, stereoisomers and modifications designed to mimic the structure of amino acids, etc. Modified and uncommon amino acids are generally described in Non- naturally occurring melanocortin analogs: A User's Guide Ibid.; Hruby et al. Biochem.J. 268:249-262 (1990); and Toniolo, Int. J. Peptide Protein Res. 35:287-300 (1990); The teachings of all these documents are incorporated into this paper by reference.

[0332] As used herein, the phrase "amino acid side chain moiety" (including as used in the specification and claims) includes any side chain of any amino acid, as the term "amino acid" is defined herein. Therefore, this includes side chain moiety present in naturally occurring amino acids. It further includes side chain moiety of modified naturally occurring amino acids, such as glycosylated amino acids. It further includes side chain moiety in naturally occurring protein amino acids, non-protein amino acids, post-translational modified amino acids, enzymatically synthesized amino acids, derived amino acids, stereoisomers designed to mimic the structure of amino acids, and modified amino acids. For example, the side chain moiety of any amino acid described herein is included within the definition. "Derivatives" of amino acid side chain moiety are included within the definition of amino acid side chain moiety.

[0333] The term "derivative" of an amino acid side chain moiety includes any modification or variation of any amino acid side chain moiety, including modifications of naturally occurring amino acid side chain moieties. By way of example, derivatives of amino acid side chain moieties include straight-chain or branched, cyclic or acyclic, substituted or unsubstituted, saturated or unsaturated alkyl, aryl, or aralkyl moieties.

[0334] In the peptides described herein, the conventional amino acid residues have, for example... Manual of Patent Examining Procedure, The conventional meanings are given in Chapter 2400 of the 8th edition. Therefore, "Ala" is alanine; "Arg" is arginine; "Asn" is asparagine; "Asp" is aspartic acid; "Cys" is cysteine; "Gln" is glutamine; "Glu" is glutamic acid; "His" is histidine; "Ile" is isoleucine; "Leu" is leucine; "Lys" is lysine; "Met" is methionine; "Phe" is phenylalanine; "Pro" is proline; "Ser" is serine; "Thr" is threonine; "Trp" is tryptophan; "Tyr" is tyrosine; and "Val" is valine. Unless otherwise indicated, all amino acid abbreviations represent isomers, i.e., L-isomers, D-isomers, or combinations thereof may be used. Therefore, for example, "L-Phe" or "lPhe" is L-phenylalanine; "D-Phe" or "dPhe" is D-phenylalanine; dVal is D-valine; dPro is D-proline; "D- / L-Phe" or "d / lPhe" is D-phenylalanine, L-phenylalanine or a combination thereof; "Phe" can also be D-phenylalanine, L-phenylalanine or a combination thereof, etc. Non-standard amino acids: "Nle" is leucine; "Nal" is naphthylalanine; "D-Nal" is D-naphthylalanine; D-Nal(2') or DNal(2') is D-2'-naphthylalanine; L-Nal(2') or LNal(2') is L-2'-naphthylalanine; L-Nal(1') is L-1'-naphthylalanine; D-Nal(1') or DNal(1') is D-1'-naphthylalanine; Tle is tertiary leucine; Nva is valine; Orn is ornithine; etc.

[0335] α-amino acids have the general formula H2N—C α HR—COOH, where R is the side chain portion, and the amino group is attached to the carbon atom (i.e., the α-carbon) immediately adjacent to the carboxylic acid group. Other types of amino acids exist when the amino group is attached to different carbon atoms. For example, 253 (β)-amino acids, where the carbon atom to which the amino group is attached is connected to the carboxylic acid group by a single carbon atom (C). β Separated. For example, α-alanine has the formula H2N—C αH(CH3)—COOH. In contrast, β-alanine has the general formula H2N—C. β H2—C α H2—COOH (i.e., 3-aminopropionic acid).

[0336] When β-amino acids are incorporated into peptides, there are two main types of β-peptides: those with a side chain residue R located on the carbon atom immediately adjacent to the amine are called β-peptides. 3 Peptides, and those with side chain residues on the carbon atom immediately adjacent to the carbonyl group, are called β-peptides. 2 Amino acids. As a non-limiting example, "β-valine" can refer to: —NH—C β H2—C α H(CH3)2—CO—, i.e., β 2 -Valine (R on the carboxyl side); —NH—C β H(CH3)2—C α H2—CO—, that is, β 3 -valine (R on the amino side); or —NH—C β H(CH3)2—C α H(CH3)2—CO—, i.e., β 2,3 -Valine (R at two positions).

[0337] Furthermore, β-amino acids can be represented by L- or D-stereochemistry. Unless otherwise indicated, all β-amino acid abbreviations represent isomers, namely L-isomers, D-isomers, or combinations thereof.

[0338] γ-amino acids are amino acids in which the carbon atom to which the amino group is attached is separated from the carboxylic acid moiety by two carbon atoms. For example, γ-aminobutyric acid has the formula H₂N—C. γ H2—C β H2—C α H2—COOH.

[0339] For information on other modified and less common amino acids, see §2422 of the MPEP, particularly Table 4 on pages 2400-24. Furthermore, “Ac” indicates an N-acetyl group, and “cyclic” indicates a cyclic structure, also referred to as “c” or “lactam” in the literature. “NH2” indicates an amine group, usually added to the C-terminus of the peptide. Therefore, as used herein, the –NH2 portion at the C-terminus of the peptide indicates an amidated C-terminus. Additionally, the following abbreviations are used herein: Harg for high-arginine; Hlys for high-lysine.

[0340] The following abbreviations are used: tBu for tert-butyl; Hyp(Bzl) for benzyl-L-hydroxy-proline; glutaric acid linker: CO—(CH2)3—CO; Pen for L-penicillamine; Aib for 2-aminoisobutyric acid; Aba for 4-amino-1,2,4,5-tetrahydro-2-benzozazepine-3-one; Pip for piperidine-2-carboxylic acid; Nip for piperidine-3-carboxylic acid; Tic for tetrahydroquinoline-3- Formic acid; Bip is biphenylalanine; Phg is α-phenyl-glycine; Sar is sarcosine; Azt is 3'-azido-3'-deoxythymidine; Oic is octahydroindole-2-carboxylic acid; Ata is 7-amino-7,8-dihydro-4H-(1,2,3)triazolo(1,5-a)(1,4)diazazo-6(5H)-one; Aia is 4-amino-1,4,5,6-tetrahydro-diazazo(4,3)-one. -b Indole-3 ( 2H )-ketone; Mamb is 3-aminomethylbenzoic acid; Atc is 2-aminotetrahydronaphthalene-2-carboxylic acid; APC is 1-amino-4-phenylcyclohexane-carboxylic acid; ACC is 4-aminophenylpiperidin-4-carboxylic acid (APPC); Accc is 1-aminocyclo-propane-1-carboxylic acid; Aic is 2-aminoindanone-2-carboxylic acid; p(Cl)Phe is p-chloro-phenylalanine (I-iodine, Br-bromine, F-fluorine, CF3-trifluoromethyl); and p(Cl)dPhe is p-chloro-D-phenylalanine (I-iodine, Br-bromine, F-fluorine, CF3-trifluoromethyl).

[0341] The term "olefin" includes unsaturated hydrocarbons containing one or more carbon-carbon double bonds. Examples of such olefin groups include ethylene, propylene, etc.

[0342] The term "alkenyl" includes straight-chain monovalent hydrocarbon groups with two to six carbon atoms containing at least one double bond, or branched monovalent hydrocarbon groups with three to six carbon atoms; examples include vinyl, 2-propenyl, etc.

[0343] The term "alkyl" as used herein includes alkyl groups with a straight-chain or branched configuration of a specified length. Examples of such alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, etc.

[0344] The term "alkynyl" includes straight-chain monovalent hydrocarbon groups with two to six carbon atoms containing at least one triple bond, or branched monovalent hydrocarbon groups with three to six carbon atoms; examples include ethynyl, propynyl, butynyl, etc.

[0345] The term "aryl" includes a monovalent or bicyclic aromatic hydrocarbon group having 6 to 12 ring atoms, optionally substituted by one or more substituents selected from: alkyl, haloalkyl, cycloalkyl, alkoxy, alkylthio, halo, nitro, acyl, cyano, amino, monosubstituted amino, disubstituted amino, hydroxy, carboxyl, or alkoxy-carbonyl. Examples of aryl groups include phenyl, biphenyl, naphthyl, 1-naphthyl and 2-naphthyl, and their derivatives.

[0346] The term "aliphatic" includes compounds with hydrocarbon chains, such as alkanes, alkenes, alkynes, and their derivatives.

[0347] The term "acyl" includes the group RCO—, where R is an organic group. An example is the acetyl group CH3CO—. This is referred to as "Ac" in this document.

[0348] The term "fatty acid" describes a carboxylic acid having an aliphatic chain, which may be fully saturated or partially unsaturated, and optionally attached to a functional group such as a hydroxyl group or a carboxyl group. The aliphatic chain may contain, for example, 6 to 26 carbon atoms and hydrogen atoms.

[0349] A peptide or aliphatic moiety is “acylated” when an alkyl or substituted alkyl group as defined above is bonded to one or more carbonyl {—(C═O)—} groups. Peptides are most commonly acylated at the N-terminus.

[0350] "ω-amino derivatives" include aliphatic moieties having terminal amino groups. Examples of ω-amino derivatives include aminoheptanoyl groups and amino acid side chain moieties of ornithine and lysine.

[0351] The term "heteroaryl" includes monocyclic and bicyclic aromatic rings containing one to four heteroatoms selected from nitrogen, oxygen, and sulfur. Five- or six-membered heteroaryl groups are monocyclic heteroaromatic rings; examples include thiazoles, oxazoles, thiophenes, furans, pyrroles, imidazoles, isoxazoles, pyrazoles, triazoles, thiadiazoles, tetraazoles, oxadiazoles, pyridines, pyridazines, pyrimidines, and pyrazines. Bicyclic heteroaromatic rings include, but are not limited to, benzothiadiazoles, indole, benzothiophenes, benzofurans, benzimidazoles, benzoisoxazoles, benzothiazides, quinolines, benzotriazoles, benzoxazoles, isoquinolines, purines, furanopyridines, and thienopyridines.

[0352] "Amine" includes compounds containing an amine group (-NH2).

[0353] "Amide" includes compounds in which a trivalent nitrogen atom is attached to a carbonyl group (i.e., —CO—NH2), such as formamide, acetamide, propionamide, etc. Peptides are usually amidated at the C-terminus by adding an amine (—NH2) moiety to the C-terminal carboxyl group.

[0354] "Imine" includes compounds with carbon-nitrogen double bonds and nitrogen atoms also attached to hydrogen (NH═CH—R).

[0355] "Imine" includes compounds containing an imide group (-OC-NH-CO-).

[0356] "Nitriles" include compounds that are carboxylic acid derivatives and contain (-CN) groups that are bound to organic groups.

[0357] The term "halogen" is intended to include halogen atoms such as fluorine, chlorine, bromine, and iodine, as well as groups containing one or more halogen atoms, such as -CF3, etc.

[0358] Amino acids (including naturally occurring amino acids, protein amino acids, non-protein amino acids, post-translational modified amino acids, enzyme-synthesized amino acids, derived amino acids, stereoisomers and modifications of constructs or structures designed to mimic amino acids (peptide mimics), etc., all of the above) are sometimes referred to herein as “residues”.

[0359] A peptide or amino acid “mimic” is a non-amino acid molecule that mimics a peptide (an amino acid chain) or a single amino acid residue.

[0360] "Significant degradation" refers to the manner or extent by which non-naturally occurring melanocortin analogs, through physiological enzymatic activity or other factors, result in side effects due to N-terminal extension, C-terminal extension, degradation of both the N-terminus and C-terminus, or degradation of other regions. According to one aspect, a non-naturally occurring melanocortin analog with C-terminal extension that is not prone to significant degradation means that no more than 50% of the applied peptide causes side effects and / or exhibits a short half-life. In some aspects, no more than 25% of the applied peptide causes side effects and / or exhibits a short half-life. More preferably, in some aspects, compared to non-naturally occurring melanocortin analogs lacking C-terminal extension, less than 10% of the applied peptide causes side effects and / or exhibits a short half-life.

[0361] The term "administering" or "administer" includes the delivery of the techniques of the present invention to a subject by local or systemic administration (e.g., combination therapies, non-natural melanocorticoid analogs (also referred to herein as peptides), anticancer agents). Administration can be local (including ocular and mucous membranes, including vaginal and rectal delivery), pulmonary (e.g., by inhalation or blowing of powders or aerosols, including via nebulizers), intratracheal, intranasal, epidermal and percutaneous, oral, or parenteral administration. Parenteral administration includes intravenous, intra-arterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial (e.g., intrathecal or intraventricular) administration.

[0362] The terms "active ingredient" and "active compound" refer to bioactive substances (whether naturally occurring or non-natural) that are the principal components of a pharmaceutical composition that can produce the intended therapeutic effect. This can be any component that drives pharmacological activity or acts directly on the diagnosis, cure, relief, treatment, or prevention of conditions (such as, but not limited to, loss of appetite and weight loss) related to the technology of this invention.

[0363] As used herein, "composition" or "pharmaceutical composition" refers to a mixture of an active ingredient with other chemical components, such as pharmaceutical carriers and / or excipients.

[0364] As used herein, a “pharmaceutical carrier” for a first or second pharmaceutical composition means a carrier or diluent that does not cause significant irritation to an organism, does not eliminate the bioactivity and properties of the applied active ingredient, and / or does not interact with other components of the composition contained therein in an adverse manner. The term “carrier” encompasses any excipient, binder, diluent, filler, salt, buffer, stabilizer, lipid, or other material well known in the art for use in pharmaceutical formulations. The choice of carrier for use in a composition will depend on the intended mode of administration of the composition. Preparation of pharmaceutical carriers and formulations containing these materials is described, for example, in Remington's Pharmaceutical Sciences, 21st edition, edited by University of the Sciences in Philadelphia, Lippincott, Williams & Wilkins, Philadelphia Pa., 2005, which is incorporated herein by reference in its entirety. Some examples of physiologically acceptable carriers include antioxidants, including ascorbic acid; low molecular weight (less than about 10 residues) peptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents, such as EDTA; sugar alcohols, such as mannitol or sorbitol; salt-forming counterions, such as sodium; and / or nonionic surfactants, such as TWEEN. ® (ICI, Inc.; Bridgewater, NJ), polyethylene glycol (PEG) and PLURONICS ™ (BASF; Florlem Park, NJ). An “excipient” in a first or second pharmaceutical composition means an inert substance added to the composition to further facilitate the administration of the compound. Examples of excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars and starches, cellulose derivatives, gelatin, vegetable oils, and types of polyethylene glycol.

[0365] As used herein, “anticancer agent-related side effects,” “anticancer agent-related adverse side effects,” or “anticancer agent-induced side effects” refer to any unwanted, adverse, or harmful biological activity that occurs during or after the use of an anticancer agent alone. Examples of such side effects include, but are not limited to, anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite. Such anticancer agents may also be administered to subjects for therapeutic purposes other than cancer, such as to treat, alleviate, or prevent symptoms or diseases in subjects who do not have cancer.

[0366] The terms “treat,” “treatment,” and “treating” refer to a manner in which a pharmaceutical composition and / or melanocorticoid analogue is delivered to alleviate a disease outcome. This includes administration techniques as described in the context of the present invention. Therapeutic efficacy can be determined by various assessment methods as described in the present invention, such as assessments of appetite, food consumption, body weight, muscle mass, fat mass, and the measurement of biomarkers. The term “biomarker” refers to a biological output used as a measure of cellular response, whether for assessing a response to treatment, a disease state (such as cachexia), or as a predictor of clinical outcomes. Biomarkers are assessed in the context of cells, tissues, or the entire organism. The term “disease” herein refers to any condition that adversely affects a biological state. This includes weight-related conditions such as cachexia. Disease can also occur in the context of human or animal health.

[0367] The terms “treat,” “treatment,” and “treating” can also refer to the reduction or inhibition of the progression and / or duration of a disease (e.g., cancer), the alleviation or improvement of the severity of the disease, and / or the improvement of one or more of its symptoms by applying one or more therapies. Specifically, these terms can refer to: (1) stabilizing, reducing (e.g., reducing a population of cancer cells and / or tumor size by more than 10%, 20%, 30%, 40%, 50%, or more than 60% prior to application) or eliminating cancer cells; (2) inhibiting cancer cell division and / or cancer cell proliferation; (3) alleviating (or preferably eliminating) to some extent one or more symptoms associated with a pathology related to or partially caused by uncontrolled or abnormal cell division; (4) increasing disease-free, relapse-free, progression-free, and / or overall survival, duration, or rate; (5) reducing hospitalization rates; (6) shortening hospital stays; (7) eradicating, removing, or controlling primary, regional, and / or metastatic cancer; and (8) stabilizing or reducing tumors or neoplasms. (9) inhibiting tumor growth (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% relative to the initial growth rate), (10) reducing mortality, (11) increasing remission rate, duration of remission, or the number of patients responding to or resolving the disease, (12) maintaining tumor size and not increasing it by less than 10%, less than 5%, less than 4%, or less than 2%, (13) reducing the need for surgery (e.g., colectomy, mastectomy), (14) preventing or reducing metastasis of cancer cells, and (15) promoting an increase in and / or maintenance of the quality of the subject, or otherwise preventing or reducing a loss of the subject's quality of life before, during, or after administration of the anticancer agent. The terms “treat,” “treatment,” and “treating” include both preventative and / or therapeutic treatment. If a treatment is administered before the clinical manifestation of the disease, it is considered preventative. Therapeutic treatment includes, for example, improving or reducing the severity of the disease, or shortening the duration or frequency of the disease.

[0368] As used herein, the term "effective dose" or "therapeutic effective dose" refers to the amount of active ingredient administered that will, to a certain extent, alleviate one or more symptoms of the disease being treated. This result can be a reduction and / or relief of the signs, symptoms, or causes of the disease, or any other desired alteration of the biological system. An appropriate "effective dose" can vary from person to person. In any individual case, an appropriate "effective dose" can be determined using techniques such as dose-escalation studies.

[0369] The term "after administration" refers to any duration following administration of a non-naturally occurring melanocortin analogue or its pharmaceutical composition and / or anticancer agent to a subject. "After administration" can also refer to the duration following completion of a single dose or completion of more than one dose (e.g., two doses, three doses, four doses, etc.). In some embodiments, "after administration" refers to completion of a dosing regimen comprising one or more doses. Similarly, the term "before administration" refers to any duration prior to administration of a non-naturally occurring melanocortin analogue or its pharmaceutical composition and / or anticancer agent to a subject. Unless otherwise stated, the durations covered by "after administration" or "before administration" can include seconds, minutes, hours, days, weeks, months, and years.

[0370] Appetite is typically assessed by a subject's and / or patient's desire to eat and / or the amount of food consumed. As used herein, appetite can be assessed using a daily questionnaire administered at a specific time of day or at random times. In the questionnaire, the subject or patient uses a scale ranging from 0 (not hungry at all) to 100 (extremely hungry) to rate their level of hunger and / or desire to eat more of a variety of foods.

[0371] "Cachexia" refers to a state of poor general health and malnutrition, characterized by weight loss, including weight loss, loss of muscle mass (skeletal muscle, smooth muscle, and / or cardiac muscle), loss of fat mass, or a combination thereof, and emaciation. It is often associated with and induced by certain diseases or conditions, such as, but not limited to, cancer, cystic fibrosis, or AIDS. The term "cancer cachexia" refers to cachexia induced by cancer. Diagnostic criteria for cachexia may include: (i) a weight loss of more than 5% in the past 6 months; and (ii) a body mass index (BMI) below 20 kg / m². 2 (iii) Patients with sarcopenia (or whose limb skeletal muscle index is consistent with sarcopenia) experienced a weight loss greater than 2%. See Fearon K et al., Lancet Oncol. 12(5):489-95 (2011). Cachexia can be used interchangeably with the term “protein energy consumption” (i.e., PEW).

[0372] "Anorexia" refers to loss of appetite, whether caused by medical, physiological, or psychological factors. Anorexia is often closely associated with cachexia observed in patients with advanced cancer and other diseases, and is often a trigger for cachexia.

[0373] Body Mass Index (BMI) is a numerical value derived from an individual's weight and height. Specifically, BMI is calculated by dividing weight (in kilograms) by the square of height (in meters). 2 ) Determined, and expressed in "kg / m 2The unit "" indicates the normal BMI range. The "normal" BMI range is known to those skilled in the art and takes into account factors such as patient sex, age, height, race, and body type. Typically, a normal BMI range is approximately 18.5 kg / m². 2 Approximately 25 kg / m 2 .

[0374] The terms "subject" and "patient" refer to any person who is being evaluated for a disease or condition or who is receiving a therapeutic or pharmaceutical composition. This includes people who have not been diagnosed or confirmed with a disease or condition. It also includes people who have been diagnosed or confirmed with a disease or condition such as cancer, loss of appetite, nausea, vomiting, anorexia, or cachexia.

[0375] As used herein, the term "control" refers to any basis used for comparison with a subject (e.g., a test subject). Controls include, but are not limited to, a given measurement of a subject at baseline, any subject not receiving treatment or a pharmaceutical composition (e.g., a non-naturally occurring melanocorticoid analog, a therapeutically effective amount of a non-naturally occurring melanocorticoid analog or a pharmaceutical composition thereof), or any subject receiving a placebo. A control can refer to a measurement from the same subject as the treated subject (e.g., a measurement at baseline or an intermediate time point), or a measurement from a different subject (e.g., a subject who does not have the same treatment or condition as the treated subject).

[0376] All publications, patents, and published patent applications listed herein are incorporated herein by reference in their entirety, including but not limited to U.S. Patent Nos. 8,541,545 and 9,534,018.

[0377] Non-natural melanocortin analogues The present invention provides a non-naturally occurring melanocortin analogue that can be administered to subjects in need. The present invention also provides a method for treating, preventing, or reducing unwanted side effects induced by anticancer agents (e.g., chemotherapy agents) and cancer-related symptoms by administering a non-naturally occurring melanocortin analogue, which may be a non-naturally occurring melanocortin analogue as described herein in any of its embodiments.

[0378] In some embodiments, the non-naturally occurring melanocortin analog comprises a sequence according to formula (I), X 1 X 2 X 3 R 1 R 2 R 3 R 4 R 5 R 6 R 7R 8 R 9 R 10 R 11 R 12 R 13 R 14 R 15 R 16 R 17 R 18 R 19 R 20 Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 (I) in: R 1 The following groups are absent or selected: cysteine, leucine (Nle), acetylated leucine (Ac-Nle), acetylated... trans -4-Guidino-proline (Ac- trans Pro(guan)), acetylation Cis -4-Guidino-proline (Ac- Cis Pro(guan)), trans -4-guanidino-proline ( trans Pro(guan)), Cis -4-guanidino-proline ( Cis Pro(guan)), acetylated cysteine, methylated D-phenylalanine, succinic acid, phthalic acid, tyrosine, D-tyrosine, dimethyltyrosine (Dmt), aspartic acid, glutaric acid, CO-cis-CH═CH—CO, n-valeryl group, n-hexanoyl group, leucine, isoleucine, valine, n-valine, alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, asparagine, acetylated D-arginine, acetylated arginine Acetylated D-methionine, acetylated D-isoleucine, acetylated D-leucine, acetylated D-valine, acetylated alanine, acetylated D-alanine, acetylated tertiary leucine (Ac-Tle), acetylated D-tertiary leucine (Ac-dTle), acetylated normal valine (Ac-Nva), acetylated glycine, acetylated D-proline, acetylated D-phenylalanine, acetylated glutamic acid, acetylated D-tyrosine, acetylated D-glutamine, and acetylated D-asparagine; R 2 The group consisting of the following items is absent or selected: proline, histidine, D-hydroxyproline (dHyp), hydroxyproline (Hyp). transPro(guan), Cis Pro(guan), D-aspartic acid, aspartic acid, D-glutamic acid, glutamic acid, glycine, lysine, alanine, D-alanine, tryptophan, cysteine, D-cysteine, leucine, arginine, succinic acid, glutaric acid, CO-cis-CH═CH—CO, valeryl group, hexanoyl group, methionine, phenylalanine, penicillamine (Pen) and D-penicillamine (dPen); R 3 The group that is absent or selected consists of the following: histidine, histidine methylated at position 1 or 3, D-proline, L-proline, hydroxyproline (Hyp), and D-hydroxyproline (dHyp). trans Pro(guan), Cis Pro(guan), alanine, D-alanine, D-methionine, valine, D-valine, glutamic acid, prolylglycine (Pro-Gly), glycylglycine (Gly-Gly), tryptophanylarginine (Trp-Arg), glycine, phenylalanine, D-phenylalanine, succinic acid, D-leucine, leucine, D-isoleucine, isoleucine, tryptophan, D-tryptophan, arginine, 4-amino-1,2,4,5-tetrahydro 2-Benzazapyroxene-3-one (Aba), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), 1-aminocyclopropane-1-carboxylic acid (Acpc), 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), 7-amino-7,8-dihydro-4H-(1,2,3)triazolo-(1,5-a)(1,4)diazapyroxene-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydroazapyroxene (4,3) -b Indole-3 ( 2H )-ketone (Aia), 1-amino-4-phenylcyclohexanecarboxylic acid (APC), 4-aminophenylpiperidin-4-carboxylic acid (APPC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indoline-2-carboxylic acid (Ioc), 2-aminoindole-2-carboxylic acid (Aic), and 1-amino-1-cyclopentanecarboxylic acid (Cpe); R 4Choose the group consisting of the following: histidine, D-phenylalanine, L-phenylalanine, D-Nal(2'), (o-Phe)Phe, aspartic acid, biphenylalanine (Bip), dBip, glycine, proline, cysteine, p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), p-iodo-D-phenylalanine (p(I)dPhe), p-fluoro-D-phenylalanine (p(F)dPhe), and p-trifluoromethyl-D-phenylalanine (p(CF3)dPhe); R 5 The following groups are not present or are selected from: arginine, homoarginine, ornithine, histidine, alanine, proline. trans Pro(guan), Cis Pro(guan), Pip, Nip, Tic, Phg, Sar, Azt, phenylalanine, D-Nal(2'), lysine, D-arginine, D-ornithine, D-histidine, D-alanine, D-lysine, glycine, aspartic acid, D-aspartic acid, glutamic acid, D-glutamic acid, cysteine ​​and p(I)dPhe; R 6 The group consisting of the following items is absent or selected: D-tryptophan, L-tryptophan, D-Nal(2'), L-Nal(2'), Tic, Bip, arginine, histidine, D-histidine, cysteine, Nal(1'), D-Nal(1'), Aia, D-phenylalanine, phenylalanine, Aba, Ata, tyrosine, D-tyrosine, Pen, dPen, alanine, and D-alanine; R 7 The following groups are not present or are selected: glycine, aspartic acid, glutamic acid, cysteine, lysine, D-cysteine, D-lysine, 2,3-diaminopropionic acid (Dap), methionine, proline, tryptophan, D-Nal(2'), ornithine, D-ornithine, Pen, dPen and tetrahydro-isoquinoline-3-carboxylic acid (Tic); R 8 It is absent or contains lysine or arginine; R 9 It is absent or contains tryptophan; R 10 It is absent or contains lysine; R 11 To R 20The following groups are not present independently or are selected from: cysteine, leucine, tyrosine, aspartic acid, leucine, isoleucine, valine, valine, alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, arginine, histidine, hydroxyproline, D-hydroxyproline, D-proline, prolylglycine (Pro-Gly), D-Nal (2'), L-Nal (2'), Bip, ornithine, and tryptophan; Where R 2 If it is a n-valeryl group or a n-hexanoyl group, then R 1 X 1 X 2 and X 3 It does not exist; X 1 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, β-homoproline, D-alanine, L-alanine, β-alanine, D-arginine, L-arginine, D-valine, L-valine, β-valine, D-leucine, L-leucine, β-leucine, D-isoleucine, L-isoleucine, β-isoleucine, piperazine-2-one ring, valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, acetylated D-arginine, acetylated L-arginine, acetylated D-valine, and acetylated leucine. X 2 The following groups are not present or are selected: D-threonine, D-proline, L-proline, β-homoproline, D-alanine, L-alanine, β-alanine, D-valine, L-valine, β-valine, D-leucine, L-leucine, β-leucine, D-isoleucine, L-isoleucine, β-isoleucine, piperazine-2-one ring, valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, and leucine; X 3 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, β-homoproline, D-alanine, L-alanine, D-valine, L-valine, β-valine, D-leucine, L-leucine, β-leucine, D-isoleucine, L-isoleucine, β-isoleucine, piperazine-2-one ring, valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, and leucine; Y 1Choose the group consisting of the following: D-alanine, L-alanine, β-alanine, D-threonine, L-threonine, β-threonine, D-valine, L-valine, β-valine, (3-methyl)-β-valine, D-leucine, L-leucine, β-leucine, D-isoleucine, L-isoleucine, β-isoleucine, D-tert-leucine, L-tert-leucine, leucine, L-proline, D-proline, β-homoproline, piperazine-2-one ring, Hyp, dHyp, glycine, aspartic acid, D-aspartic acid, L-arginine, D-arginine, L-asparagine, D-asparagine, L-lysine, D-lysine, and L-tryptophan; Y 2 The group consisting of or not present in the following groups is selected: D-proline, L-proline, β-homoproline, piperazine-2-one ring, D-threonine, L-threonine, β-threonine, D-valine, L-valine, β-valine, (3-methyl)-β-valine, D-leucine, L-leucine, β-leucine, D-isoleucine, L-isoleucine, β-isoleucine, D-tert-leucine, L-tert-leucine, ortholeucine, Hyp, dHyp, D-alanine, L-alanine, β-alanine, glycine, aspartic acid, D-aspartic acid, arginine, D-arginine, asparagine, and D-asparagine. Y 3 The group consisting of or not present in the following groups is selected: D-cysteine, L-cysteine, D-threonine, L-threonine, D-alanine, L-alanine, D-lysine, L-lysine, D-proline, L-proline, D-valine, L-valine, β-valine, (3-methyl)-β-valine, D-leucine, L-leucine, β-leucine, D-isoleucine, L-isoleucine, β-isoleucine, and piperazine-2-one ring; Y 4 It may be absent or contain D-aspartic acid, aspartic acid, D-proline or D-valine; Y 5 It is absent or is either D-proline or D-valine; Y 6 It is absent or is either D-proline or D-valine; Y 7 It is absent or is either D-proline or D-valine; Y 8 It is absent or is either D-proline or D-valine; This non-natural melanocortin analogue is optionally cyclized via a portion selected from the group consisting of: When R 1 Or R 2 For cysteine ​​and R 7or X 1 When it is cysteine, R 1 Or R 2 With R 7 or X 1 disulfide bonds between them; When R 2 and R 5 To R 20 When any one of the components is selected from the group consisting of D-cysteine, cysteine, Pen, and dPen, R 2 With R 5 To R 20 Disulfide bonds between any of them; When R 1 It is leucine and R 7 When it is glutamic acid, R 1 With R 7 The lactam bridge between them; When R 1 Or R 2 It is glutamic acid, aspartic acid, or CO-cis-CH═CH—CO and R 7 When it is lysine, D-lysine, Dap, D-ornithine, or ornithine, R 1 Or R 2 With R 7 Side-chain lactam bridges between them; When R 2 For lysine and R 7 When it is glutamic acid or aspartic acid, R 2 With R 7 Side-chain lactam bridges between them; When R 1 Or R 2 It is either glutamic acid or aspartic acid, R 8 For lysine and R 7 When it is glycine, proline or tryptophan, R 1 Or R 2 With R 8 Side-chain lactam bridges between them; When R 2 It is glutamic acid or aspartic acid and R 10 When it is lysine, R 2 Or R 4 With R 10 Side-chain lactam bridges between them; When R 1 It is succinic acid or phthalic acid and R 7 When it is lysine, R 1 With R 7 The closure of the lactam between them; and When R 2 It is succinic acid and R7 When it is 2,3-diamino-propionic acid, R 2 With R 7 The lactam closure between them; X 1 X 2 X 3 Indicates the optional presence of an N-terminus; and Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Indicates the C-terminus.

[0379] In some embodiments of equation (I): R 1 The group consisting of the following items is absent or selected: cysteine, norepinephrine (Nle), acetylated norepinephrine (Ac-Nle). trans -4-guanidino-proline ( trans Pro(guan)), Cis -4-guanidino-proline ( Cis Pro(guan)), acetylation trans -4-Guidino-proline (Ac- trans Pro(guan)), acetylation Cis -4-Guidino-proline (Ac- Cis Pro(guan)), acetylated cysteine, methylated D-phenylalanine, succinic acid, phthalic acid, tyrosine, D-tyrosine, dimethyltyrosine (Dmt), aspartic acid, glutaric acid, CO-cis-CH═CH—CO, n-valeryl group, n-hexanoyl group, leucine, isoleucine, valine, n-valine, alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, asparagine, acetylated D-arginine, acetyl Arginine, acetylated D-methionine, acetylated D-isoleucine, acetylated D-leucine, acetylated D-valine, acetylated alanine, acetylated D-alanine, acetylated tertiary leucine (Tle), acetylated D-tertiary leucine (dTle), acetylated normal valine (Nva), acetylated glycine, acetylated D-proline, acetylated D-phenylalanine, acetylated glutamic acid, acetylated D-tyrosine, acetylated D-glutamine, and acetylated D-asparagine; R 2 The group consisting of the following items is absent or selected: proline, histidine, D-hydroxyproline (dHyp), hydroxyproline (Hyp). trans Pro(guan), CisPro(guan), D-aspartic acid, aspartic acid, D-glutamic acid, glutamic acid, glycine, lysine, alanine, D-alanine, tryptophan, D-cysteine, cysteine, leucine, arginine, succinic acid, glutaric acid, CO-cis-CH═CH—CO, valeryl group, hexanoyl group, methionine, phenylalanine, penicillamine (Pen) and D-penicillamine (dPen); R 3 The group that is absent or selected consists of the following: histidine, histidine methylated at position 1 or 3, D-proline, L-proline, hydroxyproline (Hyp), and D-hydroxyproline (dHyp). trans Pro(guan), Cis Pro(guan), alanine, D-alanine, D-methionine, valine, D-valine, glutamic acid, prolylglycine (Pro-Gly), glycylglycine (Gly-Gly), tryptophanylarginine (Trp-Arg), glycine, phenylalanine, D-phenylalanine, succinic acid, D-leucine, leucine, D-isoleucine, isoleucine, tryptophan, D-tryptophan, arginine, 4-amino-1,2,4,5-tetrahydro 2-Benzazapyroxene-3-one (Aba), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), 1-aminocyclopropane-1-carboxylic acid (Acpc), 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), 7-amino-7,8-dihydro-4H-(1,2,3)triazolo-(1,5-a)(1,4)diazapyroxene-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydroazapyroxene (4,3) -b Indole-3 ( 2H )-ketone (Aia), 1-amino-4-phenylcyclohexanecarboxylic acid (APC), 4-aminophenylpiperidin-4-carboxylic acid (APPC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indoline-2-carboxylic acid (Ioc), 2-aminoindole-2-carboxylic acid (Aic), and 1-amino-1-cyclopentanecarboxylic acid (Cpe); R 4 Choose the group consisting of the following: histidine, D-phenylalanine, L-phenylalanine, D-Nal(2'), (o-Phe)Phe, aspartic acid, biphenylalanine (Bip), dBip, glycine, proline, cysteine, p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), p-iodo-D-phenylalanine (p(I)dPhe), p-fluoro-D-phenylalanine (p(F)dPhe), and p-trifluoromethyl-D-phenylalanine (p(CF3)dPhe); R 5 The following groups are not present or are selected from: arginine, homoarginine, ornithine, histidine, alanine, proline. trans Pro(guan), Cis Pro(guan), Pip, Nip, Tic, Phg, Sar, Azt, phenylalanine, D-Nal(2'), lysine, D-arginine, D-ornithine, D-histidine, D-alanine, D-lysine, glycine, aspartic acid, D-aspartic acid, glutamic acid, D-glutamic acid, cysteine ​​and p(I)dPhe; R 6 The group consisting of the following items is absent or selected: D-tryptophan, L-tryptophan, D-Nal(2'), L-Nal(2'), Tic, Bip, arginine, histidine, D-histidine, cysteine, Nal(1'), D-Nal(1'), Aia, D-phenylalanine, phenylalanine, Aba, Ata, tyrosine, D-tyrosine, Pen, dPen, alanine, and D-alanine; R 7 The following groups are not present or are selected: glycine, aspartic acid, glutamic acid, cysteine, lysine, D-cysteine, D-lysine, 2,3-diaminopropionic acid (Dap), methionine, proline, tryptophan, D-Nal(2'), ornithine, D-ornithine, Pen, dPen and tetrahydro-isoquinoline-3-carboxylic acid (Tic); R 8 It is absent or contains lysine or arginine; R 9 It is absent or contains tryptophan; R 10 It is absent or contains lysine; R 11 To R 20 The following groups are not present independently or are selected from: cysteine, leucine, tyrosine, aspartic acid, leucine, isoleucine, valine, valine, alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, arginine, histidine, hydroxyproline, D-hydroxyproline, D-proline, prolylglycine (Pro-Gly), D-Nal (2'), L-Nal (2'), Bip, ornithine, and tryptophan; Where R 2 If it is a n-valeryl group or a n-hexanoyl group, then R 1 X 1 X 2 and X 3 It does not exist; X1 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, β-homoproline, D-alanine, L-alanine, β-alanine, D-arginine, L-arginine, D-valine, L-valine, β-valine, D-leucine, L-leucine, β-leucine, D-isoleucine, L-isoleucine, β-isoleucine, piperazine-2-one ring, valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, acetylated D-arginine, acetylated L-arginine, acetylated D-valine, and acetylated leucine. X 2 The following groups are not present or are selected: D-threonine, D-proline, L-proline, β-homoproline, D-alanine, L-alanine, β-alanine, D-valine, L-valine, β-valine, D-leucine, L-leucine, β-leucine, D-isoleucine, L-isoleucine, β-isoleucine, piperazine-2-one ring, valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, and leucine; X 3 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, β-homoproline, D-alanine, L-alanine, D-valine, L-valine, β-valine, D-leucine, L-leucine, β-leucine, D-isoleucine, L-isoleucine, β-isoleucine, piperazine-2-one ring, valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, and leucine; Y 1 Choose the group consisting of the following: D-alanine, L-alanine, D-valine, L-valine, D-leucine, L-leucine, D-isoleucine, L-isoleucine, D-tert-leucine, L-tert-leucine, leucine, L-proline, D-proline, Hyp, dHyp, glycine, aspartic acid, D-aspartic acid, arginine, D-arginine, asparagine, D-asparagine, lysine, D-lysine, and tryptophan; Y 2 The group consisting of the following items is absent or selected: D-proline, L-proline, D-valine, L-valine, D-tert-leucine, L-tert-leucine, normal leucine, Hyp, dHyp, D-alanine, L-alanine, glycine, aspartic acid, D-aspartic acid, arginine, D-arginine, asparagine and D-asparagine; Y 3The group consisting of the following is absent or selected: D-lysine, L-lysine, D-proline, L-proline, D-valine, and L-valine; Y 4 It may be absent or contain D-aspartic acid, aspartic acid, D-proline or D-valine; Y 5 It is absent or is either D-proline or D-valine; Y 6 It is absent or is either D-proline or D-valine; Y 7 It is absent or is either D-proline or D-valine; Y 8 It is absent or is either D-proline or D-valine; This non-natural melanocortin analogue is optionally cyclized via a portion selected from the group consisting of: When R 1 Or R 2 For cysteine ​​and R 7 or X 1 When it is cysteine, R 1 Or R 2 With R 7 or X 1 disulfide bonds between them; When R 2 and R 5 To R 20 When any one of the following is selected from the group consisting of D-cysteine, cysteine, Dap, Pen, and dPen, R 2 With R 5 To R 20 Disulfide bonds between any of them; When R 1 It is leucine and R 7 When it is glutamic acid, R 1 With R 7 The lactam bridge between them; When R 1 Or R 2 It is glutamic acid, aspartic acid, or CO-cis-CH═CH—CO and R 7 When it is lysine, D-lysine, D-ornithine or ornithine, R 1 Or R 2 With R 7 Side-chain lactam bridges between them; When R 2 For lysine and R 7 When it is glutamic acid or aspartic acid, R 2 With R 7 Side-chain lactam bridges between them; When R1 Or R 2 It is either glutamic acid or aspartic acid, R 8 For lysine and R 7 When it is proline, glycine, or tryptophan, R 1 Or R 2 With R 8 Side-chain lactam bridges between them; When R 2 It is glutamic acid or aspartic acid and R 10 When it is lysine, R 2 Or R 4 With R 10 Side-chain lactam bridges between them; When R 1 It is succinic acid or phthalic acid and R 7 When it is lysine, R 1 With R 7 The closure of the lactam between them; and When R 2 It is succinic acid and R 7 When it is 2,3-diamino-propionic acid, R 2 With R 7 The lactam closure between them; X 1 X 2 X 3 Indicates the optional presence of an N-terminus; and Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Indicates the C-terminus.

[0380] In some embodiments of equation (I): R 1 The group consisting of the following items is absent or selected: cysteine, norepinephrine (Nle), acetylated norepinephrine (Ac-Nle). trans -4-guanidino-proline ( trans Pro(guan)), Cis -4-guanidino-proline ( Cis Pro(guan)), acetylation trans -4-Guidino-proline (Ac- trans Pro(guan)), acetylation Cis -4-Guidino-proline (Ac- CisPro(guan)), acetylated cysteine, tyrosine, D-tyrosine, dimethyltyrosine (Dmt), aspartic acid, glutaric acid, leucine, isoleucine, valine, normal valine (Nva), alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, asparagine, acetylated D-arginine, acetylated D-methionine, acetylated D-isoleucine, acetylated D-leucine, acetylated D-valine, acetylated alanine, acetylated D-alanine, acetylated tertiary leucine (Tle), acetylated D-tertiary leucine (dTle), acetylated normal valine (Ac-Nva), acetylated glycine, acetylated D-proline, acetylated D-phenylalanine, acetylated glutamic acid, acetylated D-tyrosine, acetylated D-glutamine, and acetylated D-asparagine; R 2 The group consisting of the following items is absent or selected: proline, histidine, D-hydroxyproline (dHyp), hydroxyproline (Hyp). trans Pro(guan), Cis Pro(guan), D-aspartic acid, aspartic acid, D-glutamic acid, glutamic acid, glycine, lysine, alanine, D-alanine, tryptophan, D-cysteine, cysteine, leucine, arginine, succinic acid, glutaric acid, CO-cis-CH═CH—CO, methionine, phenylalanine, penicillamine (Pen) and D-penicillamine (dPen); R 3 The group consisting of the following is absent or selected: histidine, D-proline, L-proline, hydroxyproline (Hyp), D-hydroxyproline (dHyp). trans Pro(guan), Cis Pro(guan), alanine, D-alanine, D-methionine, valine, D-valine, glutamic acid, prolylglycine (Pro-Gly), glycylglycine (Gly-Gly), tryptophanylarginine (Trp-Arg), glycine, phenylalanine, D-phenylalanine, D-leucine, leucine, D-isoleucine, isoleucine, tryptophan, D-tryptophan, arginine, 4-amino-1,2,4,5-tetrahydro-2 Benzazapyroxene-3-one (Aba), β-alanine (β-Ala), 3-aminomethylbenzoic acid (Mamb), 1-aminocyclopropane-1-carboxylic acid (Acpc), 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), 7-amino-7,8-dihydro-4H-(1,2,3)triazolo-(1,5-a)(1,4)diazapyroxene-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydroazapyroxene (4,3) -b Indole-3 ( 2H)-ketone (Aia), 1-amino-4-phenylcyclohexanecarboxylic acid (APC), 4-aminophenylpiperidin-4-carboxylic acid (APPC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indoline-2-carboxylic acid (Ioc), 2-aminoindole-2-carboxylic acid (Aic), and 1-amino-1-cyclopentanecarboxylic acid (Cpe); R 4 Choose the group consisting of the following: histidine, D-phenylalanine, L-phenylalanine, D-Nal(2'), aspartic acid, biphenylalanine (Bip), dBip, glycine, proline, cysteine, p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), p-iodo-D-phenylalanine (p(I)dPhe), p-fluoro-D-phenylalanine (p(F)dPhe), and p-trifluoromethyl-D-phenylalanine (p(CF3)dPhe); R 5 The following groups are not present or are selected from: arginine, homoarginine, ornithine, histidine, alanine, proline. trans Pro(guan), Cis Pro(guan), Pip, Nip, Tic, Phg, Sar, Azt, phenylalanine, D-Nal(2'), lysine, D-arginine, D-ornithine, D-histidine, D-alanine, D-lysine, glycine, aspartic acid, D-aspartic acid, glutamic acid, D-glutamic acid, cysteine ​​and p(I)dPhe; R 6 The group consisting of the following items is absent or selected: L-tryptophan, D-Nal(2'), L-Nal(2'), Tic, Bip, arginine, histidine, D-histidine, cysteine, Nal(1'), D-Nal(1'), Aia, D-phenylalanine, phenylalanine, Aba, Ata, tyrosine, D-tyrosine, Pen, dPen, alanine, and D-alanine; R 7 The following groups are not present or are selected: glycine, aspartic acid, glutamic acid, cysteine, lysine, D-cysteine, D-lysine, 2,3-diaminopropionic acid (Dap), methionine, proline, tryptophan, D-Nal(2'), ornithine, D-ornithine, Pen, dPen and tetrahydro-isoquinoline-3-carboxylic acid (Tic); R 8 It is absent or contains lysine or arginine; R 9 It is absent or contains tryptophan; R10 It is absent or contains lysine; R 11 To R 20 It does not exist; X 1 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, D-alanine, L-alanine, β-alanine, D-arginine, L-arginine, D-valine, L-valine, D-leucine, L-leucine, D-isoleucine, L-isoleucine, n-valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, acetylated D-arginine, acetylated L-arginine, acetylated D-valine, and acetylated n-leucine; X 2 The group consisting of the following is absent or selected: D-threonine, D-proline, L-proline, D-alanine, L-alanine, β-alanine, D-valine, L-valine, β-valine, D-leucine, L-leucine, D-isoleucine, L-isoleucine, valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, and leucine; X 3 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, D-alanine, L-alanine, D-valine, L-valine, D-leucine, L-leucine, D-isoleucine, L-isoleucine, valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, and leucine; Y 1 The following groups are not present or are selected: D-alanine, L-alanine, D-valine, L-valine, D-tert-leucine, L-tert-leucine, leucine, L-proline, D-proline, Hyp, dHyp, glycine, aspartic acid, D-aspartic acid, arginine, D-arginine, asparagine, D-asparagine, lysine, D-lysine, and tryptophan; Y 2 The group consisting of the following items is absent or selected: D-proline, L-proline, D-valine, L-valine, D-tert-leucine, L-tert-leucine, normal leucine, Hyp, dHyp, D-alanine, L-alanine, glycine, aspartic acid, D-aspartic acid, arginine, D-arginine, asparagine and D-asparagine; Y 3The group consisting of the following is absent or selected: D-lysine, L-lysine, D-proline, L-proline, D-valine, and L-valine; Y 4 It may be absent or contain D-aspartic acid, aspartic acid, D-proline or D-valine; Y 5 It is absent or is either D-proline or D-valine; Y 6 It is absent or is either D-proline or D-valine; Y 7 It is absent or is either D-proline or D-valine; Y 8 It is absent or is either D-proline or D-valine; This non-natural melanocortin analogue is optionally cyclized via a portion selected from the group consisting of: When R 1 Or R 2 For cysteine ​​and R 7 or X 1 When it is cysteine, R 1 Or R 2 With R 7 or X 1 disulfide bonds between them; When R 2 and R 5 To R 20 When any one of the following is selected from the group consisting of D-cysteine, cysteine, Dap, Pen, and dPen, R 2 With R 5 To R 20 Disulfide bonds between any of them; When R 1 It is leucine and R 7 When it is glutamic acid, R 1 With R 7 The lactam bridge between them; When R 1 Or R 2 It is glutamic acid, aspartic acid, or CO-cis-CH═CH—CO and R 7 When it is lysine, D-lysine, D-ornithine or ornithine, R 1 Or R 2 With R 7 Side-chain lactam bridges between them; When R 2 For lysine and R 7 When it is glutamic acid or aspartic acid, R 2 With R 7 Side-chain lactam bridges between them; When R1 Or R 2 It is either glutamic acid or aspartic acid, R 8 For lysine and R 7 When it is proline, glycine, or tryptophan, R 1 Or R 2 With R 8 Side-chain lactam bridges between them; When R 2 It is glutamic acid or aspartic acid and R 10 When it is lysine, R 2 Or R 4 With R 10 Side-chain lactam bridges between them; The conditions are: When R 2 When it is dAsp, then R 7 Not for dLys; When R 2 To R 4 When R is Asp-His-dNal(2'), Asp-Pro-dNal(2'), or Asp-Pro-dPhe, then 5 To R 7 Not Arg-Trp-Lys; and When Y 1 For dPro, Y 2 For dVal, Y 3 To Y 8 If it does not exist, then R 4 Not dNal(2') or R 4 It is dNal(2') and the C-terminus is not modified.

[0381] In some embodiments, non-natural melanocortin analogues comprise the sequence of formula (I), wherein: R 1 The group consisting of the following items is absent or selected: cysteine, norepinephrine (Nle), acetylated norepinephrine (Ac-Nle). trans -4-guanidino-proline ( trans Pro(guan)), Cis -4-guanidino-proline ( Cis Pro(guan)), acetylation trans -4-Guidino-proline (Ac- trans Pro(guan)), acetylation Cis -4-Guidino-proline (Ac- CisPro(guan)), tyrosine, D-tyrosine, dimethyltyrosine (Dmt), aspartic acid, glutaric acid, leucine, isoleucine, valine, normal valine (Nva), alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, asparagine, and acetylated glutamic acid; R 2 The group consisting of the following items is absent or selected: proline, histidine, D-hydroxyproline (dHyp). trans Pro(guan), Cis Pro(guan), aspartic acid, glutamic acid, glycine, lysine, alanine, D-alanine, cysteine, leucine, arginine, succinic acid, glutaric acid, methionine, and phenylalanine; R 3 The following groups are not present or are selected: histidine, L-proline, trans Pro(guan), Cis Pro(guan), D-valine, glutamic acid, tryptophanyl arginine (Trp-Arg), glycine, D-leucine, D-isoleucine, tryptophan, arginine, 4-amino-1,2,4,5-tetrahydro-2-benzozazepine-3-one (Aba), 7-amino-7,8-dihydro-4H-(1,2,3)triazol-(1,5-a)(1,4)diazepine-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydroazazepine (4,3) -b Indole-3 ( 2H )-ketone (Aia), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), and indoline-2-carboxylic acid (Ioc). R 4 Select the group consisting of the following: histidine, D-phenylalanine, L-phenylalanine, D-Nal(2'), aspartic acid, dBip, glycine, proline, cysteine, p-chloro-D-phenylalanine (p(Cl)dPhe), p-iodo-D-phenylalanine (p(I)dPhe), p-fluoro-D-phenylalanine (p(F)dPhe), and p-trifluoromethyl-D-phenylalanine (p(CF3)dPhe); R 5 The following groups are not present or are selected: arginine, high arginine, proline, trans Pro(guan), Cis Pro(guan), Pip, Nip, Tic, Phg, Sar, Azt, phenylalanine, D-Nal(2'), D-histidine, D-alanine, D-aspartic acid, D-glutamic acid, cysteine ​​and p(I)dPhe; R 6 The group consisting of the following items is absent or selected: L-tryptophan, D-phenylalanine, D-Nal(2'), L-Nal(2'), Tic, Bip, arginine, D-histidine, cysteine, D-Nal(1'), Aba, Ata, D-tyrosine, Pen, dPen and D-alanine; R 7 The group consisting of the following is absent or selected: glycine, aspartic acid, glutamic acid, cysteine, lysine, 2,3-diamino-propionic acid (Dap), methionine, proline, tryptophan, D-Nal(2') and tetrahydro-isoquinoline-3-carboxylic acid (Tic); R 8 It may be absent or contain lysine; R 9 To R 20 It does not exist; X 1 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, D-alanine, L-alanine, β-alanine, D-arginine, L-arginine, D-valine, L-valine, D-leucine, L-leucine, D-isoleucine, L-isoleucine, n-valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, acetylated D-arginine, acetylated L-arginine, acetylated D-valine, and acetylated n-leucine; X 2 It may be absent or contain D-proline; X 3 It does not exist; Y 1 The group consisting of the following is absent or selected: D-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and D-proline; Y 2 The group consisting of the following is absent or selected: D-proline, L-proline, Hyp, D-valine, L-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and glycine; Y 3 The group consisting of the following is absent or selected: D-lysine, L-lysine, D-proline, L-proline, D-valine, and L-valine; Y 4 It is absent or is either D-aspartic acid or aspartic acid; Y 5 To Y 8 It does not exist; This non-natural melanocortin analogue is optionally cyclized via a portion selected from the group consisting of: When R 1 For cysteine ​​and R 7 When it is cysteine, R 1 With R 7 disulfide bonds between them; When R 1 It is leucine and R 7 When it is glutamic acid, R 1 With R 7 The lactam bridge between them; When R 1 Or R 2 It is glutamic acid or aspartic acid and R 7 When it is lysine or Dap, R 1 Or R 2 With R 7 Side-chain lactam bridges between them; When R 2 For lysine and R 7 When it is glutamic acid or aspartic acid, R 2 With R 7 Side-chain lactam bridges between them; When R 1 Or R 2 It is either glutamic acid or aspartic acid, R 8 For lysine and R 7 When it is proline, glycine, or tryptophan, R 1 Or R 2 With R 8 Side-chain lactam bridges between them; The conditions are: When R 2 When it is dAsp, then R 7 Not for dLys; When R 2 To R 4 When R is Asp-His-dNal(2'), Asp-Pro-dNal(2'), or Asp-Pro-dPhe, then 5 To R 7 Not Arg-Trp-Lys; When Y 1 For dPro, Y 2 For dVal and Y 3 To Y 8 If it does not exist, then R 4 Not dNal(2') or R 4 It is dNal(2') and the C-terminus is not modified; When R 3For Aba, Ata, or Aia, R 6 When it is Aia, then R 4 Not dNal(2'), or R 4 For dNal(2') and R 5 Not for Arg; When R 4 When R is p(Cl)dPhe, then 3 Not Pro or His; When R 4 When the value is p(I)dPhe, this non-natural melanocortin analogue is obtained through R. 1 With R 7 The side-chain lactam bridged cyclization between them, and R 2 and R 3 At least one of them is Pro; When Y 2 To Y 4 If it does not exist, then Y 1 It is absent or contains ortholeucine; When R 2 For Pro or Y 2 When it is Hyp, then R 3 Not for Pro; When R 3 R 5 Or R 6 If it does not exist, then this non-natural melanocortin analogue is obtained through R. 1 With R 7 The cyclization of lactams between them, or X 1 To X 2 It exists and is Ac-dVal-dPro; When R 2 To R 7 When it is Asp-Pro-dNal(2')-Arg-Trp-Lys (SEQ ID NO: 526) or Cys-Pro-dNal(2')-Arg-Trp-Cys (SEQ ID NO: 527), then R 1 Not Ac-Nle or Y 1 To Y 2 Not dVal-dPro, dVal-dVal, or dPro-dPro; and When this non-natural melanocortin analogue is administered via R 2 With R 8 When the lactam bridge between them is cyclized, then R 3 Not His or Y 1 Not dVal.

[0382] In some embodiments, non-natural melanocortin analogues comprise the sequence of formula (I), wherein: R 1 The group consisting of the following items is absent or selected: cysteine, norepinephrine (Nle), acetylated norepinephrine (Ac-Nle). trans -4-guanidino-proline ( trans Pro(guan)), Cis -4-guanidino-proline ( Cis Pro(guan)), acetylation trans -4-Guidino-proline (Ac- trans Pro(guan)), acetylation Cis -4-Guidino-proline (Ac- Cis Pro(guan)), tyrosine, D-tyrosine, dimethyltyrosine (Dmt), aspartic acid, glutaric acid, leucine, isoleucine, valine, normal valine (Nva), alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, asparagine, and acetylated glutamic acid; R 2 The group consisting of the following items is absent or selected: proline, histidine, D-hydroxyproline (dHyp). trans Pro(guan), Cis Pro(guan), aspartic acid, glutamic acid, glycine, lysine, alanine, D-alanine, cysteine, leucine, arginine, succinic acid, glutaric acid, methionine, and phenylalanine; R 3 The following groups are not present or are selected: histidine, L-proline, trans Pro(guan), Cis Pro(guan), D-valine, glutamic acid, tryptophanyl arginine (Trp-Arg), glycine, D-leucine, D-isoleucine, tryptophan, arginine, 4-amino-1,2,4,5-tetrahydro-2-benzozazepine-3-one (Aba), 7-amino-7,8-dihydro-4H-(1,2,3)triazol-(1,5-a)(1,4)diazepine-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydroazazepine (4,3) -b Indole-3 ( 2H )-ketone (Aia), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), and indoline-2-carboxylic acid (Ioc). R 4Select the group consisting of the following: histidine, D-phenylalanine, L-phenylalanine, D-Nal(2'), aspartic acid, dBip, glycine, proline, cysteine, p-chloro-D-phenylalanine (p(Cl)dPhe), p-iodo-D-phenylalanine (p(I)dPhe), p-fluoro-D-phenylalanine (p(F)dPhe), and p-trifluoromethyl-D-phenylalanine (p(CF3)dPhe); R 5 The following groups are not present or are selected: arginine, high arginine, proline, trans Pro(guan), Cis Pro(guan), Pip, Nip, Tic, Phg, Sar, Azt, phenylalanine, D-Nal(2'), D-histidine, D-alanine, D-aspartic acid, D-glutamic acid, cysteine ​​and p(I)dPhe; R 6 The group consisting of the following items is absent or selected: L-tryptophan, D-phenylalanine, D-Nal(2'), L-Nal(2'), Tic, Bip, arginine, D-histidine, cysteine, D-Nal(1'), Aba, Ata, D-tyrosine, Pen, dPen and D-alanine; R 7 The group consisting of the following is absent or selected: glycine, aspartic acid, glutamic acid, cysteine, lysine, 2,3-diamino-propionic acid (Dap), methionine, proline, tryptophan, D-Nal(2') and tetrahydro-isoquinoline-3-carboxylic acid (Tic); R 8 It may be absent or contain lysine; R 9 To R 20 It does not exist; X 1 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, D-alanine, L-alanine, β-alanine, D-arginine, L-arginine, D-valine, L-valine, D-leucine, L-leucine, D-isoleucine, L-isoleucine, n-valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, acetylated D-arginine, acetylated L-arginine, acetylated D-valine, and acetylated n-leucine; X 2 It may be absent or contain D-proline; X 3 It does not exist; Y 1The group consisting of the following is absent or selected: D-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and D-proline; Y 2 The group consisting of the following is absent or selected: D-proline, L-proline, Hyp, D-valine, L-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and glycine; Y 3 The group consisting of the following is absent or selected: D-lysine, L-lysine, D-proline, L-proline, D-valine, and L-valine; Y 4 It is absent or is either D-aspartic acid or aspartic acid; Y 5 To Y 8 It does not exist; This non-natural melanocortin analogue is optionally cyclized via a portion selected from the group consisting of: When R 1 For cysteine ​​and R 7 When it is cysteine, R 1 With R 7 disulfide bonds between them; When R 1 It is leucine and R 7 When it is glutamic acid, R 1 With R 7 The lactam bridge between them; When R 1 Or R 2 It is glutamic acid or aspartic acid and R 7 When it is lysine or Dap, R 1 Or R 2 With R 7 Side-chain lactam bridges between them; When R 2 For lysine and R 7 When it is glutamic acid or aspartic acid, R 2 With R 7 Side-chain lactam bridges between them; When R 1 Or R 2 It is either glutamic acid or aspartic acid, R 8 For lysine and R 7 When it is proline, glycine, or tryptophan, R 1 Or R 2 With R 8 Side-chain lactam bridges between them; The condition is that the non-natural melanocortin analogue does not contain a sequence selected from the group consisting of: Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-NH2(SEQ ID NO: 139); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-NH2(SEQ ID NO: 140); Ac-Nle-c(Asp-Aba-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 207); Ac-Nle-c(Asp-Aia-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 208); Ac-Nle-c(Asp-Ata-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 209), Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dVal-dVal-dPro-NH2(SEQ IDNO: 192); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-dVal-dPro-NH2(SEQ IDNO: 193); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dVal-dPro-NH2(SEQ ID NO:190); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dVal-dPro-NH2(SEQ ID NO:191); Ac-Nle-c(Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:391); Ac-Nle-c(Asp-His-p(Cl)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:396); Ac-Nle-c(Asp-His-Arg-p(I)dPhe-Arg-Tic-Lys)-dVal-dPro-NH2(SEQ ID NO:376); Ac-Nle-c(Asp-Pro-p(I)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 392); Ac-Nle-c(Asp-His-p(I)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 397); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dVal-NH2(SEQ ID NO: 137); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dPro-NH2(SEQ ID NO: 138); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-OH (SEQ ID NO: 127); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-Hyp-NH2(SEQ ID NO: 129); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Val-Hyp-NH2(SEQ ID NO: 131); Ac-Nle-c(Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:198); Ac-Nle-c(Asp-Pro-Pro-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 401); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Aia-Lys)-dVal-dPro-NH2(SEQ ID NO: 114); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 3;B07); Ac-Nle-Asp-Pro-dNal(2')-Arg-Trp-Lys-dVal-dPro-NH2(SEQ ID NO: 13;A1); Ac-Nle-c(Asp-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 71); Ac-Nle-c(Cys-dNal(2')-Arg-Trp-Cys)-dVal-dPro-NH2(SEQ ID NO: 46); Ac-Nle-c(Asp-Pro-dNal(2')-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 97); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Lys)-dVal-dPro-NH2(SEQ ID NO: 112); Ac-Nle-c(Asp-Pro-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:5;D1); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Pro-Lys)-dVal-dPro-NH2(SEQ ID NO:8;D2); Ac-Nle-c(Cys-Pro-dNal(2')-Arg-Trp-Cys)-dVal-dPro-NH2(SEQ ID NO: 42); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dVal-NH2(SEQ ID NO: 286); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dPro-dVal-NH2(SEQ ID NO: 287); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-dPro-dVal-NH2(SEQ ID NO:288); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-dPro-dVal-NH2(SEQ ID NO:289); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 291); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-dVal-dPro-NH2 (SEQ ID NO: 292); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-dVal-dPro-NH2 (SEQ ID NO: 293); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-dPro-dVal-NH2 (SEQ ID NO: 420); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-dPro-dVal-NH2 (SEQ ID NO: 421); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 424); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 425); and Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-dVal-dPro-NH2 (SEQ ID NO: 426).

[0383] In some embodiments, the non-naturally occurring melanocortin analogue has one or more β-hairpin (β-hairpin) and / or β-turn (β-turn) structures. In some embodiments, the β-hairpin and / or β-turn structure of the non-naturally occurring melanocortin analogue is provided by R3 of the sequence of formula (I), which may be D-proline, L-proline, hydroxyproline, D-hydroxyproline, D-alanine, D-methionine, D-valine, prolylglycine (Pro-Gly), glycine, trans-Pro (guan), cis-Pro (guan)). In some embodiments, if present, the β-hairpin and / or β-turn structure of the non-naturally occurring melanocortin analogue is provided by disulfide bonds of the sequence of formula (I).

[0384] In some embodiments, if present, the N-terminus of the non-naturally occurring melanocortin analog is modified with a functional group selected from the group consisting of: acyl groups, imine groups, amide groups, urea groups, carbamate groups, sulfonamide groups, and alkylamine groups.

[0385] In some embodiments, if present, the N-terminus of the non-naturally occurring melanocortin analog is modified with an acyl group. In some embodiments, the acyl group is an acetyl group (e.g., In some embodiments, the acyl group is a formyl group (e.g., ).

[0386] In some embodiments, if present, the N-terminus of the non-naturally occurring melanocortin analog is modified with an imine group.

[0387] In some embodiments, if present, the N-terminus of the non-naturally occurring melanocortin analog is modified with an amide group. In some embodiments, the amide group is a pyroglutamyl (pGlu) group (e.g., In some embodiments, the amide group is derived from a fatty acid (e.g., ).

[0388] Other examples of N-terminal modifications include, but are not limited to, (urea group) (carbamate group) (Sulfanamide group) and (alkylamine group).

[0389] In some embodiments, if present, the N-terminus of the non-naturally occurring melanocortin analogue is not modified.

[0390] As discussed above, Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 The C-terminus represents a non-naturally occurring melanocortin analogue. In some embodiments, Y... 1 To Y 8 It does not exist. In some embodiments, Y 1 Existence and Y 2 To Y 8 It does not exist.

[0391] In some embodiments, Y 1 and Y 2 Existence and Y 3 To Y 8 It does not exist. In some embodiments, Y 3 To Y 8 It does not exist, and Y 1 It is D-valine and Y 2 It is D-proline, or Y 1 It is D-proline and Y2 It is D-valine.

[0392] In some embodiments, Y 3 Existence and Y 4 To Y 8 It does not exist. In some embodiments, Y 3 Existence and Y 4 To Y 8 It does not exist, and (i) Y 1 For D-valine or D-proline, (ii) Y 2 For D-valine or D-proline and / or (iii) Y 3 It is D-valine or D-proline. In some embodiments, Y... 3 Existence and Y 4 To Y 8 It does not exist, and (i) Y 1 For D-valine, Y 2 It is D-valine and Y 3 For D-proline, (ii) Y 1 For D-proline, Y 2 It is D-valine and Y 3 For D-valine, or (iii) Y 1 For D-valine, Y 2 It is D-proline and Y 3 It is D-valine.

[0393] In some embodiments, Y 3 and Y 4 Existence and Y 5 To Y 8 It does not exist. In some embodiments, Y 3 and Y 4 It exists, and Y 5 To Y 8 It does not exist, and (i) Y 1 For D-valine or D-proline, (ii) Y 2 It is D-valine or D-proline, (iii) Y 3 It is D-valine or D-proline, and / or (iv) Y 4 It is D-valine or D-proline. In some embodiments, Y... 3 and Y 4 It exists, and Y 5 To Y 8 It does not exist, and (i) Y 1 For D-valine, Y 2 For D-valine, Y 3 It is D-valine and Y 4For D-proline, (ii) Y 1 For D-proline, Y 2 For D-valine, Y 3 It is D-valine and Y 4 For D-valine, (iii) Y 1 For D-valine, Y 2 For D-proline, Y 3 It is D-valine and Y 4为D- Valine, or (iv) Y 1 For D-valine, Y 2 For D-valine, Y 3 It is D-proline and Y 4 It is D-valine.

[0394] In some embodiments, the C-terminus includes additional derivatives to extend the length of the C-terminus of non-naturally occurring melanocortin analogs. Exemplary additional C-termini include, but are not limited to, Y... 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Y 9 Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Y 9 Y 10 Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Y 9 Y 10 Y 11 Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Y 9 Y 10 Y 11 Y 12 Y 1 Y 2 Y 3 Y4 AND 5 AND 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND 13 ,AND 1 AND 2 AND 3 AND 4 AND 5 AND 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND 13 AND 14 ,AND 1 AND 2 AND 3 AND 4 AND 5 AND 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND 13 AND 14 AND 15 ,AND 1 AND 2 AND 3 AND 4 AND 5 AND 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND 13 AND 1 4 AND 15 AND 16 ,AND 1 AND 2 AND 3 AND 4 AND 5 AND 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND 13 AND 14 AND 15 AND16 AND 17 ,AND 1 AND 2 AND 3 AND 4 AND 5 AND 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND 13 AND 14 AND 15 AND 16 AND 17 AND 18 ,AND 1 AND 2 AND 3 AND 4 AND 5 AND 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND 13 AND 14 AND 15 AND 16 AND 17 AND 18 AND 19 ,AND 1 AND 2 AND 3 AND 4 AND 5 AND 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND 13 AND 14 AND 15 AND 16 AND 17 AND 18 AND 19 AND 20 ,AND 1 AND 2 AND 3 AND 4 AND 5 AND 6 AND 7 AND 8 AND 9 AND 10 AND 11 AND 12 AND13 Y 14 Y 15 Y 16 Y 17 Y 18 Y 19 Y 20 Y 21 , Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Y 9 Y 10 Y 11 Y 12 Y 13 Y 14 Y 15 Y 16 Y 17 Y 18 Y 19 Y 20 Y 21 Y 22 , Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Y 9 Y 10 Y 11 Y 12 Y 13 Y 14 Y 15 Y 16 Y 17 Y 18 Y 19 Y 20 Y 21 Y 22 Y 23 , and Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 Y 9 Y 10 Y 11 Y 12 Y 13 Y 14 Y 15 Y 16 Y 17 Y18 Y 19 Y 20 Y 21 Y 22 Y 23 Y 24 , etc., where if Y exists 9 To Y 24 Each is independently either D-proline or D-valine.

[0395] In some embodiments, if present, the C-terminus of the non-naturally occurring melanocortin analog is modified with a functional group selected from the group consisting of amide groups, ester groups, and aldehyde groups.

[0396] In some embodiments, if present, the C-terminus of a non-naturally occurring melanocortin analogue is fitted with an amide group (e.g., Modification. In the sequence of formula (I), non-natural melanocortin analogs with an amide-modified C-terminus can be represented by a terminal -NH2, for example in the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Val-Pro-NH2 (SEQ ID NO: 126). In some embodiments, the amide group is an N-alkylamide group (e.g., , ) or N-arylamide group. In some embodiments, the N-arylamide group is a p-nitroaniline group (pNA) (e.g., ) or 7-amino-4-methylcoumarin (AMC) (e.g., ).

[0397] In some embodiments, if present, the C-terminus of a non-naturally occurring melanocortin analogue is bound with an ester group (e.g., , Modification.

[0398] In some embodiments, if present, the C-terminus of a non-naturally occurring melanocortin analogue is replaced with an aldehyde (e.g., Modification.

[0399] In some embodiments, the C-terminus of the non-naturally occurring melanocortin analog is not modified. In the sequence of formula (I), a non-naturally occurring melanocortin analog with an unmodified C-terminus can be represented by -OH, for example in the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-OH (SEQ ID NO: 127), or by the absence of a C-terminal group, for example in the sequence Ac-Nle- c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro (SEQ ID NO: 2; B07a). In some embodiments, the C-terminus of the non-natural melanocortin analogue is not modified, and the sequence of formula (I) is Ac-Nle- c (Asp-Pro-dNal2'-Arg-Trp-Lys)-dVal-dPro (SEQ IDNO: 2).

[0400] In some embodiments, R 1 It does not exist, and R 2 It is D-aspartic acid. In some embodiments, R 1 It is acetylated leucine, and R 2 It is D-aspartic acid.

[0401] In some embodiments, X 1 X 2 and X 3 It does not exist. In some embodiments, X 1 Existence and X 2 and X 3 It does not exist.

[0402] In some embodiments, R 4 Not D-phenylalanine. In some embodiments, R 4 For D-Nal(2'). When R 4 When it is D-Nal(2'), the non-natural melanocortin analogues described herein can act as melanocortin receptor antagonists.

[0403] In some embodiments, the non-naturally occurring melanocortin analogues described herein are cyclized. For example, non-naturally occurring melanocortin analogues can be partially cyclized by selecting from the group consisting of: when R 1 Or R 2 For cysteine ​​and R 7 or X 1 When it is cysteine, R 1 Or R 2 With R 7 or X 1 disulfide bonds between; when R 2 and R 5 To R 20 When any one of the components is selected from the group consisting of cysteine, Pen, and dPen, R 2 With R 5 To R 20 Disulfide bonds between any of them; when R 1 It is leucine and R 7 When it is glutamic acid, R1 With R 7 The lactam bridge between; when R 1 It is aspartic acid and R 5-8 When either of them is lysine, R 1 With R 5-8 Any of the side chain lactam bridges in R; 2 For lysine and R 7 When it is aspartic acid, R 2 With R 7 The side-chain lactam bridge between; when R 2 It is glutamic acid, aspartic acid, or CO-cis-CH═CH—CO and R 7 When it is lysine, Dap, or ornithine, R 2 With R 7 The side-chain lactam bridge between; when R 2 It is either glutamic acid or aspartic acid, R 8 For lysine and R 7 When it is glycine, proline, or tryptophan, R 2 With R 8 The side-chain lactam bridge between; when R 2 Or R 4 It is glutamic acid or aspartic acid and R 10 When it is lysine, R 2 Or R 4 With R 10 The side-chain lactam bridge between; when R 1 It is succinic acid or phthalic acid and R 7 When it is lysine, R 1 With R 7 The lactam closure between; and / or when R 2 It is succinic acid and R 7 When it is 2,3-diamino-propionic acid, R 2 With R 7 The lactam closure between them. Cycloning can also begin from any X residue (optionally a stable N-terminal residue). For example, X 2 It can be aspartic acid, which can be used for cyclization.

[0404] In some embodiments, R 1 R 2 and R 7 Existence and R 8 To R 20 It does not exist, and the sequence of equation (I) passes through R. 2 and R 7 Via lactam cyclization. In some embodiments, R 1 It is acetylated leucine, R 2 It is aspartic acid, R 3Select the group consisting of free proline, hydroxyproline, and D-hydroxyproline, R 4 For D-Nal(2'), R 5 For arginine, R 6 For D-tryptophan or L-tryptophan, R 7 For lysine, Y 1 It is D-valine and / or Y 2 It is D-proline.

[0405] In some embodiments, the sequence of equation (I) is: Ac-Nle- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3; B07) or Ac-Nle- c (Asp-Hyp-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 4; D3), where c indicates that through R 2 and R 7 Cyclation via lactam bonds.

[0406] In some embodiments, R 1 R 2 R 7 and R 8 Existence and R 9 To R 20 It does not exist, and the sequence of equation (I) passes through R. 2 and R 8 Via lactam cyclization. In some embodiments, R 1 It is acetylated leucine, R 2 It is aspartic acid, R 3 Select the group consisting of proline, hydroxyproline, D-hydroxyproline, phenylalanine, and histidine, R 4 For histidine or dNal(2'), R 5 For dNal(2') or arginine, R 6 Select the group consisting of free arginine, D-tryptophan, and L-tryptophan, R 7 For tryptophan or proline, R 8 For lysine, Y 1 Select the group consisting of D-valine, D-leucine, and D-isoleucine, and / or Y 2 It is D-proline.

[0407] In some embodiments, the sequence of equation (I) is selected from the group consisting of the following: Ac-Nle- c(Asp-Pro-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 5; D1); Ac-Nle- c (Asp-Phe-His-dNal(2')-Arg-Trp-Lys)-dLeu-dPro-NH2 (SEQ ID NO: 6; D1γ); Ac-Nle- c (Asp-Phe-His-dNal(2')-Arg-Trp-Lys)-dTle-dPro-NH2 (SEQ ID NO: 7; D1δ); Ac-Nle- c (Asp-His-dNal(2')-Arg-Trp-Pro-Lys)-dVal-dPro-NH2 (SEQ ID NO: 8; D2); Ac-Nle- c (Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys)-dVal-dPro-NH2 (SEQ ID NO: 9; D4); and Ac-Nle- c (Asp-Pro-His-dNal(2')-Arg-Trp-Lys)-dPro-dVal-NH2 (SEQ ID NO: 10; D5), Where c represents through R 2 and R 8 Cyclation via lactam bonds.

[0408] In some embodiments, R 1 To R 2 and R 7 To R 10 Existence and R 11 To R 20 It does not exist, and the sequence of equation (I) passes through R. 2 and R 10 Cyclation via lactam bonds. In some embodiments, the sequence of formula (I) is Ac-Nle- c (Asp-Phe-Phe-Pro-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 11; D1α), where c represents the result of passing through R 2 and R 10 Cyclation via lactam bonds.

[0409] In some embodiments, R1 To R 2 and R 7 To R 10 Existence and R 11 To R 20 It does not exist, and the sequence of equation (I) passes through R. 4 and R 10 Cyclation via a lactam bond. In some embodiments, the sequence of formula (I) is Ac-Nle-Phe-Phe- c (Asp-Phe-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 12; D1β), where c represents the result of passing through R 4 and R 10 Cyclation via lactam bonds.

[0410] In some embodiments, the sequence of formula (I) is linear. In some embodiments, the sequence of formula (I) is Ac-Nle-Asp-Pro-dNal(2')-Arg-Trp-Lys-dVal-dPro-NH2 (SEQ ID NO: 13; A1). In some embodiments, the sequence of formula (I) is Ac-Nle-Pro-DNal(2')-Arg-Trp-dVal-dPro-NH2 (SEQ ID NO: 14; A2).

[0411] In some embodiments of the sequence of equation (I), R 1 It is acetylated leucine. Alternatively, in some embodiments, R 1 R is an acetylated amino acid other than acetylated leucine. In some embodiments, R 1 It is a non-acetylated amino acid. In some embodiments, the sequence of formula (I) is selected from the group consisting of: Ac-dArg- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 15); Ac-dMet- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 16); Ac-dIle- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 17); Ac-dLeu- c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 18); Ac-dVal- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 19); Ac-dAla- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 20); Ac-Ala- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 21); Ac-Tle- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 22); Ac-dTle- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 23); Ac-dNle- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 24); Ac-Nva- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 25); Ac-Gly- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 26); Ac-dPro- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 27); Ac-dCys- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 28); Ac-dPhe- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 29); Ac-dTyr- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 30); Ac-dGln- c (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 31); Ac-dAsn- (Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 32); Ac- trans Pro(guan)-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 33); Ac- Cis Pro(guan)-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 34); dTyr-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 35); Tyr-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 36); Dmt-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 37); Ac-Glu-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 38); and Ac-Asn-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 39), wherein c represents via R2 and R 7 Cyclation via lactam bonds.

[0412] In some embodiments, when the sequence of equation (I) is passed through R 2 and R 7 When cyclized, then R 2 For Asp and R 7 For Lys. Alternatively, in some embodiments, when the sequence of equation (I) is passed through R 2 and R 7 When cyclized, then R 2 For those other than Asp that can interact with R 7 The amino acid that forms a bond with the residue and R 7 For those other than Lys that can interact with R 2 Amino acids that form bonds with residues at a certain point. For example, when R... 2 It consists of amino acids other than Arg and R 7 When R is an amino acid other than Lys, 2 The residues at that position can interact with R 7 The residues at the position form bonds, such as lactam bonds or disulfide bonds. In some embodiments, the sequence of formula (I) is selected from the group consisting of: Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 40); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-dLys)-dVal-dPro-NH2 (SEQ ID NO: 41); Ac-Nle-c(Cys-Pro-dNal(2')-Arg-Trp-Cys)-dVal-dPro-NH2 (SEQ ID NO: 42); Ac-Nle-c(dCys-Pro-dNal(2')-Arg-Trp-Cys)-dVal-dPro-NH2 (SEQ ID NO: 43); Ac-Nle-c(Cys-Pro-dNal(2')-Arg-Trp-dCys)-dVal-dPro-NH2 (SEQ ID NO: 44); Ac-Nle-c(dCys-Pro-dNal(2')-Arg-Trp-dCys)-dVal-dPro-NH2 (SEQ ID NO: 45); Ac-Nle-c(Cys-dNal(2')-Arg-Trp-Cys)-dVal-dPro-NH2(SEQ ID NO: 46); Ac-Nle-c(dCys-dNal(2')-Arg-Trp-Cys)-dVal-dPro-NH2(SEQ ID NO: 47); Ac-Nle-c(Cys-dNal(2')-Arg-Trp-dCys)-dVal-dPro-NH2(SEQ ID NO: 48); Ac-Nle-c(dCys-dNal(2')-Arg-Trp-dCys)-dVal-dPro-NH2(SEQ ID NO: 49); Ac-Nle-c(Cys-Pro-dNal(2')-Arg-Trp-Pen)-dVal-dPro-NH2(SEQ ID NO: 50); Ac-Nle-c(dCys-Pro-dNal(2')-Arg-Trp-Pen)-dVal-dPro-NH2(SEQ ID NO: 51); Ac-Nle-c(Pen-Pro-dNal(2')-Arg-Trp-Cys)-dVal-dPro-NH2(SEQ ID NO: 52); Ac-Nle-c(Pen-Pro-dNal(2')-Arg-Trp-dCys)-dVal-dPro-NH2(SEQ ID NO: 53); Ac-Nle-c(Pen-Pro-dNal(2')-Arg-Trp-Pen)-dVal-dPro-NH2(SEQ ID NO: 54); Ac-Nle-c(dPen-Pro-dNal(2')-Arg-Trp-Pen)-dVal-dPro-NH2(SEQ ID NO: 55); Ac-Nle-c(dPen-Pro-dNal(2')-Arg-Trp-dPen)-dVal-dPro-NH2(SEQ ID NO:56); Ac-Nle-c(Pen-Pro-dNal(2')-Arg-Trp-dPen)-dVal-dPro-NH2(SEQ ID NO: 57); Ac-Nle-c(Cys-dNal(2')-Arg-Trp-Pen)-dVal-dPro-NH2(SEQ ID NO: 58); Ac-Nle-c(dCys-dNal(2')-Arg-Trp-Pen)-dVal-dPro-NH2(SEQ ID NO: 59); Ac-Nle-c(Pen-dNal(2')-Arg-Trp-Cys)-dVal-dPro-NH2(SEQ ID NO: 60); Ac-Nle-c(Pen-dNal(2')-Arg-Trp-dCys)-dVal-dPro-NH2(SEQ ID NO: 61); Ac-Nle-c(Pen-dNal(2')-Arg-Trp-Pen)-dVal-dPro-NH2(SEQ ID NO: 62); Ac-Nle-c(dPen-dNal(2')-Arg-Trp-Pen)-dVal-dPro-NH2(SEQ ID NO: 63); Ac-Nle-c(dPen-dNal(2')-Arg-Trp-dPen)-dVal-dPro-NH2(SEQ ID NO: 64); Ac-Nle-c(Pen-dNal(2')-Arg-Trp-dPen)-dVal-dPro-NH2(SEQ ID NO: 65); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Orn)-dVal-dPro-NH2(SEQ ID NO: 66); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-dOrn)-dVal-dPro-NH2(SEQ ID NO: 67); Ac-Nle-c(Glu-Pro-dNal(2')-Arg-Trp-Orn)-dVal-dPro-NH2(SEQ ID NO: 68); Ac-Nle-c(Glu-Pro-dNal(2')-Arg-Trp-dOrn)-dVal-dPro-NH2(SEQ ID NO: 69); and Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Dap)-dVal-dPro-NH2 (SEQ ID NO: 70), Where c represents through R 2 and R 6 Or R 7 Cycling via lactam bonds or disulfide bonds.

[0413] In some embodiments of the sequence of equation (I), R 3 For Pro. Alternatively, in some embodiments, R 3 The amino acid is absent or is not a protein other than Pro. In some embodiments, the sequence of formula (I) is selected from the group consisting of: Ac-Nle-c(Asp-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 71); Ac-Nle-c(Asp-Ala-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 72); Ac-Nle-c(Asp-dPro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 73); Ac-Nle-c(Asp-dAla-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 74); Ac-Nle-c(Asp-dMet-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 75); Ac-Nle-c(Asp-Pro-Gly-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO:76); Ac-Nle-c(Asp-Gly-Gly-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO:77); Ac-Nle-c(Asp-Gly-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 78); Ac-Nle-c(Asp-Leu-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 79); Ac-Nle-c(Asp-Ile-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 80); Ac-Nle-c(Asp-Val-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 81); Ac-Nle-c(Asp-dLeu-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 82); Ac-Nle-c(Asp-dIle-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 83); Ac-Nle-c(Asp-dVal-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 84); Ac-Nle-c(Asp-Trp-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 85); Ac-Nle-c(Asp-dTrp-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 86); Ac-Nle-c(Asp- trans Pro(guan)-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ IDNO: 87); Ac-Nle-c(Asp- Cis Pro(guan)-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ IDNO: 88); Ac-Nle-c(Asp-Val-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 89); Ac-Nle-c(Asp-Ile-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 90); Ac-Nle-c(Asp-Gly-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 91); Ac-Nle-c(Asp-Glu-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 92); Ac-Nle-c(Asp-Arg-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 93); Ac-Nle-c(Asp-dLeu-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 94); Ac-Nle-c(Asp-dAla-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 95); and Ac-Nle-c(Asp-dMet-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 96), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0414] In some embodiments of the sequence of equation (I), R 5 For Arg. Alternatively, in some embodiments, R 5 The amino acid is absent or consists of an amino acid other than Arg. In some embodiments, the sequence of formula (I) is selected from the group consisting of: Ac-Nle-c(Asp-Pro-dNal(2')-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 97); Ac-Nle-c(Asp-Pro-dNal(2')-Lys-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 98); Ac-Nle-c(Asp-Pro-dNal(2')-dLys-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 99); Ac-Nle-c(Asp-Pro-dNal(2')-dArg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 100); Ac-Nle-c(Asp-Pro-dNal(2')-Orn-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 101); Ac-Nle-c(Asp-Pro-dNal(2')-dOrn-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 102); Ac-Nle-c(Asp-Pro-dNal(2')-His-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 103); Ac-Nle-c(Asp-Pro-dNal(2')-Ala-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 104); Ac-Nle-c(Asp-Pro-dNal(2')-Gly-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 105); Ac-Nle-c(Asp-Pro-dNal(2')-Asp-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 106); Ac-Nle-c(Asp-Pro-dNal(2')-Glu-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 107); Ac-Nle-c(Asp-Pro-dNal(2')-dHis-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 108); Ac-Nle-c(Asp-Pro-dNal(2')-dAla-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 109); Ac-Nle-c(Asp-Pro-dNal(2')-dAsp-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 110); and Ac-Nle-c(Asp-Pro-dNal(2')-dGlu-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO:111), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0415] In some embodiments of the sequence of equation (I), R 6 For Trp. Alternatively, in some embodiments, R 6 The amino acid is absent or consists of an amino acid other than Trp. In some embodiments, the sequence of formula (I) is selected from the group consisting of: Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Lys)-dVal-dPro-NH2 (SEQ ID NO: 112); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Nal(1')-Lys)-dVal-dPro-NH2 (SEQ ID NO: 113); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Aia-Lys)-dVal-dPro-NH2 (SEQ ID NO: 114); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Phe-Lys)-dVal-dPro-NH2 (SEQ ID NO: 115); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Tyr-Lys)-dVal-dPro-NH2 (SEQ ID NO: 116); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-His-Lys)-dVal-dPro-NH2 (SEQ ID NO: 117); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Ala-Lys)-dVal-dPro-NH2 (SEQ ID NO: 118); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-dNal(1')-Lys)-dVal-dPro-NH2 (SEQ ID NO: 119); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-dPhe-Lys)-dVal-dPro-NH2 (SEQ ID NO: 120); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-dNal(2')-Lys)-dVal-dPro-NH2 (SEQ ID NO: 121); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-dTyr-Lys)-dVal-dPro-NH2 (SEQ ID NO: 122); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-dHis-Lys)-dVal-dPro-NH2 (SEQ ID NO: 123); and Ac-Nle-c(Asp-Pro-dNal(2')-Arg-dAla-Lys)-dVal-dPro-NH2 (SEQ ID NO: 124), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0416] In some embodiments of the sequence of equation (I), R 4 For dNal(2'). Alternatively, in some embodiments, R 4 Amino acids other than dNal(2'). For example, in some embodiments, when R 4 When R is an amino acid other than dNal(2'), 4 For Bip. In some embodiments, the sequence of formula (I) is Ac-Nle-c(Asp-Pro-Bip-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 125), where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0417] In some embodiments of the sequence of equation (I), Y 1 For dVal and Y 2 For dPro. Alternatively, in some embodiments, Y 1 It consists of amino acids other than dVal, and Y 2 These are amino acids other than dPro. In some embodiments, Y 1 For dVal and Y 2 These are amino acids other than dPro. In some embodiments, Y 1 It consists of amino acids other than dVal and Y 2 For dPro.

[0418] In some embodiments, Y 1 For dVal, Y 2 It is dPro, and the C-terminus is modified with NH2. In some embodiments, Y 1 Y consists of amino acids other than dVal. 2It consists of amino acids other than dPro, and its C-terminus is modified with NH2. In some embodiments, Y 1 For dVal, Y 2 It consists of amino acids other than dPro, and its C-terminus is modified with NH2. In some embodiments, Y 1 Y consists of amino acids other than dVal. 2 It is dPro, and the C-terminus is modified with NH2. In some embodiments, Y 1 For dVal, Y 2 It is dPro, and the C-terminus is not modified.

[0419] In the embodiment of formula (I), when Y 1 When Y is an amino acid other than dVal, then 1 Selected from dPro, Val, Hyp, dHyp, Pro, Ala, dAla, Gly, Asp, Arg, Asn, dAsp, dArg, dAsn, Lys, dLys, and dTle. In the embodiment of formula (I), when Y 2 When Y is an amino acid other than dPro, then 2 Alternatively, it may be selected from dVal, Val, Hyp, dHyp, Pro, Ala, dAla, Gly, Asp, Arg, Asn, dAsp, dArg, dAsn, and dTle. In some embodiments, the sequence of formula (I) is selected from the group consisting of: Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Val-Pro-NH2 (SEQ ID NO: 126); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-OH (SEQ ID NO: 127); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dVal-OH (SEQ ID NO: 128); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-Hyp-NH2 (SEQ ID NO: 129); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dHyp-NH2 (SEQ ID NO: 130); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Val-Hyp-NH2(SEQ ID NO: 131); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Val-dHyp-NH2(SEQ ID NO: 132); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Hyp-dVal-NH2(SEQ ID NO: 133); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dHyp-dVal-NH2(SEQ ID NO: 134); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Hyp-Val-NH2(SEQ ID NO: 135); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dHyp-Val-NH2(SEQ ID NO: 136); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dVal-NH2(SEQ ID NO: 137); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dPro-NH2(SEQ ID NO: 138); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-NH2(SEQ ID NO: 139); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-NH2(SEQ ID NO: 140); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Val-NH2(SEQ ID NO: 141); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Pro-NH2(SEQ ID NO: 142); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Ala-NH2(SEQ ID NO: 143); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dAla-NH2(SEQ ID NO: 144); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dHyp-NH2(SEQ ID NO: 145); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Hyp-NH2(SEQ ID NO: 146); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dAla-dAla-NH2(SEQ ID NO: 147); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Ala-Ala-NH2(SEQ ID NO: 148); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Gly-Gly-NH2(SEQ ID NO: 149); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-Asp-NH2(SEQ ID NO: 150); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-Arg-NH2(SEQ ID NO: 151); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-Asn-NH2(SEQ ID NO: 152); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dAsp-NH2(SEQ ID NO: 153); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dArg-NH2(SEQ ID NO: 154); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dAsn-NH2(SEQ ID NO: 155); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Asp-dPro-NH2(SEQ ID NO: 156); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Arg-dPro-NH2(SEQ ID NO: 157); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Asn-dPro-NH2(SEQ ID NO: 158); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dAsp-dPro-NH2(SEQ ID NO: 159); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dArg-dPro-NH2(SEQ ID NO: 160); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dAsn-dPro-NH2(SEQ ID NO: 161); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Asp-NH2(SEQ ID NO: 162); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Arg-NH2(SEQ ID NO: 163); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Asn-NH2(SEQ ID NO: 164); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dAsp-NH2(SEQ ID NO: 165); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dArg-NH2(SEQ ID NO: 166); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dAsn-NH2(SEQ ID NO: 167); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Lys-Pro-Val-NH2(SEQ ID NO:168); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Lys-dPro-dVal-NH2(SEQ ID NO:169); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dLys-dPro-dVal-NH2(SEQ ID NO:170); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Lys-dPro-NH2(SEQ ID NO: 171); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dLys-dPro-NH2(SEQ ID NO: 172); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Lys-Val-Pro-NH2(SEQ ID NO:173); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Lys-dVal-dPro-NH2(SEQ ID NO:174); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dLys-dVal-dPro-NH2(SEQ ID NO:175); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Arg-Pro-Val-NH2(SEQ ID NO:176); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Arg-dPro-dVal-NH2(SEQ ID NO:177); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dArg-dPro-dVal-NH2(SEQ ID NO:178); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Arg-Val-Pro-NH2 (SEQ ID NO: 179); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Arg-dVal-dPro-NH2 (SEQ ID NO: 180); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dArg-dVal-dPro-NH2 (SEQ ID NO: 181); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dTle-dVal-dPro-NH2 (SEQ ID NO: 182); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dTle-dPro-NH2 (SEQ ID NO: 183); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dTle-dVal-NH2 (SEQ ID NO: 184); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dTle-dTle-NH2 (SEQ ID NO: 185); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dTle-dTle-dPro-NH2 (SEQ ID NO: 186); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dTle-dTle-dVal-NH2 (SEQ ID NO: 187); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dTle-NH2 (SEQ ID NO: 188); and Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dTle-NH2 (SEQ ID NO: 189), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0420] In some embodiments of the sequence of equation (I), when Y 3 Existence and Y 4-8 If it does not exist, then Y 1 Y 2 and Y 3 Each of these is independently selected from dVal and dPro. In some embodiments of the sequence of equation (I), when Y 3 and Y 4 Existence and Y 5-8 If it does not exist, then Y 1 Y 2 Y 3 and Y 4 Each of these is independently selected from dVal and dPro. In some embodiments of the sequence of equation (I), when Y 3 To Y 5 Existence and Y 6-8 If it does not exist, then Y 1 To Y 5 Either dVal or dPro can be chosen independently. In some embodiments of the sequence of equation (I), when Y 3 To Y 6 Existence and Y 7-8 If it does not exist, then Y 1 To Y 6 Either dVal or dPro can be chosen independently. In some embodiments of the sequence of equation (I), when Y 3 To Y 7 Existence and Y 8 If it does not exist, then Y 1 To Y 7 Each of these is independently selected from dVal and dPro. In some embodiments of the sequence of equation (I), when Y 3 To Y 8 If it exists, then Y 1 To Y 8 Each of these is independently selected from dVal and dPro. In some embodiments, the sequence of equation (I) is selected from the group consisting of: Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dVal-dPro-NH2 (SEQ ID NO: 190); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dVal-dPro-NH2 (SEQ ID NO: 191); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dVal-dVal-dPro-NH2 (SEQ IDNO: 192); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-dVal-dPro-NH2 (SEQ IDNO: 193); and Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 194), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0421] In some embodiments of the sequence of equation (I), X 1 It exists and is acetylated leucine, and R 1 It is present and is leucine. In some embodiments, X... 2 It is present and is leucine. In some embodiments, X... 3 It is present and is leucine. In some embodiments, the sequence of formula (I) is selected from the group consisting of: Ac-Nle-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO:195) ; Ac-Nle-Nle-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ IDNO: 196); and Ac-Nle-Nle-Nle-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 197), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0422] As described above, some non-naturally occurring melanocortin analogs containing the sequence of formula (I) can bind to melanocortin 3 and melanocortin 4 receptors with the same or generally similar affinity. Other non-naturally occurring melanocortin analogs containing the sequence of formula (I) can bind to melanocortin 3 receptors with a greater affinity than melanocortin 4 receptors. In some embodiments, when the melanocortin antagonist of the present invention binds to melanocortin 3 receptors with a greater affinity than melanocortin 4 receptors, the sequence of formula (I) is selected from the group consisting of: Ac-Nle-c(Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 198); Ac-Nle-c(Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 199); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-dTrp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 200); c(CO-cis-CH=CH-CO-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 201); Ac-Nle-c(Asp-β-Ala-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 202); Ac-Nle-c(Asp-Mamb-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 203); Ac-Nle-c(Asp-Acpc-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 204); Ac-c(Cys-Arg-dPhe-Cys)-Trp-dVal-dPro-NH2 (SEQ ID NO: 205); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-Trp-NH2 (SEQ ID NO: 206); Ac-Nle-c(Asp-Aba-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 207); Ac-Nle-c(Asp-Aia-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 208); and Ac-Nle-c(Asp-Ata-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 209), Where c represents through R 1 Or R 2 and R 7 Or R 8 via lactam cyclization or through R 2 and R 5 Cycling via disulfide bonds.

[0423] Some non-natural melanocortin analogues containing the sequence of formula (I) can bind to the melanocortin 4 receptor with a greater affinity than the melanocortin 3 receptor. In some embodiments, when a melanocortin antagonist binds to the melanocortin 4 receptor with a greater affinity than the melanocortin 3 receptor, the sequence of formula (I) is selected from the group consisting of: Ac-Nle-c(Asp-Aic-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 210); Ac-Nle-c(Asp-Cpe-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 211); Ac-Nle-c(Asp-Che-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 212); Ac-Nle-c(Asp-Oic-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 213); Ac-Nle-c(Asp-Ioc-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 214); Ac-Nle-c(Asp-Tic-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 215); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys)-dVal-dPro-NH2(SEQ ID NO:216); Ac-Nle-c(Asp-His-dNal(2')-Pro-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 217); Ac-Nle-c(Asp-His-dNal(2')- trans Pro(guan)-Trp-Lys)-dVal-dPro-NH2(SEQ IDNO: 218); Ac-Nle-c(Asp-His-dNal(2')- Cis Pro(guan)-Trp-Lys)-dVal-dPro-NH2(SEQ IDNO: 219); Ac-Nle-c(Asp-Pro-dNal(2')-Pro-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 220); Ac-Nle-c(Asp-Pro-dNal(2')- trans Pro(guan)-Trp-Lys)-dVal-dPro-NH2(SEQ IDNO: 221); Ac-Nle-c(Asp-Pro-dNal(2')- Cis Pro(guan)-Trp-Lys)-dVal-dPro-NH2(SEQ IDNO: 222); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Aba-Lys)-dVal-dPro-NH2(SEQ ID NO: 223); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Ata-Lys)-dVal-dPro-NH2(SEQ ID NO: 224); Ac-Nle-c(Asp-Glu-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 225); Ac-Nle-c(Asp-Glu-dNal(2')-Arg-Trp-Gly-Lys)-dVal-dPro-NH2(SEQ ID NO:226); Ac-Nle-c(Asp-Pro-Glu-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 227); Ac-Nle-c(Asp-Pro-Glu-dNal(2')-Arg-Trp-Gly-Lys)-dVal-dPro-NH2 (SEQ IDNO: 228); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys)-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys)-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 230); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys)-dPro-dPro-dLys-dAsp-NH2 (SEQ ID NO: 231); Ac-Glu-c(Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys)-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 232); and Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dPro-dLys-dAsp-NH2(SEQ IDNO: 233), Where c represents through R 1 Or R 2 and R 7 Or R 8 Cyclation via lactam bonds.

[0424] In some embodiments of the sequence of equation (I), when X 1 Existence and X 2 and X 3 When it does not exist, the sequence of equation (I) is passed through R. 1 With R 5-8 Cycling of either the lactam bond or disulfide bond between them. In some embodiments, when X 1 Existence and X 2 and X 3 When it does not exist, the sequence of equation (I) is passed through R. 1 With R 6 Cyclation of lactam bonds between them. In some embodiments, when X 1 Existence and X2 and X 3 When it does not exist, the sequence of equation (I) is passed through R. 1 With R 7 Cyclation of lactam bonds between them. In some embodiments, Y 1 and Y 2 They exist and are respectively dVal and dPro, and Y 3 To Y 8 It does not exist. In some embodiments, Y 1 To Y 8 No. In some embodiments, the sequence of equation (I) is selected from the group consisting of: Ac-Nle-c(Asp-Glu-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c(Asp-Glu-His-dNal(2')-Arg-Trp-Gly-Lys)-dVal-dPro-NH2 (SEQ IDNO: 235); Ac-Nle-c(Asp-dAla-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 236); Ac-Arg-c(Asp-dAla-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 237); Ac-Arg-c(Asp-dAla-His-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 238); Ac-Arg-c(Cys-dAla-His-dNal(2')-Arg-Trp-Cys)-dVal-dPro-NH2 (SEQ ID NO: 239); Ac-dArg-c(Asp-dAla-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 240); Ac-Arg-c(Asp-dAla-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 241); Ac-dArg-c(Asp-dAla-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:242); Ac-Nle-c(Asp-Ala-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:243); Ac-Arg-c(Asp-Ala-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:244); Ac-dArg-c(Asp-Ala-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:245); Ac-Nle-c(Asp-Trp-Arg-dNal(2')-Pro-Lys)-dVal-dPro-NH2(SEQ ID NO: 246); Ac-Nle-c(Asp-Pro-Trp-dNal(2')-Lys)-dVal-dPro-NH2(SEQ ID NO: 247); Ac-Nle-c(Asp-Pro-Trp-Arg-dNal(2')-Pro-Lys)-dVal-dPro-NH2(SEQ ID NO:248); Ac-Nle-c(Asp-Pro-Trp-Arg-dNal(2')-Lys)-dVal-dPro-NH2(SEQ ID NO: 249); Ac-Nle-c(Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2(SEQ ID NO: 250); Ac-Arg-c(Cys-dAla-His-dNal(2')-Arg-Trp-Cys)-NH2(SEQ ID NO: 251); Ac-Arg-c(Asp-dAla-His-dNal(2')-Arg-Trp-Lys)-NH2(SEQ ID NO: 252); Ac-Arg-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 253); and Ac-Arg-c(Asp-Glu-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 254), Where c represents through R 1 Or R 2 and R 5-8 Either of them is cyclized via a lactam bond or a disulfide bond.

[0425] In some embodiments of the sequence of equation (I), when X 1 and X 2 Existence and X 3 It does not exist; the sequence of equation (I) is passed through R. 2 With R 7 Cyclation of lactam bonds between them. In such embodiments, X 1 and X 2 Each is independently selected from dVal and dPro. In some embodiments, the sequence of formula (I) is selected from the group consisting of: Ac-dVal-dPro-c(Asp-Trp-Arg-dNal(2')-Pro-Lys)-Nle-NH2 (SEQ ID NO: 255); Ac-dVal-dPro-c(Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-NH2 (SEQ ID NO: 256); Ac-dVal-dPro-c(Asp-Trp-Arg-dNal(2')-Pro-Lys)-Nle-Nle-NH2 (SEQ ID NO: 257); Ac-dVal-dPro-c(Lys-Trp-Arg-dNal(2')-Pro-Asp)-Nle-Nle-NH2 (SEQ ID NO: 258); Ac-dVal-dPro-c(Asp-Trp-Arg-dNal(2')-Pro-Lys)-dVal-dPro-NH2 (SEQ ID NO: 259); and Ac-dVal-dPro-c(Lys-Trp-Arg-dNal(2')-Pro-Asp)-dVal-dPro-NH2 (SEQ ID NO: 260), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0426] In some embodiments of the sequence of equation (I), R 1For Nle, and X 1 and X 2 One or more of them exist. In some embodiments, R 1 For Nle, X 1 Exists, and X 2 It does not exist. In some embodiments, R 1 For Nle, and X 1 and X 2 Yes. In some embodiments, the sequence of equation (I) is: Ac-dVal-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:261); or Tyr-Val-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 262), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0427] In some embodiments of the sequence of equation (I), R 1 For Ac-Glu. In some embodiments, R 1 For Ac-Glu, R 2 For Asp, R 3 For Glu, His, or Arg, R 4 For dNal(2'), R 5 For Arg, R 6 For Trp, and R 7 For Lys. In some embodiments, the sequence of equation (I) is selected from the group consisting of: Ac-Glu-c(Asp-Glu-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 263); Ac-Glu-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 264); and Ac-Glu-c(Asp-Arg-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 265), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

[0428] In some embodiments of the sequence of equation (I), R 5 For His. In some embodiments, when R 5 When it is His, then R 3 For His and the sequence of equation (I) through R 1 Or R 2 and R 7 Via lactam cyclization. In some embodiments, X 1 If it is Ac-Arg or does not exist, R 1 For Ac-Nle, Asp, or not present, R 2 For Asp or Pro, R 3 For His, R 4 For dNal(2'), R 5 For His, R 6 For Trp, and R 7 For Lys or Dap. In some embodiments, the sequence of equation (I) is selected from the group consisting of: Ac-Nle-c(Asp-Pro-His-dNal(2')-His-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 266); Ac-Nle-c(Asp-His-dNal(2')-His-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 267); Ac-Arg-c(Asp-Pro-His-dNal(2')-His-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 268); Ac-Arg-c(Asp-His-dNal(2')-His-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 269); Ac-Nle-c(Asp-Pro-His-dNal(2')-His-Trp-Orn)-dVal-dPro-NH2 (SEQ ID NO: 270); Ac-Nle-c(Asp-His-dNal(2')-His-Trp-Orn)-dVal-dPro-NH2 (SEQ ID NO: 271); Ac-Nle-c(Asp-Pro-His-dNal(2')-His-Trp-Lys)-dVal-Hyp-NH2 (SEQ ID NO: 272); Ac-Nle-c(Asp-His-dNal(2')-His-Trp-Lys)-dVal-Hyp-NH2 (SEQ ID NO: 273); Ac-Arg-c(Asp-Pro-His-dNal(2')-His-Trp-Orn)-dVal-dPro-NH2 (SEQ ID NO: 274); Ac-Arg-c(Asp-His-dNal(2')-His-Trp-Orn)-dVal-dPro-NH2 (SEQ ID NO: 275); Ac-Arg-c(Asp-Pro-His-dNal(2')-His-Trp-Lys)-dVal-Hyp-NH2 (SEQ ID NO: 276); Ac-Arg-c(Asp-His-dNal(2')-His-Trp-Lys)-dVal-Hyp-NH2 (SEQ ID NO: 277); Ac-Nle-c(Asp-Pro-His-dNal(2')-His-Trp-Dap)-dVal-dPro-NH2 (SEQ ID NO: 278); Ac-Nle-c(Asp-His-dNal(2')-His-Trp-Dap)-dVal-dPro-NH2 (SEQ ID NO: 279); Ac-Arg-c(Asp-Pro-His-dNal(2')-His-Trp-Dap)-dVal-dPro-NH2 (SEQ ID NO: 280); Ac-Arg-c(Asp-His-dNal(2')-His-Trp-Dap)-dVal-dPro-NH2 (SEQ ID NO: 281); Where c represents through R 1 Or R 2 and R 7 Cyclation via lactam bonds.

[0429] In some embodiments of the sequence of equation (I), R 1 For Ac-Nle, R 2 For Asp and dAsp, R 3 For Pro or His, R 4 For dNal(2'), R 5 For Arg, R 6 For Trp, and R 7For Lys and dLys. In such embodiments, Y... 1 Y 2 and Y 3 Variation. In some embodiments, the sequence of equation (I) is selected from the group consisting of the following: Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dThr-dPro-dThr-NH2 (SEQ ID NO: 282); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dThr-dPro-dThr (SEQ ID NO: 283); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-dThr-dPro-dThr (SEQ ID NO: 284); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-dThr-dPro-dThr (SEQ ID NO: 285); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dVal-NH2 (SEQ ID NO: 286); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dPro-dVal-NH2 (SEQ ID NO: 287); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-dPro-dVal-NH2 (SEQ ID NO: 288); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-dPro-dVal-NH2 (SEQ ID NO: 289); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 290); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 291); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-dVal-dPro-NH2(SEQ ID NO:292); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-dVal-dPro-NH2(SEQ ID NO:293); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Pro-β-Val-NH2(SEQ ID NO:294); Ac-Nle-c(Asp-Pro-dNal(2′)-Arg-Trp-Lys)-β 3 Pro-β 2 Val-NH2(SEQ ID NO:295); Ac-Nle-c(Asp-Pro-dNal(2′)-Arg-Trp-Lys)-β 3 Pro-β 3 Val-NH2(SEQ ID NO:296); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Pro-β-Val-NH2(SEQ ID NO:297); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Pro-β-Val-NH2(SEQ ID NO:298); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Pro-β-Val-NH2(SEQ ID NO:299); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Val-β-Pro-NH2(SEQ ID NO:300); Ac-Nle-c(Asp-Pro-dNal(2′)-Arg-Trp-Lys)-β 2 Val-β 3 Pro-NH2(SEQ ID NO:301); Ac-Nle-c(Asp-Pro-dNal(2′)-Arg-Trp-Lys)-β 3 Val-β 3 Pro-NH2(SEQ ID NO:302); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Val-β-Pro-NH2(SEQ ID NO:303); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Val-β-Pro-NH2(SEQ ID NO:304); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Val-β-Pro-NH2(SEQ ID NO:305); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Pro-β-Pro-NH2(SEQ ID NO:306); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β 3 Pro-β 3 Pro-NH2(SEQ ID NO:307)? Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Pro-β-Pro-NH2(SEQ ID NO:308); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Pro-β-Pro-NH2(SEQ ID NO:309); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Pro-β-Pro-NH2(SEQ ID NO:310); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Val-β-Val-NH2(SEQ ID NO:311); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Val-β-Val-NH2(SEQ ID NO:312); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Val-β-Val-NH2(SEQ ID NO:313); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Val-β-Val-NH2(SEQ ID NO:314); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Val-NH2(SEQ ID NO: 315); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Val-NH2(SEQ ID NO: 316); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Val-NH2(SEQ ID NO: 317); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Val-NH2(SEQ ID NO: 318); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Pro-NH2(SEQ ID NO: 319); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Pro-NH2(SEQ ID NO: 320); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Pro-NH2(SEQ ID NO: 321); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Pro-NH2(SEQ ID NO: 322); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Thr-β-Pro-β-Thr (SEQ ID NO:323); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Thr-β-Pro-β-Thr (SEQ ID NO:324); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Thr-β-Pro-β-Thr (SEQ IDNO: 325); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Thr-β-Pro-β-Thr (SEQ IDNO: 326); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dAla-NH2(SEQ ID NO: 327); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dPro-dAla-NH2(SEQ ID NO: 328); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-dPro-dAla-NH2(SEQ ID NO:329); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dPro-dAla-NH2(SEQ ID NO: 330); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dAla-dPro-NH2(SEQ ID NO: 331); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dAla-dPro-NH2(SEQ ID NO: 332); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-dAla-dPro-NH2(SEQ ID NO:333); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-dAla-dPro-NH2(SEQ ID NO:334); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Pro-β-Ala-NH2(SEQ ID NO:335); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Pro-β-Ala-NH2(SEQ ID NO:336); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Pro-β-Ala-NH2(SEQ ID NO:337); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Pro-β-Ala-NH2(SEQ ID NO:338); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Ala-β-Pro-NH2(SEQ ID NO:339); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Ala-β-Pro-NH2(SEQ ID NO:340); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Ala-β-Pro-NH2(SEQ ID NO:341); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Ala-β-Pro-NH2(SEQ ID NO:342); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Val-β-Ala-NH2(SEQ ID NO:343); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Val-β-Ala-NH2(SEQ ID NO:344); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Val-β-Ala-NH2(SEQ ID NO:345); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Val-β-Ala-NH2(SEQ ID NO:346); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Ala-NH2(SEQ ID NO: 347); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Ala-NH2(SEQ ID NO: 348); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Ala-NH2(SEQ ID NO: 349); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Ala-NH2(SEQ ID NO: 350) Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dLeu-NH2(SEQ ID NO: 351); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dPro-dLeu-NH2(SEQ ID NO: 352); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dLeu-NH2(SEQ ID NO: 353); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dPro-dLeu-NH2(SEQ ID NO: 354); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dLeu-dPro-NH2(SEQ ID NO: 355); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dLeu-dPro-NH2(SEQ ID NO: 356); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-dLeu-dPro-NH2(SEQ ID NO: 357); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-dLeu-dPro-NH2(SEQ ID NO: 358); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Pro-β-Leu-NH2(SEQ ID NO: 359); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Pro-β-Leu-NH2(SEQ ID NO:360); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Pro-β-Leu-NH2(SEQ ID NO:361); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Pro-β-Leu-NH2(SEQ ID NO:362); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Leu-β-Pro-NH2(SEQ ID NO:363); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Leu-β-Pro-NH2(SEQ ID NO:364); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Leu-β-Pro-NH2(SEQ ID NO:365); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Leu-β-Pro-NH2(SEQ ID NO:366); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-β-Val-β-Leu-NH2(SEQ ID NO:367); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-β-Val-β-Leu-NH2(SEQ ID NO:368); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-β-Val-β-Leu-NH2(SEQ ID NO:369); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Val-β-Leu-NH2(SEQ ID NO:370); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Leu-NH2 (SEQ ID NO: 371); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Leu-NH2 (SEQ ID NO: 372); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Leu-NH2(SEQ ID NO: 373); and Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Leu-NH2 (SEQID NO: 374), Where c represents through R 1 and R 7 Cyclation via lactam bonds.

[0430] Alternatively, in some embodiments, the non-naturally occurring melanocortin analogue comprises a sequence selected from the group consisting of: Ac-Nle-c(Asp-Pro-dPhe-Arg-dTrp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 375); Ac-Nle-c(Asp-His-Arg-p(I)dPhe-Arg-Tic-Lys)-dVal-dPro-NH2 (SEQ ID NO: 376); Ac-Nle-c(Asp-His-Arg-dBip-Arg-Tic-Lys)-dVal-dPro-NH2 (SEQ ID NO: 377); Ac-Nle-c(Asp-Pro-Arg-p(I)dPhe-Arg-Tic-Lys)-dVal-dPro-NH2 (SEQ ID NO: 378); Ac-Nle-c(Asp-Pro-Arg-dBip-Arg-Tic-Lys)-dVal-dPro-NH2 (SEQ ID NO: 379); Ac-Nle-c(Asp-Arg-Pro-p(I)dPhe-Arg-Tic-Lys)-dVal-dPro-NH2 (SEQ ID NO: 380); Ac-Nle-c(Asp-Arg-Pro-dBip-Arg-Tic-Lys)-dVal-dPro-NH2(SEQ ID NO: 381); Ac-Nle-c(Asp-Aba-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 382); Ac-Nle-c(Asp-Aia-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 383); Ac-Nle-c(Asp-Ata-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 384); Ac-Nle-c(Asp-Aba-p(Cl)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:385); Ac-Nle-c(Asp-Aia-p(Cl)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:386); Ac-Nle-c(Asp-Ata-p(Cl)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:387); Ac-Nle-c(Asp-Atc-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 388); Ac-Nle-c(Asp-APC-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 389); Ac-Nle-c(Asp-APPC-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 390); Ac-Nle-c(Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:391); Ac-Nle-c(Asp-Pro-p(I)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 392); Ac-Nle-c(Asp-Pro-p(Br)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:393); Ac-Nle-c(Asp-Pro-p(F)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 394); Ac-Nle-c(Asp-Pro-p(CF3)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:395); Ac-Nle-c(Asp-His-p(Cl)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:396); Ac-Nle-c(Asp-His-p(I)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 397); Ac-Nle-c(Asp-His-p(Br)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:398); Ac-Nle-c(Asp-His-p(F)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 399); Ac-Nle-c(Asp-His-p(CF3)dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:400); Ac-Nle-c(Asp-Pro-Pro-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 401); Ac-Nle-c(Asp-Trp-Pro-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 402); Ac-Nle-c(Asp-His-dPhe-Pro-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO: 403); Ac-Nle-c(Asp-His-dPhe- trans Pro(guan)-Trp-Lys)-dVal-dPro-NH2(SEQ ID NO:404); Ac-Nle-c(Asp-His-dPhe- Cis Pro(guan)-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 405); Ac-Nle-c(Asp-Pro-dPhe-Pro-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 406); Ac-Nle-c(Asp-Pro-dPhe- trans Pro(guan)-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 407); Ac-Nle-c(Asp-Pro-dPhe- Cis Pro(guan)-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 408); Ac-Nle-c(Asp-Pro-dPhe-Arg-Aia-Lys)-dVal-dPro-NH2 (SEQ ID NO: 409); Ac-Nle-c(Asp-Pro-dPhe-Arg-Aba-Lys)-dVal-dPro-NH2 (SEQ ID NO: 410); Ac-Nle-c(Asp-Pro-dPhe-Arg-Ata-Lys)-dVal-dPro-NH2 (SEQ ID NO: 411); Ac-Nle-c(Asp-Pro-p(CF3)dPhe-Arg-Aia-Lys)-dVal-dPro-NH2 (SEQ ID NO: 412); Ac-Nle-c(Asp-Pro-p(CF3)dPhe-Arg-Aba-Lys)-dVal-dPro-NH2 (SEQ ID NO: 413); Ac-Nle-c(Asp-Pro-p(CF3)dPhe-Arg-Ata-Lys)-dVal-dPro-NH2(SEQ ID NO:414); and Ac-Arg-c(Asp-dAla-His-dPhe-Arg-Trp-Lys)-NH2 (SEQ ID NO: 415), Where c represents through R 1 and R 7 Or R 8 Cyclation via lactam bonds.

[0431] In some embodiments, non-natural melanocortin analogues comprise sequences selected from the group consisting of: Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-dThr-dPro-dThr (SEQ ID NO: 416); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-dThr-dPro-dThr (SEQ ID NO: 417); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-dThr-dPro-dThr (SEQ ID NO: 418); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dlys)-dThr-dPro-dThr (SEQ ID NO: 419); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-dPro-dVal-NH2 (SEQ ID NO: 420); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-dPro-dVal-NH2 (SEQ ID NO: 421); Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dPro-dVal-NH2 (SEQ ID NO: 422); Ac-Nle-c(Asp-His-dNal(2')-Arg-Trp-Lys)-dPro-dVal-NH2 (SEQ ID NO: 423); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 424); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 425); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-dVal-dPro-NH2 (SEQ ID NO: 426); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-dVal-dPro-NH2(SEQ ID NO:427); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-βPro-βVal-NH2(SEQ ID NO: 428); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-βPro-βVal-NH2(SEQ ID NO: 429); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-βPro-βVal-NH2(SEQ ID NO: 430); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-βPro-βVal-NH2(SEQ ID NO: 431); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-βVal-βPro-NH2(SEQ ID NO: 432); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-βVal-βPro-NH2(SEQ ID NO: 433); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-βVal-βPro-NH2(SEQ ID NO: 434); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-βVal-βPro-NH2(SEQ ID NO:435); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-βPro-βPro-NH2(SEQ ID NO: 436); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-βPro-βPro-NH2(SEQ ID NO: 437); Ac-Nle-c(dAsp-Pro-dNal(2')-Arg-Trp-dLys)-βPro-βPro-NH2(SEQ ID NO:438); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-βPro-βPro-NH2(SEQ ID NO:439); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-βVal-βVal-NH2(SEQ ID NO: 440); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-βVal-βVal-NH2(SEQ ID NO: 441); Ac-Nle-c(dAsp-Pro-Phe-Arg-Trp-dLys)-βVal-βVal-NH2(SEQ ID NO: 442); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-βVal-βVal-NH2(SEQ ID NO: 443); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-(3-methyl)-βVal-βVal-NH2(SEQ ID NO:444); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-(3-methyl)-βVal-βVal-NH2(SEQ ID NO:445); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-(3-methyl)-βVal-βVal-NH2(SEQ ID NO: 446); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-(3-methyl)-βVal-βVal-NH2(SEQ ID NO: 447); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-(3-methyl)-βVal-βPro-NH2(SEQ ID NO:448); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-(3-methyl)-βVal-βPro-NH2(SEQ ID NO:449); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-(3-methyl)-βVal-βPro-NH2(SEQ ID NO: 450); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-(3-methyl)-βVal-βPro-NH2 (SEQ ID NO: 451); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-βThr-βPro-βThr (SEQ ID NO: 452); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-βThr-βPro-βThr (SEQ ID NO: 453); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-βThr-βPro-βThr (SEQ ID NO: 454); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-βThr-βPro-βThr (SEQ ID NO: 455); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-dPro-dAla-NH2 (SEQ ID NO: 456); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-dPro-dAla-NH2 (SEQ ID NO: 457); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-dPro-dAla-NH2 (SEQ ID NO: 458); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-dPro-dAla-NH2 (SEQ ID NO: 459); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-dAla-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-dAla-dPro-NH2 (SEQ ID NO: 461); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-dAla-dPro-NH2 (SEQ ID NO: 462); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-dAla-dPro-NH2(SEQ ID NO: 463); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-βPro-βAla-NH2(SEQ ID NO: 464); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-βPro-βAla-NH2(SEQ ID NO: 465); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-βPro-βAla-NH2(SEQ ID NO: 466); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-βPro-βAla-NH2(SEQ ID NO: 467); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-βAla-βPro-NH2(SEQ ID NO: 468); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-βAla-βPro-NH2(SEQ ID NO: 469); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-βAla-βPro-NH2(SEQ ID NO: 470); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-βAla-βPro-NH2(SEQ ID NO: 471); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-βVal-βAla-NH2(SEQ ID NO: 472); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-βVal-βAla-NH2(SEQ ID NO: 473); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-βVal-βAla-NH2(SEQ ID NO: 474); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-βVal-βAla-NH2(SEQ ID NO: 475); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-(3-methyl)-βVal-βAla-NH2(SEQ ID NO:476); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-(3-methyl)-βVal-βAla-NH2(SEQ ID NO:477); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-(3-methyl)-βVal-βAla-NH2(SEQ ID NO: 478); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Ala-NH2(SEQ ID NO: 479); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-dPro-dLeu-NH2(SEQ ID NO: 480); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-dPro-dLeu-NH2(SEQ ID NO: 481); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-dPro-dLeu-NH2(SEQ ID NO: 482); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-dPro-dLeu-NH2(SEQ ID NO: 483); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-dLeu-dPro-NH2(SEQ ID NO: 484); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-dLeu-dPro-NH2(SEQ ID NO: 485); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-dLeu-dPro-NH2(SEQ ID NO: 486); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-dLeu-dPro-NH2(SEQ ID NO: 487); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-β-Pro-β-Leu-NH2(SEQ ID NO: 488); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-β-Pro-β-Leu-NH2(SEQ ID NO: 489); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-β-Pro-β-Leu-NH2(SEQ ID NO: 490); Ac-Nle-c(dAsp-His-dNal(2')-Arg-Trp-dLys)-β-Pro-β-Leu-NH2(SEQ ID NO:491); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-β-Leu-β-Pro-NH2(SEQ ID NO: 492); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-β-Leu-β-Pro-NH2(SEQ ID NO: 493); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-β-Leu-β-Pro-NH2(SEQ ID NO: 494); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-β-Leu-β-Pro-NH2(SEQ ID NO: 495); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-β-Val-β-Leu-NH2(SEQ ID NO: 496); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-β-Val-β-Leu-NH2(SEQ ID NO: 497); Ac-Nle-c(dAsp-Pro-dPhe-Arg-Trp-dLys)-β-Val-β-Leu-NH2(SEQ ID NO: 498); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-β-Val-β-Leu-NH2 (SEQ ID NO: 499); Ac-Nle-c(Asp-Pro-dPhe-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Leu-NH2 (SEQ IDNO: 500); Ac-Nle-c(Asp-His-dPhe-Arg-Trp-Lys)-(3-methyl)-β-Val-β-Leu-NH2 (SEQ IDNO: 501); Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Leu-NH2 (SEQ ID NO: 502); and Ac-Nle-c(dAsp-His-dPhe-Arg-Trp-dLys)-(3-methyl)-β-Val-β-Leu-NH2 (SEQ IDNO: 503), Where c represents through R 1 and R 7 Cyclation via lactam bonds.

[0432] In some embodiments, the non-naturally occurring melanocortin analogue is a melanocortin receptor antagonist, such as a melanocortin 3 receptor and / or melanocortin 4 receptor antagonist. In some embodiments, the non-naturally occurring melanocortin analogue is a melanocortin receptor agonist, such as a melanocortin 1 receptor, melanocortin 3 receptor, melanocortin 4 receptor, and / or melanocortin 5 receptor agonist. For example, in some embodiments, the melanocortin analogue has agonist activity against melanocortin 3 and / or melanocortin 4 receptors, as well as against melanocortin 1 and melanocortin 5 receptors. In other embodiments, the melanocortin analogue has antagonist activity against melanocortin 3 and / or melanocortin 4 receptors, and agonist activity against melanocortin 1 and melanocortin 5 receptors.

[0433] In some embodiments, a non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 2 to 374. In some embodiments, a non-naturally occurring melanocortin antagonist analogue comprises any one of the sequences of SEQ ID NO: 2 to 281. In some embodiments, a non-naturally occurring melanocortin antagonist analogue comprises any one of the following sequences: SEQ ID NO: 3, 20, 29 to 32, 67 to 70, 99 to 102, 127 to 130, 159, 163 to 166, 187 to 190, 387, 391, 394, 396, 398, and 399. In some embodiments, a non-naturally occurring melanocortin antagonist analogue comprises any one of the following sequences: SEQ ID NO: 10, 14, 33 to 39, 82 to 96, 108 to 111, 119 to 124, 128, 182 to 189, 212 to 281, 394, and 399.

[0434] In some embodiments, the non-naturally occurring melanocortin analogue comprises the sequence of SEQ ID NO: 3 (TCMCB07). The structure of TCMCB07 (“B07”), comprising Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2, is shown below: TCMCB07.

[0435] anticancer agents The anticancer agents described herein are therapeutic agents that can be used to treat or prevent tumors, tumor or cancer cell division, growth, proliferation and / or metastasis in a subject; induce tumor and / or cancer cell death or apoptosis; and / or any other form of proliferative disease. In some embodiments, such anticancer agents are effective in treating, alleviating, preventing or otherwise treating a subject with a non-cancerous disease or condition or a disease or condition other than cancer. The technology of this invention is intended to be used by subjects who may receive, have received or are receiving one or more doses of anticancer agents, regardless of whether the subject has or has an underlying disease or condition.

[0436] Conventional anticancer agents include chemotherapy agents, such as platinum-based and non-platinum-based chemotherapy agents. Conventional cancer therapies may contain more than one anticancer agent, such as combinations of two or more chemotherapy agents (e.g., 5-FU plus folate calcium (FOLFOX), sunitinib plus oxaliplatin), combinations of chemotherapy agents and immunotherapy, and combinations of two or more immunotherapies. In contrast, the method of the present invention involves administering a non-naturally occurring melanocortin analogue before, during, and / or after the administration of an anticancer agent.

[0437] Exemplary chemotherapeutic agents include, but are not limited to, (i) alkylated antitumor agents such as cyclophosphamide (CYTOXAN), thiotepa, busulfan, carmustine, chlorambucil, cyclophosphamide, dacarbazine, ifosfamide, lomustine, nitrogen mustard, melphalan, mercaptopurine, and procarbazine; and (ii) antimetabolites such as 5-fluorouracil (5-FU), cladribine, cytarabine, fludarabine, gemcitabine (GEMZAR), and tegafur (UFTORAL). (iii) Cytotoxic antibiotics such as doxorubicin (including ADRIAMYCIN, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolo-doxorubicin, β-doxorubicin salts (e.g., hydrochloride), β-doxorubicin hydrochloride liposome injection (DOXIL), and deoxy-doxorubicin), doxorubicin, idarubicin, sine, valerate, clofarabine, capecitabine (XELODA), methotrexate, pemetrexed, and thioguanine; Mitomycin C, Actinomycin, Epirubicin, Carbazin, Danemycin (including Danemycin A), Aclarubicin, Octreomycin, Diazoserine, Bleomycin, Actinomycin C, Calabriacin, Carminoxetine, Carbohydrate, Chromomycin, Actinomycin D, Detoxin, 6-Diazon-5-oxo-L-leucine, Isorubicin, Idarubicin, Epsilonycin, Mycophenolic acid, Nopramine, Oligomycin, Pelomycin, Porphyromycin, Purulin (iv) Triamcinolone acetonide, rodorubicin, streptozotocin, streptozotocin, tuberculin, ubenimex, fentostatin, and zolarubicin; and (v) microtubule-binding agents such as vincristine, paclitaxel, epothilone, docetaxel, discoprostol, etoposide, vincristine, teniposide, vinorelbine, and vindesin; and (v) platinum coordination complexes such as cisplatin, oxaliplatin, carboplatin, and nedaplatin.

[0438] Other examples of chemotherapy agents include, but are not limited to, tyrosine kinase inhibitors such as imatinib, nilotinib, dasatinib, bosutinib, ponatinib, barfetinib, and sunitinib; topoisomerase inhibitors such as CPT-11 (irinotecan, CAMPTOSAR), mitoxantrone, and topotecan (HYCAMTIN); thymidine phosphorylase (TPase) inhibitors such as tipyrimidine and trifluralin; mitotic inhibitors; cell cycle inhibitors; enzymes; biological response modifiers; and anti-angiogenic agents. Genetic agents, such as MMP-2, MMP-9, and COX-2 inhibitors; antiandrogens, such as flutamide, nilumet, and bicalutamide; substituted ureas, such as hydroxyurea; adrenocortical inhibitors, such as mitotane, amylase, and triplostane; antihormonal agents, such as antiestrogens and selective estrogen receptor modulators (SERMs), such as tamoxifen (including NOLVADEX), raloxifene (EVISTA), droloxifen, 4-hydroxytamoxifen, treoxifene, ketoxifen, LY 11 7018, onanasone, and toremifene (FARESTON). ® Hormones and / or hormone antagonists, such as corticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate), and estrogens (e.g., diethylstilbestrol); androgens, such as testosterone propionate; and aromatase inhibitors, such as anastrozole (ARIMIDEX), exemestane (AROMASIN), 4(5)-imidazoles, aminoglutethimide, megestrol acetate (MEGASE), formestane, fazodazole, vorcicloazole (RJVISOR), and letrozole (FEMARA).

[0439] In some embodiments, the anticancer agent comprises chemotherapy, and the chemotherapy comprises at least one chemotherapeutic agent. In some embodiments, the at least one chemotherapeutic agent comprises one or more chemotherapeutic agents selected from the group consisting of: platinum coordination complexes, antimetabolites, microtubule-binding agents or plant alkaloids, alkylating antitumor agents, and cytotoxic antibiotics. In some embodiments, the chemotherapeutic agent is an antimetabolite, a pyrimidine antagonist, an alkylating agent, a topoisomerase inhibitor, a mitotic inhibitor, an antitumor antibiotic, a protein kinase inhibitor, a proteasome inhibitor, a poly(ADP-ribose) polymerase inhibitor, a plant alkaloid, an antimicrotubule agent, an antitumor agent, or an enzyme.

[0440] In some embodiments, the chemotherapeutic agent is an antimetabolite. Non-limiting examples of antimetabolites include fluorouracil, 5-fluorouracil, 6-mercaptopurine, azacitidine, capecitabine, cladribine, clofarabine, cytarabine, fluorouridine, fludarabine, gemcitabine, methotrexate, pemetrexed, pentostatin, pralatrexate, trifluridine, and ticpyrimidine. In some embodiments, the chemotherapeutic agent comprises antimetabolites selected from the group consisting of: 5-fluorouracil (5-FU), 6-mercaptopurine, azacitidine, capecitabine, clofarabine, cytarabine, fluorouridine, fludarabine, gemcitabine, methotrexate, pemetrexed, pentostatin, pralatrexate, trifluridine, and ticpyrimidine.

[0441] In some embodiments, the chemotherapeutic agent is a pyrimidine antagonist. Non-limiting examples of pyrimidine antagonists include vincristine, vinorelbine, paclitaxel, docetaxel, etoposide, teniposide, irinotecan, and topotecan.

[0442] In some embodiments, the chemotherapeutic agent is an alkylating agent. Non-limiting examples of alkylating agents include hexamethylmelamine, bendamustine, busulfan, carboplatin, carmustine, cisplatin, chlorambucil, cyclophosphamide, dacarbazine, ifosfamide, lomustine, melphalan, temozolomide, and trabectedin.

[0443] In some embodiments, the chemotherapeutic agent is a topoisomerase inhibitor. Non-limiting examples of topoisomerase inhibitors include irinotecan, camptothecin, etoposide, doxorubicin, topotecan, mitoxantrone, teniposide, doxorubicin, idarubicin, epirubicin, SN-38, dexrazoxane, belotecone, levofloxacin, anthracyclines, rubitecan, cetuzumab, gavitenacone, moxifloxacin, gatifloxacin, rubotecan, nalidixic acid, neomycin, enoxacin, flumethylquine, and clindamycin.

[0444] In some embodiments, the chemotherapeutic agent is a mitotic inhibitor. Non-limiting examples of mitotic inhibitors include paclitaxel, docetaxel, vinblastine, vincristine, vinorelbine, ixaprilone, colchicine, colchicine amine, etoposide, teniposide, alicate, balasetide, vorasetide, paclitaxel protein-bound particles, albumin-bound paclitaxel, ipilitinib, and eribulin.

[0445] In some embodiments, the chemotherapy agent is an antitumor antibiotic. Non-limiting examples of antitumor antibiotics include doxorubicin, liposomal doxorubicin, epirubicin, idarubicin, mitomycin, and pentorubicin.

[0446] In some embodiments, the chemotherapeutic agent is a protein kinase inhibitor. Non-limiting examples of protein kinase inhibitors include imatinib, dasatinib, nilotinib, bosutinib, ponatinib, sorafenib, sunitinib, pazopanib, cabazantinib, vandetanib, crizotinib, selitinib, alectinib, brigatinib, osimertinib, larotrectinib, entrectinib, dabrafenib, trametinib, and cobimetinib.

[0447] In some embodiments, the chemotherapeutic agent is a proteasome inhibitor. Non-limiting examples of proteasome inhibitors include bortezomib, carfilzomib, ixazomib, malizomib, delanzomib, opzomib, delanzomib, benorbutal, parbistat, romidesin, vorinostat, benorbutal, plascillatal, remistatal, gilvestal, quinalstatin, moxistat, chidamide, roxistat, and tuxistat.

[0448] In some embodiments, the chemotherapeutic agent is a poly(ADP-ribose) polymerase inhibitor. Non-limiting examples of poly(ADP-ribose) polymerase inhibitors include olaparib, rucaparib, niraparib, tarapazanib, veliparib, pamipanib, celecoxib, tarapazanib, iniparib, niraparib, olaparib, rucaparib, veliparib, tarapazanib, pamipanib, iniparib, veliparib, olaparib, tarapazanib, and rucaparib.

[0449] In some embodiments, the chemotherapeutic agent is a plant alkaloid. Non-limiting examples of plant alkaloids include vincristine, vinorelbine, vinorelbine, paclitaxel, docetaxel, etoposide, teniposide, irinotecan, and topotecan.

[0450] In some embodiments, the chemotherapeutic agent is an antimicrotubule agent. Non-limiting examples of antimicrotubule agents include docetaxel, paclitaxel, vinblastine, vincristine, vinorelbine, eribulin, ixaprone, and cabazitaxel.

[0451] In some embodiments, the chemotherapeutic agent is an antitumor agent. Non-limiting examples of antitumor agents include estradiol, mitomycin, hydroxydaunomycin, chlorambucil, cisplatin, carboplatin, oxaliplatin, methotrexate, 5-fluorouracil, capecitabine, doxorubicin, epirubicin, idarubicin, daunomycin, bleomycin, etoposide, teniposide, mitoxantrone, irinotecan, topotecan, gemcitabine, pemetrexed, paclitaxel, and docetaxel.

[0452] In some embodiments, the chemotherapeutic agent is an enzyme. Non-limiting examples of enzymes include L-asparaginase, pegaspargase, glucosidase, carboxypeptidase G2, methionine taurine, arginine deiminase, ADI-PEG 20, protease-activated receptor 1 (PAR-1) inhibitors, thymidine synthase inhibitors, topoisomerase I inhibitors, topoisomerase II inhibitors, dihydrofolate reductase inhibitors, ribonucleotide reductase inhibitors, hypoxanthine-guanine phosphoribosyltransferase inhibitors, DNA polymerase inhibitors, telomerase inhibitors, histone deacetylase inhibitors, protein kinase C inhibitors, sertuin inhibitors, and matrix metalloproteinase inhibitors.

[0453] In some embodiments, at least one chemotherapeutic agent comprises a platinum coordination complex. In some embodiments, the platinum coordination complex is carboplatin and / or cisplatin.

[0454] In some embodiments, at least one chemotherapeutic agent comprises a tubulin binder or a plant alkaloid. In some embodiments, the tubulin binder or plant alkaloid is at least one selected from the group consisting of: vincristine, vinorelbine, paclitaxel, docetaxel, etoposide, teniposide, irinotecan, and topotecan.

[0455] In some embodiments, at least one chemotherapeutic agent comprises an alkylated antitumor agent. In some embodiments, the alkylated antitumor agent is at least one selected from the group consisting of: hexamethylmelamine, busulfan, carmustine, cyclophosphamide, dacarbazine, ifosfamide, lomustine, melphalan, temozolomide, and trabectedin.

[0456] In some embodiments, at least one chemotherapeutic agent comprises a cytotoxic antibiotic. In some embodiments, the cytotoxic antibiotic is at least one selected from the group consisting of: doxorubicin, doxorubicin, liposomal doxorubicin, epirubicin, idarubicin, and pentorubicin.

[0457] In some embodiments, the platinum coordination complex is cisplatin. In some embodiments, the chemotherapy includes cisplatin, and the non-naturally occurring melanocortin analogue contains the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

[0458] In some embodiments, the antimetabolite is 5-fluorouracil (5-FU). In some embodiments, the chemotherapy includes 5-FU, and the non-naturally occurring melanocorticoid analogue contains the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

[0459] In some embodiments, the tubulin binder or the plant alkaloid is vincristine. In some embodiments, chemotherapy includes vincristine, and a non-natural melanocorticoid analogue contains the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

[0460] In some embodiments, the alkylated antitumor agent is cyclophosphamide. In some embodiments, chemotherapy includes cyclophosphamide, and a non-natural melanocortin analogue contains the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

[0461] In some embodiments, the cytotoxic antibiotic is doxorubicin. In some embodiments, chemotherapy includes doxorubicin, and a non-naturally occurring melanocorticoid analogue contains the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

[0462] This invention further encompasses combinations of two or more anticancer agents (including the aforementioned chemotherapeutic agents) as combination therapies. Non-limiting examples include combinations of gemcitabine and cisplatin; carboplatin and pemetrexed; CHOP, an abbreviation for combination therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone; and FOLFOX, an abbreviation for a treatment regimen using oxaliplatin with 5-FU and leucovorin.

[0463] In some embodiments, the method further includes administering an antibody or antigen-binding fragment thereof that specifically binds to human growth differentiation factor 15 (GDF15), such as, but not limited to, persegumab. See U.S. Patent No. 11,566,066 (or U.S. Patent Application No. 16 / 541,817, incorporated herein by reference). In some embodiments, non-naturally occurring melanocorin analogues may treat, prevent, and / or alleviate one or more side effects of antibodies or antigen-binding fragments thereof that specifically bind to GDF15.

[0464] Preparations Compositions containing the carriers and / or excipients described in this invention facilitate the delivery of non-natural melanocorticoid analogs and / or one or more anticancer agents as described in any of the embodiments herein to a subject.

[0465] In some embodiments, one or more anticancer agents are present in the composition.

[0466] In some embodiments, the non-natural melanocortin analogue is present in the composition.

[0467] In some embodiments, the non-naturally occurring melanocortin analogue is present in the composition at a concentration of 0.1 mg / mL to 500 mg / mL relative to the total volume of the composition. For example, the non-naturally occurring melanocortin analogue is present in the composition at concentrations of 0.1 mg / mL to 500 mg / mL, 0.5 mg / mL to 250 mg / mL, 1 mg / mL to 100 mg / mL, 2.5 mg / mL to 50 mg / mL, or 5 mg / mL to 25 mg / mL relative to the total volume of the composition. In some embodiments, the non-naturally occurring melanocortin analogue is present in the composition at a concentration of about 50 mg / mL relative to the total volume of the composition.

[0468] In some embodiments, the non-naturally occurring melanocortin analogue comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3), and is present in the composition at a concentration of 5 mg / mL to 100 mg / mL relative to the total volume of the composition. For example, the non-naturally occurring melanocortin analogue comprising the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3) is present in the composition at concentrations of 5 mg / mL to 100 mg / mL, 10 mg / mL to 75 mg / mL, 15 mg / mL to 50 mg / mL, 20 mg / mL to 40 mg / mL, or 25 mg / mL to 30 mg / mL relative to the total volume of the composition. In some embodiments, a non-natural melanocortin analog containing the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3) is present in the composition at a concentration of about 50 mg / mL relative to the total volume of the composition.

[0469] In some embodiments, the composition comprising the non-naturally occurring melanocorticoid analogue is administered parenterally to the subject. In some embodiments, the composition comprising the non-naturally occurring melanocorticoid analogue is administered subcutaneously to the subject.

[0470] In some embodiments, compositions formulated for parenteral (e.g., subcutaneous) administration comprise a non-natural melanocortin analog of formula (I) at concentrations of about 0.001 nmol, 0.005 nmol, 0.01 nmol, 0.02 nmol, 0.05 nmol, 0.1 nmol, 0.25 nmol, 0.5 nmol, 1 nmol, 2.5 nmol, 5 nmol, 10 nmol, 20 nmol, 25 nmol, 50 nmol, 100 nmol, 250 nmol, 500 nmol, or 1000 nmol or even higher (depending on the specific peptide selected, the desired reaction, the route of administration, the formulation, and other factors known to those skilled in the art). In some embodiments, the non-natural melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

[0471] In some embodiments, non-natural melanocortin analogs cross the blood-brain barrier (BBB) ​​of the subject.

[0472] In some embodiments, the subject is a mammal, including but not limited to humans, non-human primates (such as chimpanzees), livestock or farm animals (such as cattle, bison, sheep, pigs, goats, horses, chickens, and roosters), domestic pets (such as dogs, cats, rats, mice, and rabbits), and laboratory subjects (such as rodents, including rats, mice, and guinea pigs). In some embodiments, the subject is a human. In some embodiments, the subject is an animal, such as a rat or a dog.

[0473] In some embodiments, the subject's body mass index (BMI) was 18.5 kg / m². 2 Up to 35 kg / m 2 In some embodiments, the subject's BMI is less than 35 kg / m². 2 In some embodiments, the subject's BMI is less than 18.5 kg / m². 2 .

[0474] In some embodiments, the subjects are underweight subjects. Underweight subjects include those whose weight is below the lower limit of the "normal" BMI (e.g., 18.5 kg / m²). 2 The percentage of subjects with a rate of approximately 3%, 5% or lower, 10% or lower, 20% or lower, or 30% or lower is lower.

[0475] In some embodiments, the composition of the present invention is administered to a subject at a dose based on the subject's BMI. In some embodiments, two or more doses of the composition of the present invention are administered to a subject, wherein the two or more doses are adjusted (e.g., reversed) based on the subject's BMI at each administration.

[0476] Compositions comprising the carrier and / or excipients described in this invention facilitate the delivery (e.g., parenteral administration, particularly subcutaneous injection) of non-natural melanocorticoid analogs as described herein in any of its embodiments to a subject. Other objectives of compositions comprising the carrier and / or excipients are to enhance the dispersibility, solubility, and stability of non-natural melanocorticoid analogs and to reduce adverse injection site reactions.

[0477] The carrier and / or excipients of the composition may typically include one or more of the following components: a pH-buffered aqueous solution containing (a) sodium acetate, (b) Tris and (c) water. In some embodiments, all components are compatible with non-naturally occurring melanocortin analogs (i.e., do not react with or cause non-naturally occurring melanocortin analogs to react) and are uniformly dispersed or uniformly dissolved in the composition.

[0478] In some embodiments, the carrier and / or excipient are isotonic.

[0479] To achieve the desired tension, the compositions of the present invention may further comprise salts such as sodium chloride, sodium succinate, sodium sulfate, potassium chloride, magnesium chloride, magnesium sulfate, and calcium chloride. In some embodiments, the salts are present in the composition at concentrations of 0.1 mg / mL to 50 mg / mL, 1 mg / mL to 25 mg / mL, or 5 mg / mL to 10 mg / mL relative to the total volume of the composition.

[0480] The carrier and / or excipient of the composition further include a pH buffered aqueous solution comprising (a) sodium acetate, (b) Tris and (c) water.

[0481] The water used in this document may be used as a diluent, and includes, but is not limited to, water for injection (WFI), sterile water, bacteriostatic water for injection (BWFI), distilled water, double-distilled water, deionized water, deionized distilled water, and reverse osmosis water. In some embodiments, the water present in the pH buffer solution is water for injection.

[0482] In some embodiments, the composition contains water in amounts of about 1 wt% to about 90 wt%, about 10 wt% to about 75 wt%, or about 25 wt% to about 50 wt% relative to the total weight of the composition.

[0483] In some embodiments, sodium acetate is present in the composition at a concentration of 0.5 mg / mL to 50 mg / mL relative to the total volume of the composition. For example, sodium acetate is present in the composition at concentrations of 0.5 mg / mL to 50 mg / mL, 1 mg / mL to 40 mg / mL, 2 mg / mL to 30 mg / mL, 4 mg / mL to 20 mg / mL, 5 mg / mL to 15 mg / mL, 6 mg / mL to 12 mg / mL, or 8 mg / mL to 10 mg / mL relative to the total volume of the composition.

[0484] In some embodiments, sodium acetate is present in the composition at a concentration of about 6 mg / mL to about 8 mg / mL relative to the total volume of the composition. For example, sodium acetate is present in the composition at a concentration of 6 mg / mL, 6.5 mg / mL, 7 mg / mL, 7.1 mg / mL, 7.5 mg / mL or 8 mg / mL relative to the total volume of the composition.

[0485] In some embodiments, sodium acetate is present in the composition at a molar concentration of 5 mM to 700 mM relative to the total volume of the composition. Sodium acetate is present in the composition at molar concentrations of 5 mM to 700 mM, 10 mM to 600 mM, 20 mM to 500 mM, 30 mM to 400 mM, 40 mM to 300 mM, 50 mM to 200 mM, 60 mM to 100 mM, or 70 mM to 80 mM relative to the total volume of the composition.

[0486] In some embodiments, sodium acetate is present in the composition at a molar concentration of about 80 mM to about 100 mM relative to the total volume of the composition. For example, sodium acetate is present in the composition at a molar concentration of 80 mM, 85 mM, 87 mM, 90 mM, 95 mM or 100 mM relative to the total volume of the composition.

[0487] The term "Tris" refers to tris(hydroxymethyl)aminomethane, also known as Tris buffer, Tris base, TRIS, tromethamine, tromethamine buffer, Trizma®, Trisamine, Trometamol, Tromethane, Trisaminol, or THAM. In some embodiments, Tris is present in the composition at a concentration of 0.5 mg / mL to 50 mg / mL relative to the total volume of the composition. For example, Tris is present in the composition at concentrations of 0.5 mg / mL to 50 mg / mL, 1 mg / mL to 40 mg / mL, 2 mg / mL to 30 mg / mL, 4 mg / mL to 20 mg / mL, 5 mg / mL to 15 mg / mL, 6 mg / mL to 12 mg / mL, or 8 mg / mL to 10 mg / mL relative to the total volume of the composition.

[0488] In some embodiments, Tris is present in the composition at a concentration of about 6 mg / mL to about 8 mg / mL relative to the total volume of the composition. For example, Tris is present in the composition at a concentration of 6 mg / mL, 6.5 mg / mL, 7 mg / mL, 7.3 mg / mL, 7.6 mg / mL or 8 mg / mL relative to the total volume of the composition.

[0489] In some embodiments, Tris is present in the composition at a molar concentration of 2 mM to 500 mM relative to the total volume of the composition. For example, Tris is present in the composition at a molar concentration of 2 mM to 500 mM, 5 mM to 400 mM, 10 mM to 300 mM, 20 mM to 200 mM, 30 mM to 150 mM, 40 mM to 100 mM, 50 mM to 80 mM, or 60 mM to 70 mM relative to the total volume of the composition.

[0490] In some embodiments, Tris is present in the composition at a molar concentration of about 50 mM to about 70 mM relative to the total volume of the composition. For example, Tris is present in the composition at a molar concentration of 50 mM, 55 mM, 60 mM, 65 mM or 70 mM relative to the total volume of the composition.

[0491] In some embodiments, the pH-buffered aqueous solution brings the pH of the composition to or near physiological pH levels. This can reduce adverse reactions at the injection site and give non-natural melanocortin analogs enhanced stability and resistance to aggregation and degradation.

[0492] In addition to sodium acetate and Tris, the composition may also contain other buffers. Non-limiting examples of other buffers include saline, phosphate, phosphoric acid, citrate, succinate, gluconate, histidine, acetic acid, ascorbate, tartaric acid, maleic acid, glycine, lactate, lactic acid, ascorbic acid, imidazole, bicarbonate, carbonic acid, succinic acid, sodium benzoate, benzoic acid, gluconate, ethylenediaminetetraacetic acid, malate, imidazole, and mixtures thereof. In some embodiments, the composition contains acetic acid as an additional buffer.

[0493] In some embodiments, the weight ratio of sodium acetate to Tris is 1:4 to 4:1, 2:7 to 7:2, 1:3 to 3:1, 2:5 to 5:2, 1:2 to 2:1, 2:3 to 3:2, or about 1:1. In some embodiments, the weight ratio of sodium acetate to Tris is about 1:1.

[0494] In some embodiments, the weight ratio of the non-naturally occurring melanocortin analog to sodium acetate is 1:1 to 20:1, 3:2 to 15:1, 2:1 to 12:1, 3:1 to 10:1, 4:1 to 9:1, 5:1 to 8:1, or 6:1 to 7:1. In some embodiments, the weight ratio of the non-naturally occurring melanocortin analog to sodium acetate is about 7:1.

[0495] In some embodiments, the weight ratio of the non-naturally occurring melanocortin analog to Tris is 1:1 to 20:1, 3:2 to 15:1, 2:1 to 12:1, 3:1 to 10:1, 4:1 to 9:1, 5:1 to 8:1, or 6:1 to 7:1. In some embodiments, the weight ratio of the non-naturally occurring melanocortin analog to Tris is about 7:1.

[0496] The composition may also contain preservatives. Exemplary preservatives include, but are not limited to, ascorbic acid, cysteine ​​hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, phenol, m-cresol, benzyl alcohol, α-tocopherol, citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, benzalkonium chloride, phenoxyethanol, and methylparaben.

[0497] If present, the concentration of the preservative relative to the total volume of the composition may range from 0.001 mg / mL to 50 mg / mL, 0.01 mg / mL to 25 mg / mL, 0.1 mg / mL to 10 mg / mL, or 1 mg / mL to 5 mg / mL.

[0498] In some embodiments, the composition is in the form of an aqueous solution or a suspension. In some embodiments, the composition is in the form of an emulsion. In some embodiments, the composition is in the form of an aqueous solution. In some embodiments, the composition is in the form of an aqueous solution that is clear, colorless, and / or free of visible foreign matter.

[0499] In some embodiments, the pH range of the composition is 6.5 to 8.5. In some embodiments, the pH of the composition is about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, or 8.5.

[0500] In some embodiments, the composition is alkaline and has a pH of about 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, or 8.5. In some embodiments, the pH of the composition ranges from about 7.3 to about 7.4. In some embodiments, the pH of the composition is 7.3 or 7.4.

[0501] In some embodiments, the osmotic pressure of the composition ranges from 250 mOsm / kg to 350 mOsm / kg. For example, the osmotic pressure of the composition ranges from 250 mOsm / kg to 360 mOsm / kg, 260 mOsm / kg to 340 mOsm / kg, 270 mOsm / kg to 330 mOsm / kg, 280 mOsm / kg to 320 mOsm / kg, 290 mOsm / kg to 310 mOsm / kg, or about 300 mOsm / kg. In some embodiments, the osmotic pressure of the composition is about 250 mOsm / kg, about 260 mOsm / kg, about 270 mOsm / kg, about 280 mOsm / kg, about 290 mOsm / kg, about 300 mOsm / kg, about 310 mOsm / kg, about 320 mOsm / kg, about 330 mOsm / kg, about 340 mOsm / kg, about 350 mOsm / kg, or about 360 mOsm / kg. In some embodiments, the osmotic pressure of the composition ranges from about 275 mOsm / kg to about 330 mOsm / kg. In some embodiments, the osmotic pressure of the composition is about 279 mOsm / kg, about 314 mOsm / kg, or about 329 mOsm / kg.

[0502] In some embodiments, the viscosity of the composition ranges from 0.5 cP to 5 cP. For example, the viscosity range of the composition is 0.5 cP to 5 cP, 0.75 cP to 4.5 cP, 1.0 cP to 4 cP, 1.2 cP to 3.5 cP, 1.3 cP to 3 cP, 1.4 cP to 2.5 cP, 1.5 cP to 2 cP, or 1.6 cP to 1.8 cP. In some embodiments, the viscosity of the composition is about 0.5 cP, 0.6 cP, 0.7 cP, 0.8 cP, 0.9 cP, 1.0 cP, 1.1 cP, 1.2 cP, 1.3 cP, 1.4 cP, 1.5 cP, 1.6 cP, 1.7 cP, 1.8 cP, 1.9 cP, or 2.0 cP. In some embodiments, the viscosity of the composition is about 1.4 cP or 1.6 cP.

[0503] The compositions described herein in any of the embodiments can be formulated for parenteral administration, for example, in the form of aqueous or non-aqueous isotonic sterile injectable solutions or suspensions. As used herein, the term "parenteral" includes subcutaneous, intravenous, intraperitoneal, intramuscular, and intralesional administration or infusion techniques.

[0504] One or more active ingredients (e.g., non-natural melanocortin analogs) may be dissolved or suspended in the aforementioned carriers and / or excipients. Additional aqueous or non-aqueous carriers that may promote the dissolution of the active ingredient include, but are not limited to, ethanol, benzyl alcohol, DMSO, polyethylene glycol, propylene glycol, corn oil, cottonseed oil, peanut oil, sesame oil, and / or various buffer solutions.

[0505] In some embodiments, compositions formulated for parenteral (e.g., subcutaneous) administration comprise a non-natural melanocortin analogue at concentrations of about 0.001 nmol, 0.005 nmol, 0.01 nmol, 0.02 nmol, 0.05 nmol, 0.1 nmol, 0.25 nmol, 0.5 nmol, 1 nmol, 2.5 nmol, 5 nmol, 10 nmol, 20 nmol, 25 nmol, 50 nmol, 100 nmol, 250 nmol, 500 nmol, or 1000 nmol or even higher (depending on the specific peptide selected, the desired therapeutic response, the route of administration, the formulation, and other factors known to those skilled in the art).

[0506] In some embodiments, the composition formulated for parenteral administration (e.g., subcutaneous administration) comprises concentrations of about 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 76 mM, 77 mM, 78 mM, 79 mM, 80 mM, 81 mM, 82 mM, 83 mM, 84 mM, 85 mM, 86 mM, 87 mM, 88 mM, 89 mM, 90 mM, 91 mM, 92 mM, 93 mM, 94 mM, 95 mM, 96 mM, 97 mM, 98 mM, 99 mM, 100 mM, 105 mM, 110 mM, 120 mM, 130 mM, etc. Sodium acetate in mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM or 200 mM.

[0507] In some embodiments, the composition formulated for parenteral (e.g., subcutaneous) administration comprises Tris at concentrations of about 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM, 105 mM, 110 mM, or 120 mM.

[0508] The compositions of this invention can be formulated for intranasal delivery. In some embodiments, the intranasal composition comprises a non-naturally occurring melanocortin analog of this invention, as well as a carrier and / or excipients.

[0509] The carrier and / or excipients of the composition may typically comprise one or more of the following components: (i) one or more antioxidants, (ii) one or more preservatives, (iii) one or more buffers, (iv) one or more tension modifiers, (v) one or more surfactants, (vi) fragrances, (vii) propellants, and / or (viii) mediators or solvents. In some embodiments, all components are compatible with non-naturally occurring melanocortin analogs (i.e., do not react with or cause reactions with non-naturally occurring melanocortin analogs) and are uniformly dispersed or uniformly dissolved in the composition.

[0510] In some embodiments, the carrier and / or excipient are isotonic with nasal fluid.

[0511] To achieve the desired tension, the compositions of the present invention may further comprise salts such as sodium chloride, sodium succinate, sodium sulfate, potassium chloride, magnesium chloride, magnesium sulfate, and calcium chloride. In some embodiments, the salt is present in the composition at a concentration of 0.1 mg / mL to 50 mg / mL, 1 mg / mL to 25 mg / mL, or 5 mg / mL to 10 mg / mL relative to the total volume of the composition. In some aspects, the salt is sodium chloride at a concentration of 0.9% wt.

[0512] The carrier and / or excipient of the composition also include a pH-buffered aqueous solution, which includes a pH-buffered aqueous solution of sodium acetate, Tris and water.

[0513] The water used in this document may be used as a diluent, and includes, but is not limited to, water for injection (WFI), sterile water, bacteriostatic water for injection (BWFI), distilled water, double-distilled water, deionized water, deionized distilled water, and reverse osmosis water. In some embodiments, the water present in the pH buffer solution is water for injection.

[0514] In some embodiments, the composition contains water (e.g., water for injection) in amounts of about 1 wt% to about 90 wt%, about 10 wt% to about 75 wt%, or about 25 wt% to about 50 wt% relative to the total weight of the composition.

[0515] In some embodiments, sodium acetate is present in the composition at a concentration of 0.5 mg / mL to 50 mg / mL relative to the total volume of the composition. For example, sodium acetate is present in the composition at concentrations of 0.5 mg / mL to 50 mg / mL, 1 mg / mL to 40 mg / mL, 2 mg / mL to 30 mg / mL, 4 mg / mL to 20 mg / mL, 5 mg / mL to 15 mg / mL, 6 mg / mL to 12 mg / mL, or 8 mg / mL to 10 mg / mL relative to the total volume of the composition.

[0516] In some embodiments, sodium acetate is present in the composition at a molar concentration of about 80 mM to about 100 mM relative to the total volume of the composition. For example, sodium acetate is present in the composition at a molar concentration of 80 mM, 85 mM, 87 mM, 90 mM, 95 mM or 100 mM relative to the total volume of the composition.

[0517] The term "Tris" refers to tris(hydroxymethyl)aminomethane, also known as Tris buffer, Tris base, TRIS, tromethamine, tromethamine buffer, Trizma®, Trisamine, Trometamol, Tromethane, Trisaminol, or THAM. In some embodiments, Tris is present in the composition at a concentration of 0.5 mg / mL to 50 mg / mL relative to the total volume of the composition. For example, Tris is present in the composition at concentrations of 0.5 mg / mL to 50 mg / mL, 1 mg / mL to 40 mg / mL, 2 mg / mL to 30 mg / mL, 4 mg / mL to 20 mg / mL, 5 mg / mL to 15 mg / mL, 6 mg / mL to 12 mg / mL, or 8 mg / mL to 10 mg / mL relative to the total volume of the composition.

[0518] In some embodiments, the pH-buffered aqueous solution brings the pH of the composition to or near physiological pH levels. This can reduce adverse reactions at the injection site and give non-natural melanocortin analogs enhanced stability and resistance to aggregation and degradation.

[0519] In addition to sodium acetate and Tris, the composition may also contain other buffers. Non-limiting examples of other buffers include saline, phosphate, phosphoric acid, citrate, succinate, gluconate, histidine, acetic acid, ascorbate, tartaric acid, maleic acid, glycine, lactate, lactic acid, ascorbic acid, imidazole, bicarbonate, carbonic acid, succinic acid, sodium benzoate, benzoic acid, gluconate, ethylenediaminetetraacetic acid, malate, imidazole, and mixtures thereof. In some embodiments, the composition contains acetic acid as an additional buffer.

[0520] In some embodiments, sodium phosphate is present in the composition at a molar concentration of 5 mM to 700 mM relative to the total volume of the composition. Sodium acetate is present in the composition at a molar concentration of 5 mM to 700 mM, 10 mM to 600 mM, 20 mM to 500 mM, 30 mM to 400 mM, 40 mM to 300 mM, 50 mM to 200 mM, 60 mM to 100 mM, or 70 mM to 80 mM relative to the total volume of the composition.

[0521] The composition may also contain preservatives. Exemplary preservatives include, but are not limited to, ascorbic acid, cysteine ​​hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, phenol, m-cresol, benzyl alcohol, benzalkonium chloride, α-tocopherol, citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, benzalkonium chloride, phenoxyethanol, and methylparaben.

[0522] If present, the concentration of the preservative relative to the total volume of the composition may range from 0.001 mg / mL to 50 mg / mL, 0.01 mg / mL to 25 mg / mL, 0.1 mg / mL to 10 mg / mL, or 1 mg / mL to 5 mg / mL.

[0523] In some embodiments, the composition is in the form of an aqueous solution or a suspension. In some embodiments, the composition is in the form of an emulsion. In some embodiments, the composition is in the form of an aqueous solution. In some embodiments, the composition is in the form of an aqueous solution that is clear, colorless, and / or free of visible foreign matter.

[0524] In some embodiments, the pH of the composition is close to the normal pH range of nasal fluids. In some embodiments, the pH range of the composition is 5.5 to 6.5. In some embodiments, the pH of the composition is about 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, or 6.5.

[0525] In some embodiments, the osmotic pressure of the composition ranges from 250 mOsm / kg to 350 mOsm / kg. For example, the osmotic pressure of the composition ranges f...

Claims

1. A method for treating, preventing, or reducing one or more side effects associated with an anticancer agent in a subject, the method comprising administering to the subject a non-naturally occurring melanocortin analogue before, during, and / or after administration of the anticancer agent, wherein the one or more side effects are selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

2. A method for maintaining or increasing the weight of a subject before, during, and / or after administration of an anticancer agent, the method comprising administering to the subject a non-naturally occurring melanocortin analogue, wherein the subject's weight is maintained or increased by preventing or reducing the subject's anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and / or loss of appetite.

3. A method for maintaining or increasing the weight of a subject before, during, and / or after administration of an anticancer agent, the method comprising administering to the subject a non-naturally occurring melanocortin analogue, wherein the weight of the subject is maintained or increased by preventing or reducing one or more side effects associated with the anticancer agent, the one or more side effects being selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

4. The method according to claim 2 or 3, wherein the subject experiences a weight gain of at least about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 225%, 250%, 275%, 300%, 350%, 400%, 450%, or 500% compared to baseline or control.

5. A method for maintaining or increasing muscle mass, fat mass, or heart mass of a subject before, during, and / or after administration of an anticancer agent, the method comprising administering to the subject a non-naturally occurring melanocortin analogue.

6. The method of claim 5, wherein the subject experiences an increase in muscle mass, fat mass, or heart mass of at least about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% compared to baseline or control.

7. A method for maintaining or increasing bone mineral density in a subject before, during, and / or after administration of an anticancer agent, the method comprising administering to the subject a non-naturally occurring melanocortin analogue.

8. The method of claim 7, wherein the subject experiences an increase in bone mineral density of at least about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% compared to baseline or control.

9. A method for increasing or maintaining a subject's functional assessment of anorexia / cachexia therapy (FAACT) score before, during, and / or after administration of an anticancer agent, the method comprising administering a non-naturally occurring melanocortin analogue to the subject.

10. The method of claim 9, wherein the subject experiences an increase of at least 1, 2, 3, 4, or 5 points in the FAACT score compared to baseline or control.

11. A method for stimulating the appetite of a subject or reducing loss of appetite induced by an anticancer agent in a subject, the method comprising administering to the subject a non-naturally occurring melanocortin analogue before, during and / or after administration of the anticancer agent.

12. The method of claim 11, wherein the subject experiences an increase in appetite compared to baseline or control, as measured by an increase in food intake of approximately 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1200, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, or 3000.

13. A method for preventing, reducing, or reversing weight loss induced by an anticancer agent in a subject, the method comprising administering to the subject a non-naturally occurring melanocortin analogue before, during, and / or after administration of the anticancer agent.

14. A method for treating, preventing, or reducing one or more side effects associated with an anticancer agent in a subject who is unresponsive to antiemetic treatment, the method comprising administering to the subject a non-naturally occurring melanocortin analogue before, during, and / or after administration of the anticancer agent, wherein the one or more side effects are selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

15. A method for treating, preventing, or reducing one or more side effects associated with an anticancer agent in a subject who is unresponsive to a nutritional intervention, the method comprising administering to the subject a non-naturally occurring melanocortin analogue before, during, and / or after administration of the anticancer agent, wherein the one or more side effects are selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

16. A method for preventing or reducing anticancer agent-induced side effects in a subject with cancer, the method comprising administering to the subject: the anticancer agent; and a non-naturally occurring melanocortin analogue.

17. A method for treating, preventing, or reducing iatrogenic injury caused by an anticancer agent in a subject with cancer, the method comprising administering to the subject: the anticancer agent; and a non-naturally occurring melanocortin analogue.

18. A method for reducing, maintaining, or improving the Eastern Cooperative Oncology Group (ECOG) and / or Karnofsky Performance Status (KPS) scores of a subject with cancer relative to baseline or control, the method comprising administering an anticancer agent and a non-naturally occurring melanocortin analogue to the subject.

19. The method of claim 18, wherein the subject experiences a reduction of approximately 1, 2, or 3 in ECOG performance score compared to baseline or control.

20. The method of claim 18, wherein the subject experiences an increase in KPS score of about 100, 90, 80, 70, 60, 50, 40 or 30 compared to baseline or control.

21. A method for reducing, maintaining, or improving overall survival (OS) or progression-free survival (PFS) relative to baseline or control in a subject with cancer, the method comprising administering an anticancer agent and a non-naturally occurring melanocortin analogue to the subject.

22. The method of claim 21, wherein the subject experiences an increase in OS or PFS of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

23. A method for reducing the time of cancer treatment failure in a subject with cancer relative to a baseline or control, the method comprising administering an anticancer agent and a non-naturally occurring melanocortin analog to the subject.

24. A method for increasing or maintaining the body mass index (BMI) of a subject relative to a baseline or control, the method comprising administering an anticancer agent and a non-naturally occurring melanocortin analog to the subject.

25. The method of claim 24, wherein the subject experienced a BMI increase of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 points compared to baseline or control.

26. The method of claim 24 or 25, wherein the subject experiences a sustained increase in BMI of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

27. A method for reducing the levels of pro-inflammatory transcripts or proteins in a subject with cancer relative to baseline or a control, the method comprising administering an anticancer agent and a non-naturally occurring melanocortin analog to the subject.

28. The method of claim 27, wherein the subject experiences a reduction in inflammatory transcript levels of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

29. The method of claim 27, wherein the subject experiences a reduction in inflammatory protein levels of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

30. The method of claim 27 or claim 28, wherein the pro-inflammatory transcript is a transcript selected from the group consisting of: IL1 transcript, IL6 transcript, IL1R1 transcript, TNFα transcript, selectin P transcript, cytokine transcript, and chemokine transcript.

31. The method of claim 27 or claim 29, wherein the pro-inflammatory protein is a protein selected from the group consisting of: IL1 protein, IL6 protein, IL1R1 protein, TNFα protein, selectin P protein, and cytokine protein.

32. The method of claim 1, wherein, relative to a baseline or control, the method maintains or increases the subject's lean body mass, fat body mass, and / or body weight.

33. The method of claim 11, wherein, relative to a baseline or control, the method maintains or increases the subject's lean body mass, fat body mass, and / or body weight.

34. The method of claim 14, wherein unresponsiveness to antiemetic treatment further includes insufficient clinical and / or therapeutic weight gain, muscle mass gain, fat mass gain, appetite gain, and / or food intake gain in the subject.

35. The method of claim 15, wherein the nutritional intervention further comprises nutritional supplementation.

36. The method of claim 16, wherein the side effects are selected from the group consisting of: anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, loss of appetite, vomiting, diarrhea, nausea, and fatigue.

37. The method of claim 17, wherein the iatrogenic injury is selected from the group consisting of: anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, and loss of appetite.

38. The method of claim 18, wherein improvement, maintenance, or prevention of a reduction in the ECOG and / or KPS scores is achieved by inhibiting or reducing the subject's anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, and / or loss of appetite.

39. The method according to any one of claims 1 to 38, wherein the subject has cancer.

40. The method according to any one of claims 1 to 39, wherein the anticancer agent comprises chemotherapy.

41. The method of claim 40, wherein, relative to a baseline or control, the method reduces chemotherapy-induced weight loss and / or emaciation in the subject and increases the subject's lean body mass and body weight.

42. The method of claim 40, wherein the method maintains or increases the subject's weight before, during, or after administration of the chemotherapy, and wherein the method reduces the subject's weight loss and / or emaciation relative to a baseline or control.

43. The method according to any one of claims 1 to 18, wherein the anorexia is associated with weight loss.

44. The method according to any one of claims 1 to 43, wherein the subject has not previously received an anticancer agent.

45. The method according to any one of claims 1 to 43, wherein the subject has previously received an anticancer agent.

46. ​​The method according to any one of claims 1 to 43, wherein the subject is receiving an anticancer agent.

47. The method according to any one of claims 1 to 46, wherein the administration of the non-naturally occurring melanocortin analogue enhances the tolerance of the anticancer agent.

48. The method of claim 47, wherein the enhanced tolerability relative to a baseline or control results in a higher dose of the anticancer agent, an increased frequency of administration, and / or an increased duration of administration, wherein the baseline or control is the subject prior to administration of the non-naturally occurring melanocortin analogue and / or a subject currently receiving or having received the anticancer agent but not the non-naturally occurring melanocortin analogue.

49. The method of claim 47, wherein the anticancer agent comprises a chemotherapy comprising at least two chemotherapeutic agents, and wherein the enhanced tolerance results in the administration of a second chemotherapeutic agent to the subject during or after administration of the first chemotherapeutic agent.

50. The method according to any one of claims 1 to 49, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue prevents or reduces downward adjustment of the dosing regimen of the anticancer agent.

51. The method of claim 50, wherein the downward adjustment comprises, compared to a baseline or control, a reduced dose, a reduced frequency of administration, and / or a reduced duration of administration, wherein the baseline or control is the subject prior to administration of the non-naturally occurring melanocortin analogue and / or a subject currently receiving or having received the anticancer agent but not the non-naturally occurring melanocortin analogue.

52. The method according to any one of claims 1 to 51, wherein the subject experienced loss of appetite, decreased appetite, reduced food consumption, and / or weight loss prior to administration of the non-naturally occurring melanocorticoid analogue.

53. The method of claim 52, wherein the loss of appetite, decreased appetite, reduced food consumption, and / or weight loss are caused by cancer.

54. The method of claim 52, wherein the loss of appetite, decreased appetite, reduced food consumption, and / or weight loss are caused by the anticancer agent.

55. The method according to any one of claims 1 to 54, wherein the subject is receiving or has received an antiemetic.

56. The method of claim 55, wherein the antiemetic is cannabis, medroxyprogesterone acetate, growth hormone, or dronabinol.

57. The method according to any one of claims 1 to 56, wherein the non-naturally occurring melanocortin analogue and the anticancer agent are administered simultaneously.

58. The method according to any one of claims 1 to 56, wherein the non-naturally occurring melanocortin analogue is administered before and / or after the anticancer agent.

59. The method of claim 1, wherein the administration of the non-naturally occurring melanocortin analogue treats, prevents, or reduces one or more side effects of the anticancer agent in the subject.

60. The method of claim 2, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue maintains or increases the subject's weight by preventing or reducing the subject's anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, and / or loss of appetite.

61. The method of claim 3, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue maintains or increases the subject's weight by preventing or reducing one or more side effects selected from the group consisting of: anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, and loss of appetite.

62. The method of claim 11, wherein, relative to a baseline or control, the administration of the non-naturally occurring melanocortin analogue stimulates the subject's appetite or reduces the subject's anorexia induced by the anticancer agent.

63. The method of claim 13, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue prevents, reduces, or reverses the subject's anticancer agent-induced weight loss.

64. The method of claim 14, wherein, relative to a baseline or control, the administration of the non-naturally occurring melanocorticoid analogue treats, prevents, or reduces the one or more side effects of the subject who is clinically and / or therapeutically unresponsive to antiemetic treatment.

65. The method of claim 15, wherein, relative to a baseline or control, the administration of the non-naturally occurring melanocorticoid analogue treats, prevents, or reduces the one or more side effects of the subject who is clinically and / or therapeutically unresponsive to nutritional interventions.

66. The method of claim 16, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue prevents or reduces the side effects induced by the anticancer agent in the subject.

67. The method of claim 17, wherein, relative to a baseline or control, the non-naturally occurring melanocortin analogue is administered to treat, prevent, or reduce the iatrogenic damage to the subject caused by the anticancer agent.

68. The method of claim 18, wherein, relative to baseline or control, administration of the non-naturally occurring melanocorticoid analogue prevents, maintains, or improves the subject's ECOG and / or KPS scores.

69. The method according to any one of claims 1 to 18, wherein the subject’s mass and / or weight reduction relative to baseline is no more than 5% prior to administration of the non-naturally occurring melanocorticoid analog and / or the anticancer agent.

70. The method according to any one of claims 1 to 18, wherein the subject’s mass and / or weight reduction relative to baseline is not more than 10% prior to administration of the non-naturally occurring melanocorticoid analog and / or the anticancer agent.

71. The method according to any one of claims 1 to 70, wherein the subject's ECOG score is 1 or higher prior to administration of the non-naturally occurring melanocortin analogue and / or the anticancer agent.

72. The method according to any one of claims 1 to 70, wherein the subject's ECOG score is 2 or higher prior to administration of the non-naturally occurring melanocortin analogue and / or the anticancer agent.

73. The method of claim 71 or 72, wherein the method reduces the subject's ECOG scale relative to baseline or control.

74. The method according to any one of claims 1 to 73, wherein the subject's KPS score is no more than 70 prior to administration of the non-naturally occurring melanocortin analogue and / or the anticancer agent.

75. The method according to any one of claims 1 to 73, wherein the subject's KPS score is no more than 50 prior to administration of the non-naturally occurring melanocortin analog and / or the anticancer agent.

76. The method of claim 74 or 75, wherein the method increases the subject's KPS score relative to a baseline or control.

77. The method according to any one of claims 1 to 76, wherein the method increases the cumulative mass of the subject relative to a baseline or control.

78. The method according to any one of claims 1 to 76, wherein the method reduces the cumulative mass loss rate of the subject relative to a baseline or control.

79. The method according to any one of claims 1 to 76, wherein the method increases the net weight gain of the subject relative to a baseline or control.

80. The method of claim 79, wherein the net weight gain is a weight change between two or more time points.

81. The method of claim 79 or 80, wherein the net weight gain is a change in weight between the start and end of treatment with the non-naturally occurring melanocortin analog or the anticancer agent.

82. The method of claim 80, wherein the two or more time points include intermediate time points.

83. The method according to any one of claims 1 to 82, wherein the method increases the cumulative food intake of the subject relative to a baseline or control.

84. The method of claim 83, wherein the cumulative food intake is the total food intake between two or more time points.

85. The method of claim 83 or 84, wherein the cumulative food intake is the total food intake between the start and end of treatment with the non-naturally occurring melanocortin analogue or the anticancer agent.

86. The method of claim 80, wherein the two or more time points include intermediate time points.

87. The method according to any one of claims 1 to 86, wherein the method increases the subject's BMI relative to a baseline or control.

88. The method of claim 87, wherein the increase in BMI is a change in BMI between two or more time points.

89. The method of claim 87 or 88, wherein the increase in BMI is a change in BMI between the start and end of treatment with the non-naturally occurring melanocorticoid analog or the anticancer agent.

90. The method of claim 88, wherein the two or more time points include intermediate time points.

91. The method according to any one of claims 87 to 90, wherein the non-naturally occurring melanocortin analog is administered to the subject based on the subject's BMI at the time of administration.

92. The method of claim 91, wherein the non-naturally occurring melanocortin analogue is administered to the subject in two or more doses based on the subject's BMI at the time of each administration.

93. The method of claim 92, wherein the two or more doses are adjusted inversely based on the subject's BMI at the time of each administration.

94. The method according to any one of claims 1 to 93, wherein the non-naturally occurring melanocortin analog comprises a sequence according to formula (I), X 1 X 2 X 3 R 1 R 2 R 3 R 4 R 5 R 6 R 7 R 8 R 9 R 10 R 11 R 12 R 13 R 14 R 15 R 16 R 17 R 18 R 19 R 20 Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 (I) in: R 1 The group consisting of the following items is absent or selected: cysteine, norepinephrine (Nle), acetylated norepinephrine (Ac-Nle). trans -4-guanidino-proline ( trans Pro(guan)), Cis -4-guanidino-proline ( Cis Pro(guan)), acetylation trans -4-guanidino-proline (Ac- trans Pro(guan)), acetylation Cis -4-guanidino-proline (Ac- Cis Pro(guan)), tyrosine, D-tyrosine, dimethyltyrosine (Dmt), aspartic acid, glutaric acid, leucine, isoleucine, valine, normal valine (Nva), alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, asparagine, and acetylated glutamic acid; R 2 The group consisting of the following items is absent or selected: proline, histidine, D-hydroxyproline (dHyp). trans Pro(guan), Cis Pro(guan), aspartic acid, glutamic acid, glycine, lysine, alanine, D-alanine, cysteine, leucine, arginine, succinic acid, glutaric acid, methionine, and phenylalanine; R 3 The following groups are absent or selected: histidine, L-proline, trans Pro(guan), Cis Pro(guan), D-valine, glutamic acid, tryptophanyl arginine (Trp-Arg), glycine, D-leucine, D-isoleucine, tryptophan, arginine, 4-amino-1,2,4,5-tetrahydro-2-benzozazepine-3-one (Aba), 7-amino-7,8-dihydro-4H-(1,2,3)triazol-(1,5-a)(1,4)diazepine-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydroazazepine (4,3) -b Indole-3 ( 2H )-ketone (Aia), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), and indoline-2-carboxylic acid (Ioc). R 4 Select the group consisting of the following: histidine, D-phenylalanine, L-phenylalanine, D-Nal(2'), aspartic acid, dBip, glycine, proline, cysteine, p-chloro-D-phenylalanine (p(Cl)dPhe), p-iodo-D-phenylalanine (p(I)dPhe), p-fluoro-D-phenylalanine (p(F)dPhe), and p-trifluoromethyl-D-phenylalanine (p(CF3)dPhe); R 5 The following groups are not present or are selected: arginine, high arginine, proline, trans Pro(guan), Cis Pro(guan), Pip, Nip, Tic, Phg, Sar, Azt, phenylalanine, D-Nal(2'), D-histidine, D-alanine, D-aspartic acid, D-glutamic acid, cysteine ​​and p(I)dPhe; R 6 The group consisting of the following items is absent or selected: L-tryptophan, D-phenylalanine, D-Nal(2'), L-Nal(2'), Tic, Bip, arginine, D-histidine, cysteine, D-Nal(1'), Aba, Ata, D-tyrosine, Pen, dPen and D-alanine; R 7 The following groups are not present or are selected: glycine, aspartic acid, glutamic acid, cysteine, lysine, ornithine, 2,3-diamino-propionic acid (Dap), methionine, proline, tryptophan, D-Nal(2') and tetrahydro-isoquinoline-3-carboxylic acid (Tic). R 8 It may be absent or contain lysine; R 9 To R 20 It does not exist; X 1 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, D-alanine, L-alanine, β-alanine, D-arginine, L-arginine, D-valine, L-valine, D-leucine, L-leucine, D-isoleucine, L-isoleucine, n-valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, acetylated D-arginine, acetylated L-arginine, acetylated D-valine, and acetylated n-leucine; X 2 It may be absent or contain D-proline; X 3 It does not exist; Y 1 The group consisting of the following is absent or selected: D-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and D-proline; Y 2 The group consisting of the following is absent or selected: D-proline, L-proline, Hyp, D-valine, L-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and glycine; Y 3 The group consisting of the following is absent or selected: D-lysine, L-lysine, D-proline, L-proline, D-valine, and L-valine; Y 4 It is absent or is either D-aspartic acid or aspartic acid; Y 5 To Y 8 It does not exist; The non-natural melanocortin analogue is optionally cyclized via a portion selected from the group consisting of: When R 1 For cysteine ​​and R 7 When it is cysteine, R 1 With R 7 disulfide bonds between them; When R 1 It is leucine and R 7 When it is glutamic acid, R 1 With R 7 The lactam bridge between them; When R 1 Or R 2 It is glutamic acid or aspartic acid and R 7 When it is lysine, Dap, or ornithine, R 1 Or R 2 With R 7 The side-chain lactam bridges between them; When R 2 For lysine and R 7 When it is glutamic acid or aspartic acid, R 2 With R 7 The side-chain lactam bridges between them; When R 1 Or R 2 It is either glutamic acid or aspartic acid, R 8 For lysine and R 7 When it is proline, glycine, or tryptophan, R 1 Or R 2 With R 8 The side-chain lactam bridges between them; The conditions are: When R 2 When it is dAsp, then R 7 Not for dLys; When R 2 To R 4 When R is Asp-His-dNal(2'), Asp-Pro-dNal(2'), or Asp-Pro-dPhe, then 5 To R 7 Not Arg-Trp-Lys; When Y 1 For dPro, Y 2 For dVal and Y 3 To Y 8 If it does not exist, then R 4 Not dNal(2') or R 4 It is dNal(2') and the C-terminus is not modified; When R 3 For Aba, Ata, or Aia, R 6 For Aia, or R 7 When it is Orn, then R 4 Not dNal(2'), or R 4 For dNal(2') and R 5 Not for Arg; When R 4 When R is p(Cl)dPhe, then 3 Not Pro or His; When R 4 When p(I)dPhe is used, the non-natural melanocortin analogue is obtained through R. 1 With R 7 The side-chain lactam bridged cyclization between them, and R 2 and R 3 At least one of them is Pro; When Y 2 To Y 4 If it does not exist, then Y 1 It is absent or contains ortholeucine; When R 2 For Pro or Y 2 When it is Hyp, then R 3 Not for Pro; When R 3 R 5 Or R 6 If it is not present, then the non-naturally occurring melanocortin analogue is obtained through R. 1 With R 7 The cyclization of lactams between them, or X 1 To X 2 It exists and is Ac-dVal-dPro; When R 2 To R 7 When it is Asp-Pro-dNal(2')-Arg-Trp-Lys (SEQ ID NO: 526) or Cys-Pro-dNal(2')-Arg-Trp-Cys (SEQ ID NO: 527), then R 1 Not Ac-Nle or Y 1 To Y 2 Not dVal-dPro, dVal-dVal, or dPro-dPro; and When the aforementioned non-naturally occurring melanocortin analogue is administered via R 2 With R 8 When the lactam bridge between them is cyclized, then R 3 Not His or Y 1 Not dVal.

95. The method according to any one of claims 1 to 18 and 73, wherein the non-naturally occurring melanocortin analog comprises any one of the following sequences: SEQ ID NO: 10, 14, 33 to 39, 82 to 96, 108 to 111, 119 to 124, 126 to 135, 138, 192 to 199, 222 to 295, 408 and 413.

96. The method according to any one of claims 1 to 18 and 73 to 74, wherein the non-naturally occurring melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

97. The method of claim 40, wherein the chemotherapy comprises at least one chemotherapeutic agent.

98. The method of claim 97, wherein the at least one chemotherapeutic agent comprises one or more chemotherapeutic agents selected from the group consisting of: platinum coordination complexes, antimetabolites, microtubule binders or plant alkaloids, alkylated antitumor agents and cytotoxic antibiotics.

99. The method of claim 98, wherein the at least one chemotherapeutic agent comprises a platinum coordination complex.

100. The method of claim 98, wherein the at least one chemotherapeutic agent comprises antimetabolites.

101. The method of claim 98, wherein the at least one chemotherapeutic agent comprises a tubulin binder or a plant alkaloid.

102. The method of claim 98, wherein the at least one chemotherapeutic agent comprises an alkylated antitumor agent.

103. The method of claim 98, wherein the at least one chemotherapeutic agent comprises a cytotoxic antibiotic.

104. The method according to claim 99, wherein the platinum coordination complex is carboplatin and / or cisplatin.

105. The method of claim 100, wherein the antimetabolite is at least one selected from the group consisting of: 5-fluorouracil (5-FU), 6-mercaptopurine, azacitidine, capecitabine, flufarabine, cytarabine, fluorouridine, fludarabine, gemcitabine, methotrexate, pemetrexed, pentostatin, pralatrexate, trifluorouridine, and tilpyridamole.

106. The method of claim 101, wherein the tubulin binder or the plant alkaloid is at least one selected from the group consisting of: vincristine, vinblastine, vinorelbine, paclitaxel, docetaxel, etoposide, teniposide, irinotecan, and topotecan.

107. The method of claim 102, wherein the alkylated antitumor agent is at least one selected from the group consisting of: hexamethylmelamine, busulfan, carmustine, cyclophosphamide, dacarbazine, ifosfamide, lomustine, melphalan, temozolomide, and trabectedin.

108. The method of claim 103, wherein the cytotoxic antibiotic is at least one selected from the group consisting of: daunorubicin, doxorubicin, liposomal doxorubicin, epirubicin, idarubicin, and pentorubicin.

109. The method according to claim 99, wherein the platinum coordination complex is cisplatin.

110. The method of claim 109, wherein the chemotherapy comprises cisplatin, and the non-naturally occurring melanocortin analogue comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

111. The method of claim 100, wherein the antimetabolite is 5-fluorouracil (5-FU).

112. The method of claim 111, wherein the chemotherapy comprises 5-FU, and the non-naturally occurring melanocortin analogue comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

113. The method according to claim 101, wherein the tubulin binder or the alkaloid is vincristine.

114. The method according to claim 102, wherein the alkylated antitumor agent is cyclophosphamide.

115. The method of claim 103, wherein the cytotoxic antibiotic is doxorubicin.

116. The method of claim 115, wherein the chemotherapy comprises doxorubicin, and the non-naturally occurring melanocorticoid analogue comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

117. The method according to claims 39 or 40, wherein the cancer is at least one selected from the group consisting of: bone cancer, testicular cancer, gastric cancer, sarcoma, lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, head and neck cancer, squamous cell head and neck cancer, thymic cancer, epithelial cancer, salivary gland cancer, liver cancer, gastric cancer, thyroid cancer, lung cancer, ovarian cancer, breast cancer, prostate cancer, esophageal cancer, pancreatic cancer, glioma, leukemia, multiple myeloma, renal cell carcinoma, bladder cancer, cervical cancer, choriocarcinoma, colorectal cancer, oral cancer, skin cancer, and melanoma.

118. The method of claim 39 or 40, wherein the cancer is at least one selected from the group consisting of: bone cancer, lung cancer, testicular cancer, breast cancer, prostate cancer, colorectal cancer, non-Hodgkin's lymphoma, ovarian cancer, cervical cancer, bladder cancer, and head and neck cancer.

119. The method according to claims 39 or 40, wherein the cancer is breast cancer, and wherein the anticancer agent is at least one selected from the group consisting of: anthracyclines, cyclophosphamide, epirubicin, fluorouracil, methotrexate, taxane, and docetaxel.

120. The method of claim 119, wherein the anthracycline is doxorubicin.

121. The method according to claim 119, wherein the paclitaxel is paclitaxel.

122. The method according to claim 39 or 40, wherein the cancer is lung cancer, and wherein the anticancer agent is at least one selected from the group consisting of: cisplatin, carboplatin, paclitaxel, albumin-bound paclitaxel, docetaxel, gemcitabine, vinorelbine, etoposide, and pemetrexed.

123. The method of claim 39 or 40, wherein the cancer is prostate cancer, and wherein the anticancer agent is at least one selected from the group consisting of: docetaxel, cabazitaxel, mitoxantrone, and estradiol.

124. The method according to claim 39 or 40, wherein the cancer is colorectal cancer, and wherein the anticancer agent is at least one selected from the group consisting of: 5-FU, capecitabine, irinotecan, oxaliplatin, trifluorouridine, and tipyrimidine.

125. The method of claim 40 or 41, wherein the cancer is colorectal cancer, wherein the subject is receiving radiotherapy, and wherein the chemotherapy is at least one selected from the group consisting of cisplatin, cisplatin plus 5-FU, and mitomycin plus 5-FU.

126. The method of claim 40 or 41, wherein the cancer is colorectal cancer, wherein the subject is not receiving radiation therapy, and wherein the chemotherapy is at least one selected from the group consisting of: gemcitabine plus cisplatin, methotrexate, vincristine, doxorubicin plus cisplatin, cisplatin, methotrexate plus vincristine, and gemcitabine plus paclitaxel.

127. The method according to any one of claims 39 to 41, wherein the cancer is melanoma, and wherein the anticancer agent is dacarbazine and / or temozolomide.

128. The method according to claim 39 or 40, wherein the cancer is non-Hodgkin's lymphoma, and wherein the anticancer agent is at least one selected from the group consisting of: cyclophosphamide, chlorambucil, bendamustine, ifosfamide, prednisone, dexamethasone, cisplatin, carboplatin, oxaliplatin, fludarabine, pentostatin, cladribine (2-CdA), cytarabine (ara-C), gemcitabine, methotrexate, pralatrexate, doxorubicin, liposomal doxorubicin, hydroxydaunorubicin, vincristine, mitoxantrone, etoposide, and bleomycin.

129. The method according to any one of claims 1 to 128, wherein the method does not reduce the efficacy of the anticancer agent.

130. The method of claim 39 or 40, wherein the subject with cancer has previously undergone treatment with the anticancer agent.

131. The method of claim 130, wherein the subject has previously experienced one or more adverse side effects while being treated with the anticancer agent, wherein the adverse side effects are selected from the group consisting of: anorexia, weight loss, muscle loss, fat loss, emaciation, and decreased or absent appetite.

132. The method according to any one of claims 1 to 131, wherein the subject is a human being.

133. The method according to any one of claims 1 to 131, wherein the subject is an animal.

134. The method according to any one of claims 1 to 38, wherein the muscle mass loss is cardiac muscle mass loss, skeletal muscle mass loss, or both.

135. The method of claim 134, wherein the loss of myocardial mass is determined by measuring changes in heart weight.

136. The method of claim 134, wherein the skeletal muscle mass loss is determined by measuring changes in the weight of the gastrocnemius muscle tissue.

137. The method according to any one of claims 1 to 38, wherein anorexia is determined by daily food intake, daily food consumption and / or weekly food intake.

138. The method of claim 137, wherein the daily food intake is determined by the total calories (kcal) consumed in a day or the mass (grams or kilograms) of food consumed in a day.

139. The method of claim 137, wherein the daily food consumption is determined by the daily food intake normalized relative to the subject's daily body weight.

140. The method of claim 137, wherein the weekly food intake is determined by the total calories (kcal) consumed in a day or the mass (grams or kilograms) of food consumed in a week.

141. The method according to any one of claims 1 to 38, wherein the weight loss is determined by daily weight and / or daily weight gain.

142. The method according to any one of claims 1 to 38, wherein the fat mass of the subject treated by the method is at least 10% to 100% greater than that of the baseline or control, wherein the baseline or control is the subject before administration of the non-naturally occurring melanocortin analogue and / or a subject who is receiving or has received the anticancer agent but has not received the non-naturally occurring melanocortin analogue.

143. The method according to any one of claims 1 to 38, wherein the heart weight of the subject treated by the method is at least 0.1% to 10% greater than that of the baseline or control, wherein the baseline or control is the subject before administration of the non-naturally occurring melanocortin analogue and / or a subject who is receiving or has received the anticancer agent but has not received the non-naturally occurring melanocortin analogue.

144. The method according to any one of claims 1 to 38, wherein the weight of the gastrocnemius muscle tissue of the subject treated by the method is at least 0.1% to 10% greater than that of the baseline or control, wherein the baseline or control is the subject before administration of the non-naturally occurring melanocortin analogue and / or the subject who is receiving or has received the anticancer agent but has not received the non-naturally occurring melanocortin analogue.

145. The method according to any one of claims 1 to 38, wherein the daily food intake of the subject treated by the method is at least 5% to 50% greater than that of a baseline or control, wherein the baseline or control is the subject before administration of the non-naturally occurring melanocortin analogue and / or a subject who is receiving or has received the anticancer agent but has not received the non-naturally occurring melanocortin analogue.

146. The method according to any one of claims 1 to 38, wherein the daily weight of the subject treated by the method is at least 1% to 15% greater than the baseline or control, wherein the baseline or control is the subject before administration of the non-naturally occurring melanocortin analogue and / or a subject who is receiving or has received the anticancer agent but has not received the non-naturally occurring melanocortin analogue.

147. The method according to any one of claims 1 to 38, wherein after administration of the non-naturally occurring melanocortin analogue, the subject's appetite increases by at least 10% to 200%.

148. The method according to any one of claims 1 to 38, wherein after administration of the non-naturally occurring melanocortin analogue, the subject's appetite increases by at least 25% to 100%.

149. The method according to claim 147 or 148, wherein during the period of administration, appetite increases for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

150. The method according to claim 147 or 148, wherein during the administration period, appetite increases for at least 1 day, 5 days, 7 days, 14 days, 21 days, 28 days, 35 days, 40 days, 45 days, 50 days, 60 days, 75 days, 90 days, 100 days, 110 days, or 120 days.

151. The method according to any one of claims 147 to 150, wherein after the application is stopped, the increased appetite is maintained for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 3 months, 6 months, 1 year or 5 years.

152. The method according to any one of claims 147 to 151, wherein the appetite is assessed by a scale for measuring food cravings, hunger and / or satiety levels.

153. The method of claim 152, wherein the appetite is assessed between meals.

154. The method according to any one of claims 147 to 152, wherein the subject comprises two or more subjects, and wherein the appetite is the average appetite of the two or more subjects.

155. The method according to any one of claims 1 to 38, wherein anorexia is determined by food consumption.

156. The method according to any one of claims 1 to 18, wherein the non-naturally occurring melanocortin analogue is present in the pharmaceutical composition.

157. The method of claim 156, wherein the pharmaceutical composition further comprises a pharmaceutical salt.

158. The method of claim 156, wherein the pharmaceutical composition further comprises a pharmaceutical carrier.

159. The method of claim 156, wherein the non-naturally occurring melanocortin analogue is present in the pharmaceutical composition at a concentration of 0.1 mg / mL to 500 mg / mL relative to the total volume of the pharmaceutical composition.

160. The method of claim 159, wherein the non-naturally occurring melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3), and wherein the non-naturally occurring melanocortin analog is present in the pharmaceutical composition at a concentration of 5 mg / mL to 100 mg / mL relative to the total volume of the pharmaceutical composition.

161. The method of claim 160, wherein the non-naturally occurring melanocortin analogue is present in the pharmaceutical composition at a concentration of about 10 mg / mL, about 20 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, or about 60 mg / mL relative to the total volume of the pharmaceutical composition.

162. The method of claim 161, wherein the non-naturally occurring melanocortin analog is present in the pharmaceutical composition at a concentration of about 50 mg / mL relative to the total volume of the pharmaceutical composition.

163. The method according to any one of claims 1 to 18, wherein the non-naturally occurring melanocorticoid analogue is administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intravenous, intranasal, or oral administration.

164. The method according to any one of claims 156 to 162, wherein the pharmaceutical composition comprising the non-naturally occurring melanocorticoid analogue is administered parenterally to the subject.

165. The method according to any one of claims 156 to 162, wherein the pharmaceutical composition comprising the non-naturally occurring melanocortin analogue is administered subcutaneously to the subject.

166. The method according to any one of claims 1 to 18, wherein the non-naturally occurring melanocortin analog crosses the blood-brain barrier of the subject.

167. The method of claim 158, wherein the pharmaceutical carrier comprises water.

168. The method according to any one of claims 1 to 18, wherein the non-naturally occurring melanocortin analogue is administered to the subject before or after a meal.

169. The method according to any one of claims 1 to 18, wherein the non-naturally occurring melanocortin analogue is administered to the subject with a meal.

170. The method according to any one of claims 1 to 18, wherein a therapeutically effective amount of the non-naturally occurring melanocortin analogue is administered, and wherein the therapeutically effective amount of the non-naturally occurring melanocortin analogue is from 0.001 mg / kg to 25 mg / kg, depending on the weight of the subject.

171. The method according to any one of claims 170, wherein the therapeutically effective amount of the non-naturally occurring melanocortin analogue is from 0.5 mg / kg to 10 mg / kg, depending on the weight of the subject.

172. The method according to any one of claims 1 to 18, wherein the non-naturally occurring melanocorticoid analogue is administered at least once daily in an amount ranging from 0.001 mg / kg to 25 mg / kg, depending on the weight of the subject.

173. The method according to any one of claims 1 to 18, wherein the non-naturally occurring melanocorticoid analogue is administered at least once daily in an amount ranging from about 0.5 mg / kg to about 10 mg / kg, depending on the weight of the subject.

174. The method of claim 173, wherein the non-naturally occurring melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3), and the non-naturally occurring melanocortin analog is administered at least once daily in an amount ranging from 0.001 mg / kg to 25 mg / kg, depending on the weight of the subject.

175. The method of claim 173, wherein the non-naturally occurring melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3), and the non-naturally occurring melanocortin analog is administered at least once daily in an amount ranging from 0.5 mg / kg to 10 mg / kg, depending on the weight of the subject.

176. The method according to any one of claims 1 to 18, wherein the non-naturally occurring melanocortin analogue is administered to the subject for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

177. The method according to any one of claims 1 to 18, wherein the non-naturally occurring melanocortin analogue is administered to the subject for 1, 5, 7, 14, 21, 28, 35, 40, 45, 50, 60, 75, 90, 100, 110 or 120 days.

178. The method according to any one of claims 1 to 18, wherein the anticancer agent and the non-naturally occurring melanocortin analog are administered simultaneously as a single composition.

179. The method of claim 178, wherein the non-naturally occurring melanocortin analog is present in the single composition at a concentration of 0.1 mg / mL to 500 mg / mL relative to the total volume of the single composition.

180. The method of claim 179, wherein the non-naturally occurring melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3), and wherein the non-naturally occurring melanocortin analog is present in the single composition at a concentration of 5 mg / mL to 100 mg / mL relative to the total volume of the single composition.

181. The method of claim 180, wherein the non-naturally occurring melanocortin analogue is present in the single composition at a concentration of about 10 mg / mL, about 20 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, or about 60 mg / mL relative to the total volume of the single composition.

182. The method of claim 180, wherein the non-naturally occurring melanocortin analog is present in the single composition at a concentration of about 50 mg / mL relative to the total volume of the single composition.

183. The method of claim 180, wherein the non-naturally occurring melanocortin analog is present in the single composition at a dose of about 5 mg to about 500 mg in a dose volume of about 1 mL to 20 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

184. The method of claim 180, wherein the non-naturally occurring melanocortin analog is present in the single composition at a dose of about 50 mg to about 100 mg in a dose volume of about 2 mL to 10 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

185. The method of claim 180, wherein the non-naturally occurring melanocortin analog is present in the single composition at a dose of about 75 mg in a dose volume of about 5 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

186. The method according to any one of claims 183 to 185, wherein the application is performed once daily.

187. The method according to any one of claims 1 to 18, wherein: The anticancer agent is present in the first pharmaceutical composition; and The non-natural melanocortin analogue is present in the second pharmaceutical composition.

188. The method of claim 187, wherein the first pharmaceutical composition and the second pharmaceutical composition are different and are administered sequentially.

189. The method of claim 187, wherein the first pharmaceutical composition and the second pharmaceutical composition are different and are administered simultaneously but separately.

190. The method according to any one of claims 187 to 189, wherein the second pharmaceutical composition is administered subcutaneously.

191. The method according to any one of claims 187 to 190, wherein the anticancer agent comprises chemotherapy, and the chemotherapy is present in the first pharmaceutical composition at a concentration of 0.001 mg / mL to 1,000 mg / mL relative to the total volume of the first pharmaceutical composition.

192. The method of claim 191, wherein the chemotherapy is cisplatin, and cisplatin is present in the first pharmaceutical composition at a concentration of 0.01 mg / mL to 50 mg / mL relative to the total volume of the first pharmaceutical composition.

193. The method of claim 191, wherein the chemotherapy is 5-FU, and the 5-FU is present in the first pharmaceutical composition at a concentration of 0.1 mg / mL to 500 mg / mL relative to the total volume of the first pharmaceutical composition.

194. The method of claim 191, wherein the chemotherapy is doxorubicin, and doxorubicin is present in the first pharmaceutical composition at a concentration of 0.01 mg / mL to 50 relative to the total volume of the first pharmaceutical composition.

195. The method of claim 187, wherein the non-naturally occurring melanocortin analogue is present in the second pharmaceutical composition at a concentration of 0.1 mg / mL to 500 mg / mL relative to the total volume of the second pharmaceutical composition.

196. The method of claim 195, wherein the non-naturally occurring melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3), and wherein the non-naturally occurring melanocortin analog is present in the second pharmaceutical composition at a concentration of 5 mg / mL to 100 mg / mL relative to the total volume of the second pharmaceutical composition.

197. The method of claim 196, wherein the non-naturally occurring melanocortin analogue is present in the second pharmaceutical composition at a concentration of about 10 mg / mL, about 20 mg / mL, about 30 mg / mL, about 40 mg / mL, about 50 mg / mL, or about 60 mg / mL relative to the total volume of the second pharmaceutical composition.

198. The method of claim 196, wherein the non-naturally occurring melanocortin analog is present in the second pharmaceutical composition at a concentration of about 50 mg / mL relative to the total volume of the second pharmaceutical composition.

199. The method of claim 187, wherein the non-naturally occurring melanocortin analogue is present in the second pharmaceutical composition in a dose of about 5 mg to about 500 mg in a dose volume of about 1 mL to 20 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

200. The method of claim 187, wherein the non-naturally occurring melanocortin analog is present in the second pharmaceutical composition at a dose of about 50 mg to about 100 mg in a dose volume of about 2 mL to 10 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

201. The method of claim 187, wherein the non-naturally occurring melanocortin analog is present in the second pharmaceutical composition at a dose of about 75 mg in a dose volume of about 5 mL, and wherein the administration is performed once, twice, three times, four times, five times, or ten times daily.

202. The method according to any one of claims 199 to 201, wherein the application is performed once daily.

203. The method of claim 187, wherein the anticancer agent comprises cisplatin, and wherein cisplatin is administered orally and / or intraperitoneally.

204. The method of claim 187, wherein the anticancer agent comprises 5-FU, and wherein the 5-FU is administered orally and / or intraperitoneally.

205. The method of claim 187, wherein the anticancer agent comprises doxorubicin, and wherein doxorubicin is administered intraperitoneally.

206. The method of claim 187, wherein the non-naturally occurring melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO:3).

207. The method according to any one of claims 187 to 206, wherein a therapeutically effective amount of the anticancer agent is administered at least once a week.

208. The method of claim 207, wherein the anticancer agent comprises cisplatin, and the therapeutically effective amount of cisplatin is from 0.01 mg / kg to 25 mg / kg, depending on the weight of the subject.

209. The method of claim 208, wherein the therapeutically effective dose of cisplatin is about 2.5 mg / kg based on the subject's weight.

210. The method of claim 207, wherein the anticancer agent comprises 5-FU, and the therapeutically effective amount of 5-FU is from 0.1 mg / kg to 700 mg / kg, depending on the weight of the subject.

211. The method of claim 210, wherein the therapeutically effective dose of 5-FU is about 70 mg / kg, depending on the weight of the subject.

212. The method of claim 207, wherein the anticancer agent comprises doxorubicin, and the therapeutically effective amount of doxorubicin is from 0.005 mg / kg to 50 mg / kg, depending on the weight of the subject.

213. The method of claim 212, wherein the therapeutically effective dose of doxorubicin is about 2 mg / kg, depending on the weight of the subject.

214. The method according to any one of claims 207 to 213, wherein the non-naturally occurring melanocorticoid analogue is administered at least once daily in an amount ranging from 0.001 mg / kg to 25 mg / kg, depending on the weight of the subject.

215. The method according to any one of claims 207 to 213, wherein the non-naturally occurring melanocorticoid analogue is administered at least once daily in an amount ranging from about 0.5 mg / kg to about 10 mg / kg, depending on the weight of the subject.

216. The method of claim 187, wherein the anticancer agent comprises cisplatin, and cisplatin is administered at intervals of about 7 days, about 14 days, about 21 days, or about 28 days, at a dose of 0.01 mg / kg to 25 mg / kg, depending on the weight of the subject.

217. The method of claim 187, wherein the anticancer agent comprises 5-FU, and the 5-FU is administered at intervals of about 7 days, about 14 days, about 21 days, or about 28 days, at a dose of 0.1 mg / kg to 700 mg / kg, depending on the weight of the subject.

218. The method of claim 187, wherein the non-naturally occurring melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3), and the non-naturally occurring melanocortin analog is administered at a daily dose of 0.001 mg / kg to 25 mg / kg, depending on the weight of the subject.

219. Use of a non-naturally occurring melanocortin analogue for the treatment, prevention, or reduction of one or more side effects associated with an anticancer agent in a subject, said one or more side effects being selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite, wherein the non-naturally occurring melanocortin analogue is administered to the subject before, during, and / or after administration of said anticancer agent.

220. Use of a non-naturally occurring melanocortin analogue to maintain or increase the weight of a subject before, during, and / or after administration of an anticancer agent, wherein the weight of the subject is maintained or increased by preventing or reducing anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and / or loss of appetite in the subject.

221. Use of a non-naturally occurring melanocortin analogue to maintain or increase the weight of a subject before, during, and / or after administration of an anticancer agent, the use comprising administering the non-naturally occurring melanocortin analogue to the subject, wherein the subject's weight is maintained or increased by preventing or reducing one or more side effects associated with the anticancer agent, the one or more side effects being selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

222. The use according to claim 220 or 221, wherein the subject experiences a weight gain of at least about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 225%, 250%, 275%, 300%, 350%, 400%, 450%, or 500% compared to baseline or control.

223. Use of non-natural melanocorticoid analogues to maintain or increase muscle mass, fat mass, or cardiac mass in subjects before, during, and / or after administration of anticancer agents.

224. The use according to claim 223, wherein the subject experiences an increase in muscle mass, fat mass, or heart mass of at least about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% compared to baseline or control.

225. Use of non-natural melanocortin analogues to maintain or increase bone mineral density in subjects before, during and / or after administration of anticancer agents.

226. The use according to claim 225, wherein the subject experiences an increase in bone mineral density of at least about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 12%, 14%, 16%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% compared to baseline or control.

227. Use of non-naturally occurring melanocorticoid analogues to maintain or increase the functional assessment of anorexia / cachexia therapy (FAACT) scores of subjects before, during and / or after administration of anticancer agents.

228. The use according to claim 227, wherein the subject experiences an increase of at least 1, 2, 3, 4 or 5 points in the FAACT score compared to baseline or control.

229. Use of non-natural melanocortin analogues to stimulate appetite or reduce anorexia induced by anticancer agents in subjects.

230. The use according to claim 229, wherein the subject experiences an increase in appetite compared to baseline or control, as measured by an increase in food intake of approximately 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1200, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, or 3000.

231. Use of non-naturally occurring melanocortin analogues for the prevention, reduction or reversal of weight loss induced by anticancer agents in subjects.

232. The use of non-naturally occurring melanocortin analogues for the treatment, prevention or reduction of one or more side effects associated with anticancer agents in subjects unresponsive to antiemetic treatment, said one or more side effects being selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite and loss of appetite.

233. The use of non-naturally occurring melanocortin analogues for the treatment, prevention or reduction of one or more side effects associated with anticancer agents in subjects who are unresponsive to nutritional interventions, said one or more side effects being selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite and loss of appetite.

234. Use of non-naturally occurring melanocortin analogues for the prevention or reduction of anticancer agent-induced side effects in subjects with cancer.

235. Use of non-naturally occurring melanocortin analogues for the treatment, prevention or reduction of iatrogenic injury caused by anticancer agents in subjects with cancer.

236. Use of a non-naturally occurring melanocortin analogue, relative to baseline or control, before, during, and / or after administration of an anticancer agent, to prevent, maintain, or improve the ECOG and / or KPS scores of subjects with cancer.

237. The use according to claim 236, wherein the subject experiences a reduction of approximately 1, 2, or 3 in ECOG fitness score compared to baseline or control.

238. The use according to claim 236, wherein the subject experiences an increase in KPS score of about 100, 90, 80, 70, 60, 50, 40 or 30 compared to baseline or control.

239. Use of non-naturally occurring melanocortin analogues relative to baseline or control, before, during and / or after administration of an anticancer agent, to prevent reduction, maintenance or improvement of overall survival (OS) or progression-free survival (PFS) in subjects with cancer.

240. The use according to claim 239, wherein the subject experiences an increase in OS or PFS of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

241. Use of a non-naturally occurring analogue, relative to baseline or control, before, during and / or after administration of an anticancer agent, to reduce the time of cancer treatment failure in subjects with cancer.

242. Use of non-naturally occurring melanocortin analogues to increase or maintain body mass index (BMI) in subjects before, during, and / or after administration of anticancer agents, relative to baseline or control.

243. The use according to claim 242, wherein the subject experienced a BMI increase of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 points compared to baseline or control.

244. The use according to claim 242 or 243, wherein the subject experiences a sustained increase in BMI of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

245. Use of non-naturally occurring melanocortin analogues to reduce the levels of pro-inflammatory transcripts or proteins in subjects with cancer before, during, and / or after administration of an anticancer agent, relative to baseline or control.

246. The use according to claim 245, wherein the subject experiences a reduction of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% in inflammatory transcript levels compared to baseline or control.

247. The use according to claim 245, wherein the subject experiences a reduction in inflammatory protein levels of at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% compared to baseline or control.

248. The use according to claim 245 or claim 329, wherein the pro-inflammatory transcript is a transcript selected from the group consisting of: IL1 transcript, IL6 transcript, IL1R1 transcript, TNFα transcript, selectin P transcript, cytokine transcript and chemokine transcript.

249. The use according to claim 245 or claim 329, wherein the pro-inflammatory protein is a protein selected from the group consisting of: IL1 protein, IL6 protein, IL1R1 protein, TNFα protein, selectin P protein, cytokine protein, and chemokine protein.

250. The use according to claim 219, wherein the use maintains or increases the subject's lean body mass, fat body mass, and / or body weight relative to a baseline or control.

251. The use according to claim 229, wherein the use maintains or increases the subject's lean body mass, fat body mass, and / or body weight relative to a baseline or control.

252. The use according to claim 232, wherein unresponsiveness to antiemetic treatment further includes insufficient weight gain, muscle mass gain, fat mass gain, appetite gain, and / or food intake gain in the clinically and / or therapeutically described subject.

253. The use according to claim 233, wherein the nutritional intervention further comprises nutritional supplementation.

254. The use according to claim 234, wherein the side effects are selected from the group consisting of: anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, loss of appetite, vomiting, diarrhea, nausea, and fatigue.

255. The use according to claim 235, wherein the iatrogenic injury is selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite and loss of appetite.

256. The use according to claim 236, wherein improvement, maintenance or prevention of reduction of said scores is achieved by inhibiting or reducing said subject's anorexia, weight loss, muscle mass loss, fat mass loss, emaciation, decreased appetite and / or loss of appetite.

257. The use according to any one of claims 219 to 256, wherein the subject has cancer.

258. The use according to any one of claims 219 to 257, wherein the anticancer agent comprises chemotherapy.

259. The use according to claim 258, wherein, relative to baseline or control, the use reduces chemotherapy-induced weight loss and / or emaciation in the subject and increases the subject's lean body mass and body weight.

260. The use according to claim 258, wherein the use maintains or increases the subject's weight before, during, or after the administration of the chemotherapy, and wherein the use reduces the subject's weight loss and / or emaciation relative to a baseline or control.

261. The use according to any one of claims 219 to 236, wherein the anorexia is associated with weight loss.

262. The use according to any one of claims 219 to 261, wherein the subject has not previously received an anticancer agent.

263. The use according to any one of claims 219 to 261, wherein the subject has previously received an anticancer agent.

264. The use according to any one of claims 219 to 261, wherein the subject is receiving an anticancer agent.

265. The use according to any one of claims 219 to 264, wherein the administration of the non-naturally occurring melanocortin analogue enhances tolerance to the anticancer agent.

266. The use according to claim 265, wherein the enhanced tolerability relative to a baseline or control results in a higher dose of the anticancer agent, an increased frequency of administration, and / or an increased duration of administration, wherein the baseline or control is the subject prior to administration of the non-naturally occurring melanocortin analogue and / or a subject currently receiving or having received the anticancer agent but not the non-naturally occurring melanocortin analogue.

267. The use according to claim 265, wherein the anticancer agent comprises a chemotherapy comprising at least two chemotherapeutic agents, and wherein the enhanced tolerance results in the administration of a second chemotherapeutic agent to the subject during or after administration of the first chemotherapeutic agent.

268. The use according to any one of claims 219 to 267, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue prevents or reduces downward adjustment of the dosing regimen of the anticancer agent.

269. The use according to claim 268, wherein the downward adjustment comprises, compared to a baseline or control, a reduced dose, a reduced frequency of administration, and / or a shortened duration of administration, wherein the baseline or control is the subject prior to administration of the non-naturally occurring melanocortin analogue and / or a subject currently receiving or having received the anticancer agent but not the non-naturally occurring melanocortin analogue.

270. Use according to any one of claims 219 to 269, wherein the subject experienced decreased appetite, reduced food consumption, and / or weight loss prior to administration of the non-naturally occurring melanocorticoid analogue.

271. The use according to claim 270, wherein the loss of appetite, decreased appetite, reduced food consumption, and / or weight loss are caused by cancer.

272. The use according to claim 270, wherein the loss of appetite, decreased appetite, reduced food consumption, and / or weight loss are caused by the anticancer agent.

273. The use according to any one of claims 219 to 272, wherein the subject is receiving or has received an antiemetic.

274. The use according to claim 273, wherein the antiemetic is cannabis, medroxyprogesterone acetate, growth hormone, or dronabinol.

275. The use according to any one of claims 219 to 274, wherein the non-naturally occurring melanocortin analogue and the anticancer agent are administered in parallel.

276. The use according to any one of claims 219 to 274, wherein the non-naturally occurring melanocortin analogue is administered before and / or after the anticancer agent.

277. The use according to claim 219, wherein the administration of the non-naturally occurring melanocortin analogue treats, prevents, or reduces one or more side effects associated with the anticancer agent in the subject.

278. The use according to claim 220, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue maintains or increases the subject's weight by preventing or reducing the subject's anorexia, weight loss, muscle loss, fat loss, emaciation, decreased appetite, and / or loss of appetite.

279. The use according to claim 221, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue maintains or increases the subject's weight by preventing or reducing one or more side effects selected from the group consisting of: anorexia, weight loss, loss of muscle mass, loss of fat mass, emaciation, decreased appetite, and loss of appetite.

280. The use according to claim 229, wherein, relative to a baseline or control, the administration of the non-naturally occurring melanocortin analogue stimulates the appetite of the subject or reduces the subject's anorexia induced by the anticancer agent.

281. The use according to claim 231, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue prevents, reduces, or reverses the subject's weight loss induced by the anticancer agent.

282. The use according to claim 232, wherein, relative to a baseline or control, the administration of the non-naturally occurring melanocorticoid analogue treats, prevents, or reduces one or more of the side effects in subjects who are clinically and / or therapeutically unresponsive to antiemetic treatment.

283. The use according to claim 233, wherein, relative to a baseline or control, the administration of the non-naturally occurring melanocorticoid analogue treats, prevents, or reduces one or more of the side effects in subjects who are clinically and / or therapeutically unresponsive to nutritional interventions.

284. The use according to claim 234, wherein, relative to a baseline or control, administration of the non-naturally occurring melanocortin analogue prevents or reduces the side effects induced by the anticancer agent in the subject.

285. The use according to claim 235, wherein, relative to a baseline or control, the administration of the non-naturally occurring melanocortin analogue treats, prevents, or reduces the iatrogenic damage to the subject caused by the anticancer agent.

286. The use according to claim 236, wherein, relative to baseline or control, administration of the non-naturally occurring melanocortin analogue prevents, maintains, or improves the subject's ECOG and / or KPS scores.

287. The use according to any one of claims 219 to 236, wherein the subject’s mass and / or weight reduction relative to baseline is not more than 5% prior to administration of the non-naturally occurring melanocortin analog and / or the anticancer agent.

288. The use according to any one of claims 219 to 236, wherein the subject’s mass and / or weight reduction relative to baseline is not more than 10% prior to administration of the non-naturally occurring melanocortin analog and / or the anticancer agent.

289. The use according to any one of claims 219 to 288, wherein the subject's ECOG score is 1 or higher prior to administration of the non-naturally occurring melanocortin analogue and / or the anticancer agent.

290. The use according to any one of claims 219 to 288, wherein the subject's ECOG score is 2 or higher prior to administration of the non-naturally occurring melanocortin analogue and / or the anticancer agent.

291. The use according to claim 289 or 290, wherein the use reduces the subject's ECOG score relative to baseline or control.

292. The use according to any one of claims 219 to 291, wherein the subject’s KPS score is no more than 70 prior to administration of the non-naturally occurring melanocortin analogue and / or the anticancer agent.

293. The use according to any one of claims 219 to 291, wherein the subject’s KPS score is no more than 50 prior to administration of the non-naturally occurring melanocortin analogue and / or the anticancer agent.

294. The use according to claim 292 or 293, wherein the use increases the subject's KPS score relative to baseline or control.

295. The use according to any one of claims 219 to 294, wherein the use increases the cumulative mass of the subject relative to a baseline or control.

296. The use according to any one of claims 219 to 294, wherein the use reduces the cumulative mass loss rate of the subject relative to baseline or control.

297. The use according to any one of claims 219 to 294, wherein the use increases the net weight gain of the subject relative to baseline or control.

298. The use according to claim 297, wherein the increase in net weight is a change in weight between two or more time points.

299. The use according to claim 297, wherein the net weight gain is the weight change between the start and end of treatment with the non-naturally occurring melanocortin analog or the anticancer agent.

300. The use according to claim 298, wherein the two or more time points include intermediate time points.

301. The use according to any one of claims 219 to 300, wherein the use increases the cumulative food intake of the subject relative to a baseline or control.

302. The use according to claim 301, wherein the cumulative food intake is the total food intake between two or more time points.

303. The use according to claim 301, wherein the cumulative food intake is the total food intake between the start and end of treatment with the non-naturally occurring melanocortin analogue or the anticancer agent.

304. According to the use described in 366, the two or more time points include intermediate time points.

305. The use according to any one of claims 219 to 304, wherein the use increases the subject's BMI relative to a baseline or control.

306. The use according to claim 305, wherein the increase in BMI is a change in BMI between two or more time points.

307. The use according to claim 305, wherein the increase in BMI is a change in BMI between the start and end of treatment with the non-naturally occurring melanocortin analog or the anticancer agent.

308. The use according to claim 306, wherein the two or more time points include intermediate time points.

309. The use according to any one of claims 305 to 390, wherein the non-naturally occurring melanocortin analogue is administered to the subject based on the subject's BMI at the time of administration.

310. The use according to claim 309, wherein the non-naturally occurring melanocortin analogue is administered to the subject in two or more doses based on the subject's BMI at the time of each administration.

311. The use according to claim 310, wherein the two or more doses are adjusted in reverse based on the subject's BMI at the time of each administration.

312. The use according to any one of claims 219 to 311, wherein the non-naturally occurring melanocortin analog comprises the sequence according to formula (I), X 1 X 2 X 3 R 1 R 2 R 3 R 4 R 5 R 6 R 7 R 8 R 9 R 10 R 11 R 12 R 13 R 14 R 15 R 16 R 17 R 18 R 19 R 20 Y 1 Y 2 Y 3 Y 4 Y 5 Y 6 Y 7 Y 8 (I) in: R 1 The group consisting of the following items is absent or selected: cysteine, norepinephrine (Nle), acetylated norepinephrine (Ac-Nle). trans -4-guanidino-proline ( trans Pro(guan)), Cis -4-guanidino-proline ( Cis Pro(guan)), acetylation trans -4-guanidino-proline (Ac- trans Pro(guan)), acetylation Cis -4-guanidino-proline (Ac- Cis Pro(guan)), tyrosine, D-tyrosine, dimethyltyrosine (Dmt), aspartic acid, glutaric acid, leucine, isoleucine, valine, normal valine (Nva), alanine, glycine, proline, methionine, lysine, phenylalanine, glutamic acid, asparagine, and acetylated glutamic acid; R 2 The group consisting of the following items is absent or selected: proline, histidine, D-hydroxyproline (dHyp). trans Pro(guan), Cis Pro(guan), aspartic acid, glutamic acid, glycine, lysine, alanine, D-alanine, cysteine, leucine, arginine, succinic acid, glutaric acid, methionine, and phenylalanine; R 3 The following groups are absent or selected: histidine, L-proline, trans Pro(guan), Cis Pro(guan), D-valine, glutamic acid, tryptophanyl arginine (Trp-Arg), glycine, D-leucine, D-isoleucine, tryptophan, arginine, 4-amino-1,2,4,5-tetrahydro-2-benzozazepine-3-one (Aba), 7-amino-7,8-dihydro-4H-(1,2,3)triazol-(1,5-a)(1,4)diazepine-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydroazazepine (4,3) -b Indole-3 ( 2H )-ketone (Aia), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), and indoline-2-carboxylic acid (Ioc). R 4 Select the group consisting of the following: histidine, D-phenylalanine, L-phenylalanine, D-Nal(2'), aspartic acid, dBip, glycine, proline, cysteine, p-chloro-D-phenylalanine (p(Cl)dPhe), p-iodo-D-phenylalanine (p(I)dPhe), p-fluoro-D-phenylalanine (p(F)dPhe), and p-trifluoromethyl-D-phenylalanine (p(CF3)dPhe); R 5 The following groups are not present or are selected: arginine, high arginine, proline, trans Pro(guan), Cis Pro(guan), Pip, Nip, Tic, Phg, Sar, Azt, phenylalanine, D-Nal(2'), D-histidine, D-alanine, D-aspartic acid, D-glutamic acid, cysteine ​​and p(I)dPhe; R 6 The group consisting of the following items is absent or selected: L-tryptophan, D-phenylalanine, D-Nal(2'), L-Nal(2'), Tic, Bip, arginine, D-histidine, cysteine, D-Nal(1'), Aba, Ata, D-tyrosine, Pen, dPen and D-alanine; R 7 The following groups are not present or are selected: glycine, aspartic acid, glutamic acid, cysteine, lysine, ornithine, 2,3-diamino-propionic acid (Dap), methionine, proline, tryptophan, D-Nal(2') and tetrahydro-isoquinoline-3-carboxylic acid (Tic). R 8 It may be absent or contain lysine; R 9 To R 20 It does not exist; X 1 The group consisting of the following is absent or selected: D-cysteine, L-cysteine, D-threonine, D-proline, L-proline, D-alanine, L-alanine, β-alanine, D-arginine, L-arginine, D-valine, L-valine, D-leucine, L-leucine, D-isoleucine, L-isoleucine, n-valine, glycine, methionine, lysine, phenylalanine, tyrosine, glutamic acid, asparagine, aspartic acid, acetylated D-arginine, acetylated L-arginine, acetylated D-valine, and acetylated n-leucine; X 2 It may be absent or contain D-proline; X 3 It does not exist; Y 1 The group consisting of the following is absent or selected: D-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and D-proline; Y 2 The group consisting of the following is absent or selected: D-proline, L-proline, Hyp, D-valine, L-valine, D-tert-leucine, L-tert-leucine, ortholeucine, and glycine; Y 3 The group consisting of the following is absent or selected: D-lysine, L-lysine, D-proline, L-proline, D-valine, and L-valine; Y 4 It is absent or is either D-aspartic acid or aspartic acid; Y 5 To Y 8 It does not exist; The non-natural melanocortin analogue is optionally cyclized via a portion selected from the group consisting of: When R 1 For cysteine ​​and R 7 When it is cysteine, R 1 With R 7 disulfide bonds between them; When R 1 It is leucine and R 7 When it is glutamic acid, R 1 With R 7 The lactam bridge between them; When R 1 Or R 2 It is glutamic acid or aspartic acid and R 7 When it is lysine, Dap, or ornithine, R 1 Or R 2 With R 7 The side-chain lactam bridges between them; When R 2 For lysine and R 7 When it is glutamic acid or aspartic acid, R 2 With R 7 The side-chain lactam bridges between them; When R 1 Or R 2 It is either glutamic acid or aspartic acid, R 8 For lysine and R 7 When it is proline, glycine, or tryptophan, R 1 Or R 2 With R 8 The side-chain lactam bridges between them; The conditions are: When R 2 When it is dAsp, then R 7 Not for dLys; When R 2 To R 4 When R is Asp-His-dNal(2'), Asp-Pro-dNal(2'), or Asp-Pro-dPhe, then 5 To R 7 Not Arg-Trp-Lys; When Y 1 For dPro, Y 2 For dVal and Y 3 To Y 8 If it does not exist, then R 4 Not dNal(2') or R 4 It is dNal(2') and the C-terminus is not modified; When R 3 For Aba, Ata, or Aia, R 6 For Aia, or R 7 When it is Orn, then R 4 Not dNal(2'), or R 4 For dNal(2') and R 5 Not for Arg; When R 4 When R is p(Cl)dPhe, then 3 Not Pro or His; When R 4 When p(I)dPhe is used, the non-natural melanocortin analogue is obtained through R. 1 With R 7 The side-chain lactam bridged cyclization between them, and R 2 and R 3 At least one of them is Pro; When Y 2 To Y 4 If it does not exist, then Y 1 It is absent or contains ortholeucine; When R 2 For Pro or Y 2 When it is Hyp, then R 3 Not for Pro; When R 3 R 5 Or R 6 If it is not present, then the non-naturally occurring melanocortin analogue is obtained through R. 1 With R 7 The cyclization of lactams between them, or X 1 To X 2 It exists and is Ac-dVal-dPro; When R 2 To R 7 When it is Asp-Pro-dNal(2')-Arg-Trp-Lys (SEQ ID NO: 526) or Cys-Pro-dNal(2')-Arg-Trp-Cys (SEQ ID NO: 527), then R 1 Not Ac-Nle or Y 1 To Y 2 Not dVal-dPro, dVal-dVal, or dPro-dPro; and When the aforementioned non-naturally occurring melanocortin analogue is administered via R 2 With R 8 When the lactam bridge between them is cyclized, then R 3 Not His or Y 1 Not dVal.

313. Use according to any one of claims 219 to 236 and 373, wherein the non-naturally occurring melanocortin analog comprises any one of the following sequences: SEQ ID NO: 10, 14, 33 to 39, 82 to 96, 108 to 111, 119 to 124, 126 to 135, 138, 192 to 199, 222 to 295, 408 and 413.

314. Use according to any one of claims 219 to 236 and 373 to 374, wherein the non-naturally occurring melanocortin analog comprises the sequence Ac-Nle-c(Asp-Pro-dNal(2')-Arg-Trp-Lys)-dVal-dPro-NH2 (SEQ ID NO: 3).

Citation Information

Patent Citations

  • Paper pulp packing material and mfg. method thereof

    CN1179846C

  • Apparatus for treating seeds by imitating weight-loss state

    CN2509828Y

  • Laser beam focusing-forming integral mirror

    CN2510880Y

  • Horizontal dust collector for gas pipelines

    CN2511379Y

  • Gloves with automatic ventilation device

    CN2515982Y